var title_f31_1_31760="Bilateral facet dislocation CT";
var content_f31_1_31760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Bilateral facet dislocations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These CT images show a bilateral facet dislocation (red arrows) at the C6-C7 level.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31760=[""].join("\n");
var outline_f31_1_31760=null;
var title_f31_1_31761="Complex rearrangement in CML";
var content_f31_1_31761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complex rearrangement in chronic myeloid leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequential g-band (top) and FISH (bottom) images of metaphase chromosomes from a complex variant Philadelphia rearrangement without the typical Philadelphia chromosome. The FISH probe is a dual-color combination of probes that span the ABL (green) and BCR (red) breakpoint regions. Juxtaposition of the ABL and BCR signals on the derivative chromosome 22 results in a yellow fusion signal. This complex rearrangement involves submicroscopic insertion of most of the ABL gene into chromosome 22.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Athena Cherry, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31761=[""].join("\n");
var outline_f31_1_31761=null;
var title_f31_1_31762="Patient information: Bacterial meningitis (The Basics)";
var content_f31_1_31762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/35/16946\">",
"         Patient information: Aseptic meningitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/31/3570\">",
"         Patient information: Headache (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/43/3763\">",
"         Patient information: Meningitis in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/56/28546\">",
"         Patient information: Seizures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/4/23619\">",
"         Patient information: Vaccines for adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/7/18547\">",
"         Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/34/28194\">",
"         Patient information: Viral meningitis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/48/1796\">",
"         Patient information: Meningitis in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Bacterial meningitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/bacterial-meningitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H5971859\">",
"      <span class=\"h1\">",
"       What is meningitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Meningitis is a condition that can cause a fever, headache, and stiff neck. It happens when the lining that covers the brain and spinal cord (called the &ldquo;meninges&rdquo;) gets inflamed or infected.",
"     </p>",
"     <p>",
"      There are 2 main types of meningitis, depending on which germs are causing the infection. Bacteria cause bacterial meningitis. Viruses cause viral meningitis. Both types of meningitis can cause similar symptoms.",
"     </p>",
"     <p>",
"      It is very important that doctors figure out what kind of meningitis a person has. That&rsquo;s because bacterial meningitis is a medical emergency. If it is not treated quickly, it can lead to brain problems such as hearing loss or learning problems. It can also lead to death.",
"     </p>",
"     <p>",
"      This article discusses bacterial meningitis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5971874\">",
"      <span class=\"h1\">",
"       What are the symptoms of bacterial meningitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of bacterial meningitis usually come on suddenly, so people can get very sick over a short period of time. Common symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Fever &ndash; But some people have a temperature that is lower than normal instead of a fever.",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Stiff neck &ndash; This happens most often in adults and children. Babies might not get a stiff neck.",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Acting confused, or being hard to wake up",
"       </li>",
"       <li>",
"        Having light bother a person&rsquo;s eyes",
"       </li>",
"       <li>",
"        A rash that looks like red or purple spots on the skin that do not go away when touched",
"       </li>",
"       <li>",
"        Seizures &ndash; Seizures are waves of abnormal electrical activity in the brain. They can make people pass out, or move or behave strangely.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Babies can also have other symptoms, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Being more sleepy or fussy than usual",
"       </li>",
"       <li>",
"        Not feeding well",
"       </li>",
"       <li>",
"        A bulging soft spot on the skull",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5971889\">",
"      <span class=\"h1\">",
"       Should I see the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have a fever, headache, and stiff neck, go to the emergency room right away. If you think your child has meningitis, bring him or her to the emergency room right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5971904\">",
"      <span class=\"h1\">",
"       Will I have tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor will learn about your symptoms and do an exam. He or she will do tests to make sure you have meningitis and see what type of bacteria is causing the infection. The tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A lumbar puncture (sometimes called a &ldquo;spinal tap&rdquo;) &ndash; During this procedure, a doctor puts a thin needle into your lower back and removes a small amount of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. He or she will do lab tests on the spinal fluid.",
"       </li>",
"       <li>",
"        A CT scan of the brain &ndash; This is an imaging test that creates pictures of the brain.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5971921\">",
"      <span class=\"h1\">",
"       How is bacterial meningitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People are treated in the hospital with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotic medicines that go into a vein through a tube called an &ldquo;IV&rdquo; &ndash; The antibiotics used depend on the type of bacteria causing the infection.",
"       </li>",
"       <li>",
"        Fluids and other medicines that go into a vein &ndash; These medicines sometimes include &ldquo;steroids.&rdquo; The steroids help protect your brain from the effects of the bacterial meningitis. They are different from the steroids athletes take to build muscle.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5971936\">",
"      <span class=\"h1\">",
"       Can bacterial meningitis be spread from one person to another?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. It depends on the type of bacteria that&rsquo;s causing the infection. Some types of bacteria can be spread from 1 person to another.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5971953\">",
"      <span class=\"h1\">",
"       Can bacterial meningitis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. Certain vaccines can help prevent bacterial meningitis. Vaccines are treatments that can prevent certain serious infections.",
"     </p>",
"     <p>",
"      To help prevent bacterial meningitis, make sure that you and your children have had all of the vaccines you need to prevent the following infections:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Meningococcus",
"       </li>",
"       <li>",
"        Pneumococcus",
"       </li>",
"       <li>",
"        Haemophilus influenzae type B, called &ldquo;Hib&rdquo; (for babies and young children)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If someone in your home has bacterial meningitis, ask your doctor or nurse if you should take antibiotics. Sometimes, other people at home need to take antibiotics to keep from getting the infection.",
"     </p>",
"     <p>",
"      Plus, you can help avoid getting sick by washing your hands well before eating, and not sharing cups or silverware.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5971968\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/43/3763?source=see_link\">",
"       Patient information: Meningitis in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/34/28194?source=see_link\">",
"       Patient information: Viral meningitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/35/16946?source=see_link\">",
"       Patient information: Aseptic meningitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=see_link\">",
"       Patient information: Headache (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18547?source=see_link\">",
"       Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=see_link\">",
"       Patient information: Vaccines for adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=see_link\">",
"       Patient information: Seizures (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/48/1796?source=see_link\">",
"       Patient information: Meningitis in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/1/31762?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16956 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31762=[""].join("\n");
var outline_f31_1_31762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971859\">",
"      What is meningitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971874\">",
"      What are the symptoms of bacterial meningitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971889\">",
"      Should I see the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971904\">",
"      Will I have tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971921\">",
"      How is bacterial meningitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971936\">",
"      Can bacterial meningitis be spread from one person to another?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971953\">",
"      Can bacterial meningitis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5971968\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/35/16946?source=related_link\">",
"      Patient information: Aseptic meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/48/1796?source=related_link\">",
"      Patient information: Meningitis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/43/3763?source=related_link\">",
"      Patient information: Meningitis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/7/18547?source=related_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/34/28194?source=related_link\">",
"      Patient information: Viral meningitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_1_31763="Erythema multiforme arm";
var content_f31_1_31763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72055&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous plaques with dusky centers are present on the arms of this patient with erythema multiforme.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31763=[""].join("\n");
var outline_f31_1_31763=null;
var title_f31_1_31764="Pulmonary LAM microscopy Low";
var content_f31_1_31764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66775%7EPULM%2F77252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66775%7EPULM%2F77252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microscopic features of lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low magnification photomicrograph showing a portion of a cystic space in lymphangioleiomyomatosis. The periphery of the cystic space consists of alveolar septa and peribronchiolar interstitium that has been expanded by a population of spindle cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microscopic features of lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High magnification photomicrograph showing the abnormal spindle cells that characterize lymphangioleiomyomatosis. The proliferating spindle cells have many characteristics of modified smooth muscles cells and frequently stain for smooth muscle-associated intermediate filaments using immunohistochemistry.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31764=[""].join("\n");
var outline_f31_1_31764=null;
var title_f31_1_31765="Zuclopenthixol: Patient drug information";
var content_f31_1_31765=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Zuclopenthixol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/19/10551?source=see_link\">",
"     see \"Zuclopenthixol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F236396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Clopixol-Acuphase&reg;;",
"     </li>",
"     <li>",
"      Clopixol&reg;;",
"     </li>",
"     <li>",
"      Clopixol&reg; Depot",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3528243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called Neuroleptic malignant syndrome (NMS) may happen. Call your doctor right away if you have any fever, muscle cramps or stiffness, dizziness, very bad headache, confusion, change in thinking, fast heartbeat, heartbeat that does not feel normal, or are sweating a lot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia. It may take 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703154",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to zuclopenthixol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Brain problem or drink too much alcohol.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12020 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-425BDFC11D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31765=[""].join("\n");
var outline_f31_1_31765=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236396\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011184\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011186\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011185\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011190\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011191\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011193\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011188\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011189\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011194\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011195\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/19/10551?source=related_link\">",
"      Zuclopenthixol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_1_31766="Angina treatment — medical therapy";
var content_f31_1_31766=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Angina treatment ��������� medical therapy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/1/31766/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/1/31766/contributors\" id=\"au6237\">",
"       Julian M Aroesty, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/1/31766/contributors\" id=\"au4742\">",
"       Joseph P Kannam, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/1/31766/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/1/31766/contributors\" id=\"se4323\">",
"       Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/1/31766/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/1/31766/contributors\" id=\"de1101\">",
"       Gordon M Saperia, MD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/1/31766?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ANGINA TREATMENT OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Chest pain that originates from the heart muscle is called angina pectoris. Angina is a signal that the heart muscle is not getting sufficient blood flow, specifically sufficient oxygen. Lack of oxygen is termed ischemia. Blood flow is most often reduced by coronary artery disease (CAD), which causes a narrowing of the arteries that carry blood to the heart muscle (",
"     <a class=\"graphic graphic_figure graphicRef78029 \" href=\"mobipreview.htm?36/60/37826\">",
"      figure 1",
"     </a>",
"     ). Narrowing in the coronary arteries occurs as a result of calcium and fatty deposits, called plaques. In more severe cases, heart attack (myocardial infarction), heart failure, or rhythm abnormalities can cause sudden cardiac death.",
"    </p>",
"    <p>",
"     Angina may be provoked by an activity or exercise or any other physical or mental stress, which increases the heart's demand for blood. Angina can be \"stable\" or \"unstable\". Angina is unstable when there is a change in the usual pattern, such as a change in frequency, occurrence with less exertion, or occurrence at rest. Unstable angina, which may or may not be associated with damage to the heart muscle (or heart attack), is called",
"     <strong>",
"      acute coronary syndrome",
"     </strong>",
"     and requires immediate evaluation in a hospital. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=see_link\">",
"      \"Patient information: Chest pain (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A number of articles about coronary artery disease are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=see_link\">",
"      \"Patient information: Chest pain (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/10/43170?source=see_link\">",
"      \"Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=see_link\">",
"      \"Patient information: Aspirin and cardiovascular disease (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=see_link\">",
"      \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"      \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHICH TREATMENT IS RIGHT FOR ME?",
"     </span>",
"    </p>",
"    <p>",
"     All treatments for coronary heart disease have the same goals: to improve quality of life and relieve symptoms, particularly angina. The medicines used to treat coronary heart disease and angina reduce the risk of dying for many people with these conditions.",
"    </p>",
"    <p>",
"     The choice between taking a medicine and having a surgery to open narrowed or blocked blood vessels depends upon a number of individual factors. These are discussed in detail separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/10/43170?source=see_link\">",
"      \"Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"      \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      MEDICINES FOR STABLE ANGINA",
"     </span>",
"    </p>",
"    <p>",
"     There are currently four types of medicines used to treat stable angina:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Nitrates",
"      </li>",
"      <li>",
"       Beta blockers",
"      </li>",
"      <li>",
"       Calcium channel blockers",
"      </li>",
"      <li>",
"       Ranolazine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Nitrates or beta blockers are usually preferred for initial treatment of angina, and calcium channel blockers may be added if needed. The number and type of medicines used are often tailored to how frequently angina occurs in an average week.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       One or fewer &mdash; People who have one or fewer angina episodes per week are usually advised to take sublingual (under the tongue) nitroglycerin when an episode of angina occurs and immediately before activities that could cause angina. (See",
"       <a class=\"local\" href=\"#H4\">",
"        'Nitrates'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Two or more &mdash; People who have two or more angina episodes per week are usually advised to take longer-acting antianginal medicines. This may include a long-acting nitrate or a beta blocker.",
"      </li>",
"      <li>",
"       Treatment with added medicines &mdash; If angina persists while taking one medicine, a second medicine may be added. Combined treatment may relieve angina more effectively than a single medicine.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If angina persists on two medicines, a third medicine or coronary angiography may be recommended. Angiography can help determine how severe coronary artery disease is and if a stent or bypass surgery is needed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      NITRATES",
"     </span>",
"    </p>",
"    <p>",
"     Nitrates improve blood flow by relaxing and dilating (expanding) veins and arteries, including the coronary arteries. They reduce the amount of blood returning to the heart. Several different nitrate preparations are available.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Sublingual nitroglycerin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sublingual (under the tongue) nitroglycerin (NTG) is usually recommended to treat sudden attacks of angina and to prevent angina while engaging in activities that typically trigger angina, such as mowing the lawn, playing sports, or walking up a hill (especially in the cold).",
"    </p>",
"    <p>",
"     Sublingual NTG is a small pill that is placed under the tongue where it rapidly dissolves and is absorbed. The membranes underneath the tongue must be moist to facilitate this process, so a drink of water is recommended to moisten a dry mouth. Sublingual NTG becomes effective within two to five minutes and its effects last 15 to 30 minutes. There is no risk of explosion with NTG pills.",
"    </p>",
"    <p>",
"     For people with frequent angina, a physician may recommend repeating the dose of NTG for a total of two or three doses every five minutes before calling 911. If chest pain lasts more than five minutes after taking up to three NTG pills,",
"     <strong>",
"      call 911 immediately",
"     </strong>",
"     , unless a different plan has been discussed with a physician. The emergency medical services (EMS) personnel in your community will respond as rapidly as possible, and will take you to the nearest hospital.",
"    </p>",
"    <p>",
"     It is very important to store NTG pills properly since they are sensitive to light, moisture, and heat. Most pills should be stored in a dark, tightly capped bottle in the refrigerator; you should carry a small number with you at all times. You should renew your sublingual NTG prescriptions every three to six months and discard any tablets that crumble easily. NTG pills that are still effective cause a mild tingling sensation when placed under the tongue.",
"    </p>",
"    <p>",
"     Sublingual NTG is also available in a spray form. This spray is less popular than the pill form, although it is equally effective; it has a shelf life of two to three years and does not require refrigeration.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Oral nitrates",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oral nitrates have a longer-lasting effect than sublingual NTG, and are equally effective in controlling angina on a chronic basis. Oral nitrates are available in two forms: isosorbide dinitrate (ISDN) and isosorbide-5-mononitrate (ISMN).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Isosorbide dinitrate",
"     </span>",
"     &nbsp;&mdash;&nbsp;ISDN, often taken two or three times per day, begins acting within 15 to 30 minutes and lasts for three to six hours. ISDN allows you to exercise for up to eight hours. The body tends to develop a tolerance (decreased sensitivity) to ISDN when it is used continuously over 24 hours, but a carefully planned dose schedule may prevent this problem. (See",
"     <a class=\"local\" href=\"#H10\">",
"      'Nitrates and tolerance'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Isosorbide-5-mononitrate",
"     </span>",
"     &nbsp;&mdash;&nbsp;ISMN usually begins acting within 30 minutes and its effects last six to eight hours. The body tends to develop a tolerance (decreased sensitivity) to ISMN when it is used continuously over 24 hours. A carefully planned dose schedule and use of extended release forms of ISMN may prevent this problem. The extended release form of ISMN is taken only once per day.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Transdermal nitroglycerin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Transdermal NTG (NTG patch) is a convenient type of long-lasting nitrate treatment. These patches deliver a constant dose of NTG.",
"    </p>",
"    <p>",
"     Transdermal NTG begins acting within 30 minutes and its effects last for 8 to 14 hours. Wearing a patch continuously leads to tolerance, so patches must be removed each day to allow for a \"nitrate-free\" interval. Since most people experience angina with activity, the patch is usually applied in the morning and removed in the evening. In contrast, people who have nocturnal (nighttime) angina should apply the patches at night and remove them in the morning.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Nitrates and tolerance",
"     </span>",
"     &nbsp;&mdash;&nbsp;Continuous nitrate treatment leads to tolerance of the drug within 24 to 48 hours; at this time, normal doses of nitrates are no longer effective. Tolerance is a problem with long-acting nitrates (oral and transdermal nitrates), which is why a nitrate-free interval is necessary. Nitrate tolerance does not usually develop with sublingual NTG.",
"    </p>",
"    <p>",
"     The best way to avoid tolerance is to use long-acting nitrates intermittently, by scheduling 8-hour to 12-hour nitrate-free breaks, frequently done during periods of sleep. Some people notice that angina worsens during this nitrate-free period, which is a phenomenon called rebound angina. This can be treated by increasing the dose of other drugs. Several medications and antioxidant vitamins are being evaluated for their ability to prevent nitrate tolerance; however, they are still investigational and they are not yet widely available.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Timing of nitrates",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have stress or exertional angina (angina during activity or exercise) are usually advised to take nitrates during the day, whereas people with nighttime angina or heart failure are usually advised to take nitrates in the evening. Nitrates may alleviate certain nighttime symptoms of heart failure, such as shortness of breath when lying down or waking up breathless in the middle of the night.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effects of nitrates are headache, lightheadedness, flushing, and an increase in heart rate. Elderly people are often susceptible to lightheadedness and should be especially careful in hot weather. Alcohol may also worsen dizziness and lightheadedness.",
"    </p>",
"    <p>",
"     Nitrates can also cause a decrease in blood pressure and may cause some people to faint (especially when other medications that lower blood pressure are being used or the patient is dehydrated). Paradoxically, nitrates can worsen angina in some people. These side effects tend to improve over time, but it is still important to discuss any side effects you are having with your healthcare provider.",
"    </p>",
"    <p>",
"     The combination of nitrates and medications for erectile dysfunction (eg, Viagra&reg;, Cialis&reg;, Levitra&reg;) is particularly hazardous. Erectile dysfunction medications",
"     <strong>",
"      must be avoided",
"     </strong>",
"     while taking a nitrate medication (short or long-acting). If you take nitrates and are considering treatment for erectile dysfunction, speak with your healthcare provider. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/33/29205?source=see_link\">",
"      \"Patient information: Sexual problems in men (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      BETA BLOCKERS",
"     </span>",
"    </p>",
"    <p>",
"     Beta blockers reduce the heart rate, blood pressure, and the force of the heart's contractions, thereby decreasing the amount of oxygen the heart requires to pump blood. Along with nitrates, beta blockers are usually the first choice for the treatment of stable angina, and are particularly beneficial in people who have angina during exercise or activity.",
"    </p>",
"    <p>",
"     Another important benefit of beta blockers is that they improve survival and prevent another heart attack in people who have suffered a recent heart attack.",
"    </p>",
"    <p>",
"     Most beta blockers are available as long-acting preparation that is taken once per day.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Classes",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are different types of beta blockers and, although all are equally effective in the treatment of angina, there are settings in which one type is more or less desirable.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Nonselective beta blockers (such as propranolol) block",
"       <strong>",
"        all",
"       </strong>",
"       types of beta receptors throughout the body and are therefore more likely to cause side effects. As a general rule, these drugs should not be used in patients who have asthma since they may block the effect of adrenaline in the lungs, possibly causing an asthma attack.",
"      </li>",
"      <li>",
"       At low doses, cardioselective beta blockers (such as atenolol and metoprolol) selectively block the beta receptors found in the heart and are less likely to cause side effects. These medications may be better than nonselective beta blockers for people with obstructive lung disease, asthma, poor circulation, diabetes, and depression. However, at the high doses often needed to control angina, these medications lose their selectivity and may also block other types of beta receptors throughout the body, producing more side effects.",
"      </li>",
"      <li>",
"       Some beta blockers (such as acebutolol and pindolol) are less likely to depress cardiac function or cause a slow resting heart rate and may be a better choice for people who have specific cardiac conditions or are more sensitive to the effects of beta blockers.",
"      </li>",
"      <li>",
"       Some beta blockers (such as labetalol or carvedilol) also block alpha receptors, which are another type of receptor found in the blood vessels. These medications have the added benefit of dilating blood vessels.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people notice only mild side effects when taking beta blockers. However, all classes of beta blockers can cause side effects. Most of the side effects are directly related to their beta blocking action; these side effects may be cardiac (those that affect the heart)",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     noncardiac (those that affect other systems). Other side effects are unrelated to the beta blocking action.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Cardiac effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The cardiac benefits of beta blockers in angina limit their use in people with certain heart conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Heart failure &mdash; Beta blockers can worsen heart failure in a small percentage of people with preexisting damage of the heart muscle (decompensated heart failure). However, careful therapy with beta blockers is still recommended due to the benefit of improved survival.",
"      </li>",
"      <li>",
"       Slowing of the heart rate &mdash; Beta blockers slow the resting heart rate and are therefore must be used cautiously or avoided in people who have a slow baseline heart rate and those who take other medications that slow the heart rate.",
"      </li>",
"      <li>",
"       Beta blocker withdrawal &mdash; People who abruptly stop taking beta blockers may experience a dangerous withdrawal syndrome that can lead to worsening of angina, heart attack, and death. Side effects after abrupt withdrawal are most likely to occur in people who take short-acting beta blockers at a high dose and are less likely to occur in people who take long-acting beta blockers at a low dose. It is very important to talk to a healthcare provider before stopping a beta blocker.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Noncardiac effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most of the more common side effects of beta blockers occur when these medications block beta receptors throughout the body.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Constriction of airways &mdash; Beta blockers can block receptors in the lung, preventing the airways from relaxing and making it difficult to breathe. Therefore, many beta blockers are not recommended for people with lung disease.",
"      </li>",
"      <li>",
"       Circulatory problems &mdash; Beta blockers may worsen symptoms in people who have poor circulation in their extremities or pain in their legs with walking. Beta blockers with stimulatory effects and cardioselective beta blockers used at low doses are less likely to have this effect. People who have vascular spasm (Raynaud phenomenon) may find their problem while using a beta blocker. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/49/30481?source=see_link\">",
"        \"Patient information: Raynaud phenomenon (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Impotence &mdash; Beta blockers can cause impotence in men. This side effect occurs in more than 10 percent of men, although the frequency varies with the beta blocker used. However, it is safe to take beta blockers in combination with medications for erectile dysfunction (eg, Viagra&reg;, Cialis&reg;, Levitra&reg;) as long as the person does not also take a nitrate.",
"      </li>",
"      <li>",
"       Central nervous system effects &mdash; Beta blockers can cause dreams, hallucinations, insomnia, and fatigue. These side effects may be more common in older people.",
"      </li>",
"      <li>",
"       Worsening of angina &mdash; Beta blockers can promote arterial spasm and may actually worsen angina in people with variant angina (angina caused by spasm). This is an uncommon problem.",
"      </li>",
"      <li>",
"       Drug interactions &mdash; Beta blockers can interact with certain other cardiac drugs, including calcium channel blockers and some drugs used to treat arrhythmias (irregular heart beat).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      CALCIUM CHANNEL BLOCKERS",
"     </span>",
"    </p>",
"    <p>",
"     Calcium channel blockers dilate arteries and lower blood pressure, which decreases the force of the heart's contractions. They also dilate veins, reducing the amount of blood returning to the heart, which reduces the workload of the heart. Some calcium channel blockers slow the heart rate, which also reduces the work of the heart.",
"    </p>",
"    <p>",
"     Nitrates or beta blockers are usually recommended first for people with stable angina. Calcium channel blockers are an alternative if there are side effects or other conditions that limit the use of beta blockers and nitrates. Calcium channel blockers may also be used if nitrates and beta blockers do not control angina when used in combination.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Dihydropyridines",
"     </span>",
"     &nbsp;&mdash;&nbsp;The dihydropyridine calcium channel blockers include amlodipine, felodipine, nifedipine, nicardipine, and nitrendipine. These work to dilate blood vessels; this effect is greater for dihydropyridines than for other classes of calcium channel blockers. They also slightly decrease the strength of the heart's contractions. Dihydropyridines have little effect on the conduction of electrical impulses in the heart.",
"    </p>",
"    <p>",
"     Although dihydropyridines are effective for the treatment of angina, some may not be as effective as beta blockers.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Side effects &mdash; The side effects of the dihydropyridines are related to their powerful dilation of blood vessels. These effects occur in up to 20 percent of people and include flushing, dizziness and lightheadedness, headache, and peripheral edema (swelling of the feet and ankles). This type of edema cannot be relieved with diuretics. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"        \"Patient information: Edema (swelling) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Verapamil",
"     </span>",
"     &nbsp;&mdash;&nbsp;Verapamil slows the heart's conduction of electrical impulses, decreases the force of the heart's contractions, and dilates blood vessels. Although it is less effective than beta blockers for slowing the heart rate, it is a safe and effective alternative; the choice between beta blockers and calcium channel blockers depends upon individual factors. Verapamil is effective for variant (vasospastic) angina. Verapamil is available in sustained release form, which is taken once per day.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Side effects &mdash; Constipation is the major side effect of verapamil, occurring in over 25 percent of people taking the medication. Other side effects are similar to those occurring with the dihydropyridines, although peripheral edema (swelling of the extremities) is uncommon.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Depression of cardiac function is a concern with verapamil. Verapamil decreases the force of the heart's contractions and slows its conduction of electrical impulses. These effects can produce a pronounced slowing of heart rate, heart block (impaired electrical conduction in the heart), and worsening of heart failure. Verapamil must be used cautiously or avoided in people with cardiac conditions such as sick sinus syndrome and atrioventricular block. It is generally not used in combination with beta blockers.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Diltiazem",
"     </span>",
"     &nbsp;&mdash;&nbsp;The effects of diltiazem lie between those of the dihydropyridines and those of verapamil, neither markedly dilating blood vessels nor markedly depressing cardiac function. Diltiazem dilates blood vessels (especially coronary arteries), decreases the heart's force of contraction, and slows the heart's conduction of electrical impulses.",
"    </p>",
"    <p>",
"     Diltiazem is not as effective as beta blockers in the treatment of stable angina, but may be preferable because it causes fewer side effects. Diltiazem is available in sustained release form that is taken once per day.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Side effects &mdash; When compared to dihydropyridines and verapamil, diltiazem has a lower frequency of side effects and has a more balanced effect, neither markedly dilating blood vessels nor markedly depressing cardiac function.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Combined treatment with beta blockers",
"     </span>",
"     &nbsp;&mdash;&nbsp;The dihydropyridines and, in some cases, diltiazem can be used in combination with beta blockers for better control of angina. Verapamil, however, is usually not combined with beta blockers because combining the two drugs can markedly slow the heart rate. The selection of a specific combination of medications depends upon individual factors.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Beta blockers versus calcium channel blockers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beta blockers are more effective than calcium channel blockers for reducing the frequency of angina, but similar in terms of improving exercise tolerance and decreasing the need for NTG. However, people taking calcium channel blockers, especially nifedipine, are much more likely to stop taking the medication because of side effects.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16331735\">",
"     <span class=\"h1\">",
"      RANOLZAINE",
"     </span>",
"    </p>",
"    <p>",
"     Ranolazine is the most recent addition to the medical treatment of angina. It has a complicated mechanism of action. Patients on a combination of beta blockers, calcium channel blockers, or nitrates who continue with angina, may benefit from the addition of ranolazine. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39513?source=see_link&amp;anchor=H3#H3\">",
"      \"New therapies for angina pectoris\", section on 'Ranolazine'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      ASPIRIN",
"     </span>",
"    </p>",
"    <p>",
"     Narrowed coronary arteries often develop a blood clot before a heart attack. Aspirin helps to prevent blood clotting, keeping these narrowed arteries open and lowering the risk of a heart attack. Healthcare providers often recommend daily aspirin for people with stable angina. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=see_link\">",
"      \"Patient information: Aspirin and cardiovascular disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      OTHER MEASURES TO SLOW OR REVERSE CAD",
"     </span>",
"    </p>",
"    <p>",
"     Regardless of whether medical or interventional therapy is chosen, it is very important that people with coronary artery disease follow guidelines to reduce the risk that their heart disease will worsen. These guidelines, which should be discussed with a healthcare provider, include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Treat high blood pressure (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"        \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Treat high cholesterol (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"        \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Quit smoking (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"        \"Patient information: Quitting smoking (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Lose excess weight (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=see_link\">",
"        \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Reduce stress",
"      </li>",
"      <li>",
"       Exercise regularly (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/42/7844?source=see_link\">",
"        \"Patient information: Exercise (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Avoid or minimize activities that provoke angina, such as exercising during cold weather or exercising vigorously, particularly after a meal",
"      </li>",
"      <li>",
"       Learn to use nitroglycerin preventively",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287567663\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12678317\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/34/21027?source=see_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=see_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/27/21940?source=see_link\">",
"      Patient information: Medicines after a heart attack (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/35/1587?source=see_link\">",
"      Patient information: Medicines for angina (chest pain) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/24/39298?source=see_link\">",
"      Patient information: Angioplasty and stenting for the heart (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/14/30946?source=see_link\">",
"      Patient information: Treatment choices for angina (chest pain) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12678355\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=see_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/10/43170?source=see_link\">",
"      Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/54/40803?source=see_link\">",
"      Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/62/31717?source=see_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/33/29205?source=see_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/49/30481?source=see_link\">",
"      Patient information: Raynaud phenomenon (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/53/32594?source=see_link\">",
"      Patient information: Edema (swelling) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=see_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/42/7844?source=see_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30679?source=see_link\">",
"      Beta blockers in the management of stable angina pectoris",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31576?source=see_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/37/9816?source=see_link\">",
"      Calcium channel blockers in the management of stable angina pectoris",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5802?source=see_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19864?source=see_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=see_link\">",
"      Coronary heart disease and myocardial infarction in young men and women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34042?source=see_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26634?source=see_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11658?source=see_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/20/44361?source=see_link\">",
"      Epidemiology of coronary heart disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=see_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/51/9018?source=see_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/29/2521?source=see_link\">",
"      Nitrates in the management of stable angina pectoris",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=see_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15144?source=see_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41769?source=see_link\">",
"      Prognosis after myocardial infarction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26521?source=see_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/58/2986?source=see_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/1/31766/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2010.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/1/31766?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31766/abstract/1\">",
"      Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31766/abstract/2\">",
"      Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31766/abstract/3\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007) www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31766/abstract/5\">",
"      Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet 1993; 341:573.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f31_1_31766=[""].join("\n");
var outline_f31_1_31766=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ANGINA TREATMENT OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHICH TREATMENT IS RIGHT FOR ME?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           MEDICINES FOR STABLE ANGINA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           NITRATES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           BETA BLOCKERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           CALCIUM CHANNEL BLOCKERS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16331735\">",
"           RANOLZAINE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           ASPIRIN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           OTHER MEASURES TO SLOW OR REVERSE CAD",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/60/37826\" title=\"figure 1\">",
"           Angina PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f31_1_31767="Treatment and prevention of parvovirus B19 infection";
var content_f31_1_31767=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of parvovirus B19 infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/1/31767/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/1/31767/contributors\">",
"     Jeanne A Jordan, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/1/31767/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/1/31767/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/1/31767/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/1/31767/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/1/31767/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/1/31767/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human parvovirus B19 infections are common. They are usually mild or asymptomatic, and do not require treatment. In some cases, however, infection is associated with sufficiently severe complications that treatment is indicated and may be lifesaving.",
"   </p>",
"   <p>",
"    The major clinical manifestations that can occur with B19 infection include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Erythema infectiosum",
"     </li>",
"     <li>",
"      Arthritis or arthralgia",
"     </li>",
"     <li>",
"      Transient aplastic crisis",
"     </li>",
"     <li>",
"      Fetal hydrops",
"     </li>",
"     <li>",
"      Chronic infection with or without anemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major issues related to the treatment of symptomatic B19 infection and to prevention of infection will be reviewed here. The clinical syndromes, diagnosis, and management of parvovirus B19 infection in pregnancy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32312?source=see_link\">",
"     \"Epidemiology and laboratory diagnosis of parvovirus B19 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40408?source=see_link\">",
"     \"Parvovirus B19 infection during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific antiviral drug available for the treatment of parvovirus B19 infection. Management of symptomatic B19 infection varies with the clinical manifestation (",
"    <a class=\"graphic graphic_table graphicRef50679 \" href=\"mobipreview.htm?10/42/10923\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Erythema infectiosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema infectiosum (\"fifth\" disease) is a self-limited, mild illness most often occurring in children. There is no specific therapy and usually no indication for symptomatic treatment. In some patients, symptomatic therapy for arthralgias, arthritis, or pruritus may be indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Arthritis or arthralgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis or arthralgia are most often reported in adult females, but can occur in either gender and at any age. The joint symptoms usually last one to two weeks, but can persist for weeks, months, and even years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=see_link&amp;anchor=H5#H5\">",
"     \"Specific viruses that cause arthritis\", section on 'Parvovirus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonsteroidal antiinflammatory drugs can provide symptomatic relief. Intravenous immune (IVIG) has been given to two patients with presumed chronic B19 infection and chronic arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/4\">",
"     4",
"    </a>",
"    ]. The arthritis was not cured but there may have been a short-term decrease in symptoms. These limited data do not support the use of IVIG treatment for B19-associated arthropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transient aplastic crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute parvovirus B19 is a cause of transient aplastic crisis (TAC), which is usually manifest as pure red cell aplasia but can also affect the other hematopoietic cell lines. B19 replicates in and destroys proerythroblasts, and bone marrow examination reveals characteristic giant proerythroblasts containing viral inclusions.",
"   </p>",
"   <p>",
"    TAC most often occurs when B19 infection develops in patients with underlying hematologic abnormalities such as sickle cell disease, thalassemia, and hereditary spherocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The interruption of red cell production in this setting can rapidly lead to a severe anemia. In a longitudinal study of 308 patients with homozygous sickle cell (SS) disease, 91 of 114 (80 percent) patients who were infected with B19 developed TAC; B19 accounted for all of the cases of aplasia seen in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/5\">",
"     5",
"    </a>",
"    ]. The remaining 23 patients had slight or no hematologic changes. No patient had a second episode of either B19 infection or aplasia. In a similar study, 280 patients with SS disease were followed from birth. By the age of 20 years, 70 percent of patients showed evidence of seroconversion to B19, with 118 (67 percent) demonstrating aplastic crisis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anemia is often sufficiently severe (hemoglobin levels below 6",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    with few or no reticulocytes) to require transfusion until the patient's immune response eliminates the infection and red cell production returns. In a series of 62 SS patients with TAC, 54 (87 percent) required blood transfusions, 39 (63 percent) were hospitalized, and one (1.6 percent) died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/6\">",
"     6",
"    </a>",
"    ]. The one death illustrates the importance of prompt diagnosis and treatment with transfusion therapy if indicated by the patient's condition.",
"   </p>",
"   <p>",
"    The usual course of parvovirus associated-anemia is spontaneous resolution within a few days to weeks. More aggressive therapy with IVIG is generally limited to patients with chronic B19 infection and chronic anemia (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chronic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion described the major clinical manifestations associated with acute B19 infection. Chronic infection also can occur, producing anemia or other signs or symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Chronic infection with anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with chronic B19 infection and anemia have received immunosuppressive therapy for cancer, leukemia, or tissue transplantation, have a congenital immunodeficiency, or have HIV-associated immunodeficiency. Reports of pure red cell aplasia have occurred in HIV-infected patients with advanced immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Most of these reports have occurred prior to the availability of potent antiretroviral therapy (ART).",
"   </p>",
"   <p>",
"    In a retrospective study of 10 patients with pure red cell aplasia and proven B19 infection who were treated with IVIG, anemia resolved in 9 of 10 within a mean of 80 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients received a mean of 2.7 IVIG courses at an average dose of 1.3 &plusmn; 0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per course. The only patient who did not respond to IVIG had underlying myelodysplasia. Among the seven patients with available follow-up blood B19 polymerase chain reaction (PCR) results, five had negative PCR results within a mean of 97 days (range 35 to 159 days). None of the nine responders had a relapse during 12 months of follow-up. In a review of published studies that was part of the same report, hemoglobin level was corrected after the first IVIG course in 124 of 133 patients (93 percent) with pure red cell aplasia caused by B19 infection, but disease relapsed in 42 (34 percent) at a mean of 4.3 months.",
"   </p>",
"   <p>",
"    Patients have been treated with several different IVIG regimens, such as 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of commercial IVIG for 5 or 10 days or 1000",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for 3 days, both with good results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. One HIV-infected patient with chronic B19 infection and anemia apparently responded to treatment with 5 mL of intramuscular immune globulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/12\">",
"     12",
"    </a>",
"    ]. Most literature that exists on treating anemia in B19-infected individuals describes treatment schedules for those individuals who are coinfected with HIV. Suggested treatments for HIV-infected individuals with pure red cell aplasia related to B19 coinfection have included regimens of IVIG with 1 to 2",
"    <span class=\"nowrap\">",
"     grams/kg/day",
"    </span>",
"    for two to five days. Relapses in these patients have been successfully treated with maintenance IVIG at doses of 0.4",
"    <span class=\"nowrap\">",
"     grams/kg/day",
"    </span>",
"    every four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence of anemia and reappearance or increases in B19 DNA in serum have usually responded to additional courses of IVIG treatment. Furthermore, if the immunodeficiency improves (eg, after discontinuation of immunosuppressive therapy or with the initiation of antiretroviral therapy for HIV), chronic infection and anemia may resolve spontaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Chronic infection without anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic B19 infection has been demonstrated in patients without anemia or underlying immunodeficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. It is not clear if IVIG treatment is helpful in this setting. One such patient with thrombocytopenia received IVIG without an obvious response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/14\">",
"     14",
"    </a>",
"    ], while two patients with presumed chronic infection and arthritis had no virologic but possibly a transient clinical response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/4\">",
"     4",
"    </a>",
"    ]. In comparison, three patients with systemic vasculitis had an apparent clinical and virologic response after IVIG therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/13\">",
"     13",
"    </a>",
"    ]. Further study is needed to determine the role of IVIG in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92115240\">",
"    <span class=\"h2\">",
"     Fetal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of fetal anemia and hydrops secondary to parvovirus B19 infection is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40408?source=see_link&amp;anchor=H21#H21\">",
"     \"Parvovirus B19 infection during pregnancy\", section on 'Management of anemia and hydrops'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best measures currently available to prevent B19 infection are those designed to interrupt transmission by good infection control practices. Immunoprophylactic therapy has been considered in some instances, but insufficient data are available to determine if it is efficacious.",
"   </p>",
"   <p>",
"    Studies of candidate vaccines against parvovirus B19 have been hindered by potential side effects. A recombinant human parvovirus B19 vaccine, composed of the VP1 and VP2 capsid proteins was evaluated in a randomized, double-blind, phase 1 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/16\">",
"     16",
"    </a>",
"    ]. The vaccine was given to 24 seronegative adults in a series of three doses over six months. The vaccine was found to be safe and highly immunogenic. However, a National Institute of Allergy and Infectious Diseases (NIAID)-initiated phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trial to assess the safety and immunogenicity of a recombinant B19-parvovirus vaccine was suspended due to vaccine-associated adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/17\">",
"     17",
"    </a>",
"    ]. A separate trial of a viral-like particle vaccine was also halted early because of unexplained and unusual skin manifestations in two vaccine and one placebo recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mode of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual mode of transmission of B19 infection in the community is not known. B19 spreads efficiently in households [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/19\">",
"     19",
"    </a>",
"    ] but often takes months to spread through schools [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. These observations suggest that transmission usually involves close contact, eg, person-to-person, fomites,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    large droplets. The relatively high efficiency of transmission in households but low efficiency in schools argues against aerosol transmission. Patients with normal immune systems appear to be infectious before but not after the onset of B19-associated rash, arthralgias, or arthritis.",
"   </p>",
"   <p>",
"    B19 has consistently been found in respiratory secretions during the viremic phase of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ], suggesting that respiratory tract secretions are likely to be an important source of infectious virus. The respiratory tract is also likely to be one site where virus can gain entry and cause infection; in one report, for example, human volunteers were successfully infected by the intranasal route of inoculation of B19 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to their non-enveloped virion capsid, parvoviruses, including B19, are stable in the environment, making fomites a likely and important source for transmission. B19 DNA was detected on surfaces in a room two hours after a B19-infected hydropic abortus was delivered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    B19 has frequently been detected in blood specimens of patients shortly before and shortly after the onset of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/19,22,24,25\">",
"     19,22,24,25",
"    </a>",
"    ], and blood or blood products have been implicated in transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/26\">",
"     26",
"    </a>",
"    ]. B19 has also been detected in urine, but urine has not yet been shown to be involved in transmission of the virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Risk of infection after different exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Household transmission appears to be especially efficient with about 50 percent of susceptible subjects becoming infected after household exposure to erythema infectiosum or TAC in several outbreaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. The risk of transmission in schools or child care centers is also significant. In one outbreak, approximately 20 percent of susceptible staff were infected but this varied from 8 to 50 percent depending upon the intensity of the exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many infections occur with no clearly defined exposure, especially during community outbreaks. During one outbreak, the risk of infection without a clearly defined exposure was 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/28\">",
"     28",
"    </a>",
"    ]. Other studies found that 0.5 percent to 1.5 percent of women without a specific exposure or defined community outbreak became infected during one year or during their pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nosocomial transmission of B19 can occur from patient-to-patient, patient-to-staff, staff-to-patient, and staff-to-staff. In one study, for example, transmission from two patients with TAC was noted in 4 of 11 (36 percent) and 8 of 19 (42 percent) susceptible contacts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/31\">",
"     31",
"    </a>",
"    ]. In several other reports, no source for infection was identified, but transmission apparently occurred between staff and patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, other series did not find nosocomial transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/23,34\">",
"     23,34",
"    </a>",
"    ]; in these studies, the rate of infection in exposed or at-risk staff was similar to unexposed staff",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    community controls. It is therefore likely that many cases of presumed nosocomial transmission may actually represent infection acquired in the community during outbreaks of B19.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Infected blood products",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, individuals infected with B19 can be viremic during the acute and often asymptomatic phase of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/19,22,24,25\">",
"     19,22,24,25",
"    </a>",
"    ]. If these otherwise healthy, asymptomatic individuals donate blood it can result in B19-contaminated blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/26\">",
"     26",
"    </a>",
"    ]. The risk of B19 contamination of a single unit of blood is relatively small, between 1 in 200 and 1 in 20,000 units of blood depending upon the detection system. The higher prevalence has been found with polymerase chain reaction (PCR) assays and the lower prevalence with antigen detection assays.",
"   </p>",
"   <p>",
"    Furthermore, since this nonenveloped virus is difficult to inactivate with solvent detergents and its small size makes it difficult to remove, it frequently contaminates multiunit blood products, such as factor VIII or factor IX. In one study, 87 percent of 75 start pools were positive for B19 DNA by a PCR assay despite a variety of purification and inactivation procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/35\">",
"     35",
"    </a>",
"    ]. Contamination was also found in 3 of 12 lots of albumin, 7 of 7 lots of factor VIII, 3 of 15 lots of IVIG, and 3 of 4 lots of intramuscular immune globulin. One patient was reportedly infected after tattooing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Preventing transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention to good infection control practices should reduce the risk of transmitting B19. Studies of rhinoviruses and enteroviruses, which are also spread by person-to-person contact, fomites, and large droplet aerosol and are stable in the environment, suggest that hand washing and not sharing food or drinks is likely to prevent, at least partially, spread of B19 in a variety of settings. One report of B19 infections in a hospital suggested that good hygienic practices by staff may have decreased their risk of acquiring infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/33\">",
"     33",
"    </a>",
"    ]. Staff who reported washing their hands rarely or only occasionally after contact with patients had a higher infection rate (p = 0.07).",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) recommends that patients with TAC be placed on droplet isolation precautions for seven days and that immunodeficient patients with chronic infection be placed on droplet precautions for the duration of their hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/37\">",
"     37",
"    </a>",
"    ]. In comparison, patients with normal immune systems are probably not infectious after the onset of B19-associated rash, arthralgias, or arthritis, when a robust antibody response would take place and dramatically reduce the patient's viral load.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Groups or persons that might benefit from infection control measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good infection control practices in the home, workplace, and hospital should be emphasized to decrease the risk of transmission to persons with compromised immune systems, those with a need for increased production of red cells (eg, SS disease), and pregnant women.",
"   </p>",
"   <p>",
"    The possibility of fetal hydrops and death has generated considerable concern, especially during community outbreaks of B19. As noted above, there is no specific prevention available. Frequently, during B19 outbreaks, supervisors, healthcare workers, pregnant women, and others will ask whether avoiding the workplace or outbreak settings such as schools or child care centers will decrease the risk to the fetus. CDC recommends that pregnant women be informed about the risks of infection and make their own decision after consultation with healthcare workers, public health officials, and family members [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Understanding the risk is essential to making this decision. The primary risk is fetal death, and this risk is given by the following equation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;Rate of fetal death &nbsp;= &nbsp;(rate of susceptibility &nbsp;x &nbsp;rate of infection from the exposure) &nbsp;&divide; &nbsp;(rate of fetal death with infection)",
"   </p>",
"   <p>",
"    Estimates for each of these factors are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women in their childbearing years, between 40 and 60 percent, depending on the community and antibody detection assay used, will test positive for B19 IgG antibodies and are presumably not susceptible to infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/29,39\">",
"       29,39",
"      </a>",
"      ]. IgG antibodies against the VP1-unique region offer lifelong protection against B19 reinfection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of fetal death with maternal infection is less than 10 percent and probably between 2 and 5 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/38,41,42\">",
"       38,41,42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If we assume the risk of fetal death with infection is between 2 and 5 percent and the rate of susceptibility is 50 percent, then the risk of fetal death associated with the following settings can be estimated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Between 0.5 percent and 1.25 percent for a household exposure, assuming a 50 percent infection rate",
"     </li>",
"     <li>",
"      Between 0.2 and 0.5 percent from working in a school with an erythema infectiosum outbreak, assuming a 20 percent infection rate",
"     </li>",
"     <li>",
"      Between 0.06 and 0.15 percent from living in a community with an erythema infectiosum outbreak, assuming a 6 percent infection rate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The available data suggest that B19 uncommonly, if ever, causes congenital anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31767/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/5/13394?source=see_link\">",
"       \"Patient information: Erythema infectiosum (fifth disease) (The Basics )\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parvovirus B19 infections are common, usually mild or asymptomatic, and generally require no or only symptomatic therapy. However, some uncommon severe complications of infection may warrant specific treatment (",
"      <a class=\"graphic graphic_table graphicRef50679 \" href=\"mobipreview.htm?10/42/10923\">",
"       table 1",
"      </a>",
"      ). There is no specific antiviral drug available for the treatment of parvovirus B19 infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Erythema infectiosum'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Arthritis or arthralgia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transient aplastic crisis can occur when B19 infection occurs in patients with underlying hematologic abnormalities, such as sickle cell disease, thalassemia, and hereditary spherocytosis, and causes severe anemia. The anemia is typically severe enough to warrant red blood cell transfusion but usually resolves spontaneously within a few days to weeks. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Transient aplastic crisis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous immune globulin (IVIG) in addition to red blood cell transfusion can be helpful in patients with chronic parvovirus B19 infection and anemia, which generally occurs in patients with immunodeficiency. Chronic infection may also resolve with a decrease in immunosuppression or immune reconstitution, if possible. It is unclear if IVIG is beneficial in the setting of chronic parvovirus B19 infection without anemia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Chronic infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of fetal anemia and hydrops is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40408?source=see_link&amp;anchor=H21#H21\">",
"       \"Parvovirus B19 infection during pregnancy\", section on 'Management of anemia and hydrops'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prevention of parvovirus B19 infection depends on good infection control practices targeted towards the various modes of transmission. As parvovirus B19 is likely spread in the community through close contact (eg, person to person, through fomites, or through large droplets), hand washing and not sharing food or drink is likely to help prevent spread of B19 in a variety of settings. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nosocomial transmission of B19 can occur between patients and staff but can be difficult to distinguish from infection acquired in the community during outbreaks. Droplet precautions are indicated for seven days for patients with transient aplastic crisis and for the duration of the hospitalization for immunodeficient patients with chronic infection. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Preventing transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parvovirus B19 is frequently detected at high viral loads in the blood of patients with acute infection; thus, blood products could be contaminated with the virus when asymptomatic but infected individuals donate blood. Because its size and lack of envelope make the virus difficult to remove from blood or inactivate, transfusion-related infection is possible and difficult to prevent. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Infected blood products'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Good hygiene and infection control practices should be emphasized for patients with compromised immune systems, those with underlying hematologic abnormalities, and pregnant women. Because of the risk of fetal death in the setting of maternal infection, pregnant women should understand the risk of infection during parvovirus B19 outbreaks or exposures. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Groups or persons that might benefit from infection control measures'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40408?source=see_link\">",
"       \"Parvovirus B19 infection during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/1\">",
"      Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/2\">",
"      Naides SJ, Scharosch LL, Foto F, Howard EJ. Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience. Arthritis Rheum 1990; 33:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/3\">",
"      Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/4\">",
"      Saag KG, True CA, Naides SJ. Intravenous immunoglobulin treatment of chronic parvovirus B19 arthropathy. Arthritis Rheum 1993; 36(Suppl):S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/5\">",
"      Serjeant GR, Serjeant BE, Thomas PW, et al. Human parvovirus infection in homozygous sickle cell disease. Lancet 1993; 341:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/6\">",
"      Goldstein AR, Anderson MJ, Serjeant GR. Parvovirus associated aplastic crisis in homozygous sickle cell disease. Arch Dis Child 1987; 62:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/7\">",
"      Serjeant BE, Hambleton IR, Kerr S, et al. Haematological response to parvovirus B19 infection in homozygous sickle-cell disease. Lancet 2001; 358:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/8\">",
"      Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990; 113:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/9\">",
"      Koduri PR. Parvovirus B19-related anemia in HIV-infected patients. AIDS Patient Care STDS 2000; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/10\">",
"      Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis 2013; 56:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/11\">",
"      Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/12\">",
"      Naides SJ, Howard EJ, Swack NS, et al. Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy. J Infect Dis 1993; 168:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/13\">",
"      Finkel TH, T&ouml;r&ouml;k TJ, Ferguson PJ, et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 1994; 343:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/14\">",
"      Oeda E, Shinohara K, Inoue H, Nomiyama J. Parvovirus B19 infection causing severe peripheral blood thrombocytopenia and persistent viremia. Am J Hematol 1994; 45:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/15\">",
"      Kerr JR, Curran MD, Moore JE, et al. Persistent parvovirus B19 infection. Lancet 1995; 345:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/16\">",
"      Ballou WR, Reed JL, Noble W, et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003; 187:675.",
"     </a>",
"    </li>",
"    <li>",
"     B-19 parvovirus vaccine study by clinical trials. file://clinicaltrialsfeed.org/clinical-trials/show/NCT00379938 (Accessed on August 07, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/18\">",
"      Bernstein DI, El Sahly HM, Keitel WA, et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine 2011; 29:7357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/19\">",
"      Chorba T, Coccia P, Holman RC, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis 1986; 154:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/20\">",
"      Gillespie SM, Cartter ML, Asch S, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990; 263:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/21\">",
"      Plummer FA, Hammond GW, Forward K, et al. An erythema infectiosum-like illness caused by human parvovirus infection. N Engl J Med 1985; 313:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/22\">",
"      Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/23\">",
"      Dowell SF, T&ouml;r&ouml;k TJ, Thorp JA, et al. Parvovirus B19 infection in hospital workers: community or hospital acquisition? J Infect Dis 1995; 172:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/24\">",
"      Erdman DD, Usher MJ, Tsou C, et al. Human parvovirus B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum. J Med Virol 1991; 35:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/25\">",
"      Saarinen UM, Chorba TL, Tattersall P, et al. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood 1986; 67:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/26\">",
"      Zanella A, Rossi F, Cesana C, et al. Transfusion-transmitted human parvovirus B19 infection in a thalassemic patient. Transfusion 1995; 35:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/27\">",
"      Christensen LS, Madsen TV, Barfod T. Persistent erythrovirus B19 urinary tract infection in an HIV-positive patient. Clin Microbiol Infect 2001; 7:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/28\">",
"      Cartter ML, Farley TA, Rosengren S, et al. Occupational risk factors for infection with parvovirus B19 among pregnant women. J Infect Dis 1991; 163:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/29\">",
"      Koch WC, Adler SP. Human parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J 1989; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/30\">",
"      Gay NJ, Hesketh LM, Cohen BJ, et al. Age specific antibody prevalence to parvovirus B19: how many women are infected in pregnancy? Commun Dis Rep CDR Rev 1994; 4:R104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/31\">",
"      Bell LM, Naides SJ, Stoffman P, et al. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med 1989; 321:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/32\">",
"      Harrison J, Jones CE. Human parvovirus B19 infection in healthcare workers. Occup Med (Lond) 1995; 45:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/33\">",
"      Seng C, Watkins P, Morse D, et al. Parvovirus B19 outbreak on an adult ward. Epidemiol Infect 1994; 113:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/34\">",
"      Ray SM, Erdman DD, Berschling JD, et al. Nosocomial exposure to parvovirus B19: low risk of transmission to healthcare workers. Infect Control Hosp Epidemiol 1997; 18:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/35\">",
"      Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996; 93:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/36\">",
"      Shneerson JM, Mortimer PP, Vandervelde EM. Febrile illness due to a parvovirus. Br Med J 1980; 280:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/37\">",
"      Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/38\">",
"      Centers for Disease Control (CDC). Risks associated with human parvovirus B19 infection. MMWR Morb Mortal Wkly Rep 1989; 38:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/39\">",
"      Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988; 25:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/40\">",
"      Zuffi E, Manaresi E, Gallinella G, et al. Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol 2001; 14:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/41\">",
"      Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. BMJ 1990; 300:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31767/abstract/42\">",
"      Kerr JR, O'Neill HJ, Coyle PV, Thompson W. An outbreak of parvovirus B19 infection; a study of clinical manifestations and the incidence of fetal loss. Ir J Med Sci 1994; 163:65.",
"     </a>",
"    </li>",
"    <li>",
"     Adler SP, Koch WC. Human parvovirus infections. In: Infectious Diseases of the Fetus and Newborn Infant, 6th Ed, Remington JS, Klein JO, Wilson CB, Baker CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.867.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8330 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-B2700F0D78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31767=[""].join("\n");
var outline_f31_1_31767=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Erythema infectiosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Arthritis or arthralgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transient aplastic crisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chronic infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Chronic infection with anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Chronic infection without anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92115240\">",
"      Fetal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mode of transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk of infection after different exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Infected blood products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Preventing transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Groups or persons that might benefit from infection control measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8330\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8330|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/42/10923\" title=\"table 1\">",
"      Treatment of parvovirus B19",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32312?source=related_link\">",
"      Epidemiology and laboratory diagnosis of parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40408?source=related_link\">",
"      Parvovirus B19 infection during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/5/13394?source=related_link\">",
"      Patient information: Erythema infectiosum (fifth disease) (The Basics )",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_1_31768="Triamcinolone (systemic): Drug information";
var content_f31_1_31768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triamcinolone (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/49/5910?source=see_link\">",
"    see \"Triamcinolone (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/11/27831?source=see_link\">",
"    see \"Triamcinolone (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15387300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Fungal Meningitis Outbreak Associated with Contaminated Injectables",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For information regarding the recent meningitis outbreak from products compounded by the New England Compounding Center (NECC), including treatment recommendations, please refer to the following websites:",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       <a href=\"file://www.cdc.gov/hai/outbreaks/meningitis.html\" target=\"_blank\">",
"        file://www.cdc.gov/hai/outbreaks/meningitis.html",
"       </a>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm285497.htm\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm285497.htm",
"       </a>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm323947.htm?source=govdelivery\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm323947.htm?source=govdelivery",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9606510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aristospan&reg;;",
"     </li>",
"     <li>",
"      Kenalog&reg;-10;",
"     </li>",
"     <li>",
"      Kenalog&reg;-40",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9606511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aristospan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9606878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Systemic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9606702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The lowest possible dose should be used to control the condition; when dose reduction is possible, the dose should be reduced gradually.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dermatoses (steroid-responsive, including contact/atopic dermatitis):",
"     </b>",
"     Injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acetonide: Intradermal: Initial: 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hexacetonide: Intralesional, sublesional: Up to 0.5 mg/square inch of affected skin; range: 2-48 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hay fever/pollen asthma:",
"     </b>",
"     I.M.: 40-100 mg as a single injection/season",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple sclerosis (acute exacerbation):",
"     </b>",
"     I.M.: 160 mg daily for 1 week, followed by 64 mg every other day for 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatic or arthritic disorders:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intra-articular (or similar injection as designated):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Acetonide: Intra-articular, intrabursal, tendon sheaths: Initial: Smaller joints: 2.5-5 mg, larger joints: 5-15 mg; may require up to 10 mg for small joints and up to 40 mg for large joints; maximum dose/treatment (several joints at one time): 20-80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hexacetonide: Intra-articular: Average dose: 2-20 mg; smaller joints: 2-6 mg; larger joints: 10-20 mg. Frequency of injection into a single joint is every 3-4 weeks as necessary; to avoid possible joint destruction use as infrequently as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Acetonide: Range: 2.5-100 mg/day; Initial: 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Triamcinolone Dosing",
"     </caption>",
"     <col width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"110\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Acetonide",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hexacetonide",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         Intrasynovial",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-40 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         Intralesional",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-30 mg (usually 1 mg per injection site); 10 mg/mL suspension usually used",
"        </p>",
"       </td>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Up to 0.5 mg/sq inch affected area",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         Sublesional",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-30 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         Systemic I.M.",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-60 mg/dose (usual adult dose: 60 mg; may repeat with 20-100 mg dose when symptoms recur)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         Intra-articular",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-40 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-20 mg average",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:2em;\">",
"         large joints",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-15 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10-20 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:2em;\">",
"         small joints",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-5 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-6 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         Tendon sheaths",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-10 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         Intradermal",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 mg/site",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9606701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/11/27831?source=see_link\">",
"      see \"Triamcinolone (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Rheumatic conditions:",
"     </b>",
"     <i>",
"      I.M. (acetonide):",
"     </i>",
"     Range: 2.5-100 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Initial: 0.11-1.6 mg/kg/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-12 years: Initial: 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9606703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9606831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension, as acetonide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kenalog&reg;-10: 10 mg/mL (5 mL) [contains benzyl alcohol, polysorbate 80;",
"     <b>",
"      not",
"     </b>",
"     for I.V., I.M., intraocular, epidural, or intrathecal use]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kenalog&reg;-40: 40 mg/mL (1 mL, 5 mL, 10 mL) [contains benzyl alcohol, polysorbate 80;",
"     <b>",
"      not",
"     </b>",
"     for I.V., intradermal, intraocular, epidural, or intrathecal use]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension, as hexacetonide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aristospan&reg;: 5 mg/mL (5 mL); 20 mg/mL (1 mL, 5 mL) [contains benzyl alcohol, polysorbate 80;",
"     <b>",
"      not",
"     </b>",
"     for I.V. use]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9606532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9606737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Shake well before use to ensure suspension is uniform. Inspect visually to ensure no clumping; administer immediately after withdrawal so settling does not occur in the syringe. Do",
"     <b>",
"      not",
"     </b>",
"     administer any product I.V. or via the epidural or intrathecal route.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aristospan&reg; (20 mg/mL concentration): For intra-articular and soft tissue administration only; a &ge;23-gauge needle is preferred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aristospan&reg; (5 mg/mL concentration): For intralesional or sublesional administration only; a &ge;23-gauge needle is preferred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kenalog&reg;-10 injection: For intra-articular or intralesional administration only. When administered intralesionally, inject directly into the lesion (ie, intradermally or subcutaneously). Tuberculin syringes with a 23- to 25-gauge needle are preferable for intralesional injections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kenalog&reg;-40 injection:  For intra-articular, soft tissue or I.M. administration. When administered I.M., inject deep into the gluteal muscle using a minimum needle length of 1",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inches for adults. Obese patients may require a longer needle. Alternate sites for subsequent injections.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9606533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intra-articular (soft tissue): Acute gouty arthritis, acute/subacute bursitis, acute tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intralesional: Alopecia areata, discoid lupus erythematosus, keloids, granuloma annulare lesions (localized hypertrophic, infiltrated, or inflammatory), lichen planus plaques, lichen simplex chronicus plaques, psoriatic plaques, necrobiosis lipoidica diabeticorum, cystic tumors of aponeurosis or tendon (ganglia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Systemic: Adrenocortical insufficiency, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic and neoplastic disorders, nervous system disorders, nephrotic syndrome, rheumatic disorders, allergic states, respiratory diseases, systemic lupus erythematosus (SLE), and other diseases requiring anti-inflammatory or immunosuppressive effects",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9606492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kenalog&reg; may be confused with Ketalar&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       TAC (occasional abbreviation for triamcinolone) is an error-prone abbreviation (mistaken as tetracaine-adrenaline-cocaine)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9606576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined; reactions reported with corticosteroid therapy in general:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, cardiac arrest, cardiac enlargement, CHF, circulatory collapse, edema, hypertension, hypertrophic cardiomyopathy (premature infants), myocardial rupture (following recent MI), syncope, tachycardia, thromboembolism, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Arachnoiditis (I.T.), depression, emotional instability, euphoria, headache, insomnia, intracranial pressure increased, malaise, meningitis (I.T.), mood changes, neuritis, neuropathy, personality change, pseudotumor cerebri (with discontinuation), seizure, spinal cord infarction, stroke, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Abscess (sterile), acne, allergic dermatitis, angioedema, atrophy (cutaneous/subcutaneous), bruising, dry skin, erythema, hair thinning, hirsutism, hyper-/hypopigmentation, hypertrichosis, impaired wound healing, lupus erythematosus-like lesions, petechiae, purpura, rash, skin test suppression, striae, thin skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Carbohydrate intolerance, Cushingoid state, diabetes mellitus, fluid retention, glucose intolerance, growth suppression (children), hypokalemia, hypokalemic alkalosis, menstrual irregularities, negative nitrogen balance, sodium retention, sperm motility altered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, appetite increased, GI hemorrhage, GI perforation, nausea, pancreatitis, peptic ulcer, ulcerative esophagitis, weight gain",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Hepatomegaly, liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Aseptic necrosis of femoral and humeral heads, calcinosis, Charcot-like arthropathy, fractures, joint tissue damage, muscle mass loss, myopathy, osteoporosis, parasthesia, paraplegia, quadriplegia, tendon rupture, vertebral compression fractures, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ocular: Cataracts, cortical blindness, exophthalmos, glaucoma, ocular pressure increased, papilledema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Renal: Glycosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Abnormal fat deposits, anaphylactoid reaction, anaphylaxis, diaphoresis, hiccups, infection, moon face",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9606539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to triamcinolone or any component of the formulation; systemic fungal infections; cerebral malaria; idiopathic thrombocytopenic purpura (I.M. injection)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9606540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head injury: Increased mortality was observed in patients receiving high-dose I.V. methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex, cerebral malaria, or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment). Use with caution in patients with threadworm infection; may cause serious hyperinfection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy: Acute myopathy has been reported with high-dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with HF or hypertension; long-term use has been associated with fluid retention and hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head injury: Increased mortality was observed in patients receiving high-dose I.V. methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred, especially during initial treatment with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarct (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention and hypertension may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis: Restrict corticosteroid use to fulminating or disseminated tuberculosis; must be used in conjunction with appropriate tuberculosis regimen. Monitor closely in patients with latent tuberculosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Patients should not be immunized with live, viral vaccines while receiving immunosuppressive doses of corticosteroids. The ability to respond to dead viral vaccines is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: Benzyl alcohol: Some injection suspension formulations contain benzyl alcohol; benzyl alcohol has been associated with the \"gasping syndrome\" in neonates and low-birth-weight infants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration: Administer products only via recommended route (depending on product used). Do",
"     <b>",
"      not",
"     </b>",
"     administer any triamcinolone product via the epidural or intrathecal route; serious adverse events, including fatalities, have been reported following epidural or intrathecal administration of corticosteroids.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9606603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May enhance the adverse/toxic effect of Triamcinolone (Systemic). Specifically, risks of developing iatrogenic Cushing syndrome and secondary adrenal insufficiency may be increased. Ritonavir may increase the serum concentration of Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9887154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9606535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Triamcinolone was shown to be teratogenic in animal reproduction studies. Some studies have shown an association between first trimester corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9606537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9606538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticosteroids are excreted in human milk; information specific to triamcinolone has not been located.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9606736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate intake of calcium and vitamins (or consider supplementation) in patients on medium-to-high doses of systemic corticosteroids.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Aristospan Intra-Articular Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (1 mL): $12.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Aristospan Intralesional Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (5 mL): $21.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Kenalog Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (5 mL): $13.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (5 mL): $52.07",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adcortyl (GB, IE);",
"     </li>",
"     <li>",
"      Aftach (HK, TW);",
"     </li>",
"     <li>",
"      Albicort (BE);",
"     </li>",
"     <li>",
"      Amcicort (TW);",
"     </li>",
"     <li>",
"      Amtocort (ID);",
"     </li>",
"     <li>",
"      Arcocort (GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Aristospan Injection (NZ);",
"     </li>",
"     <li>",
"      Avcort (IN);",
"     </li>",
"     <li>",
"      Azmacort (BR, NZ, PK);",
"     </li>",
"     <li>",
"      Corticord (TW);",
"     </li>",
"     <li>",
"      Delphicort (DE);",
"     </li>",
"     <li>",
"      Flamicort (ID);",
"     </li>",
"     <li>",
"      Fortcinolona (AR);",
"     </li>",
"     <li>",
"      Hexatrione (FR);",
"     </li>",
"     <li>",
"      Ioncort (UY);",
"     </li>",
"     <li>",
"      Kanalone-F (MY);",
"     </li>",
"     <li>",
"      Kenacort (AE, AR, BH, CH, ET, FR, ID, IL, IN, IQ, IT, JO, KE, KW, LB, LY, NL, OM, PK, QA, SA, SY, TW, TZ, UG, UY, VE, YE);",
"     </li>",
"     <li>",
"      Kenacort A (AR, BE, CH, CN, NL);",
"     </li>",
"     <li>",
"      Kenacort Retard (FR);",
"     </li>",
"     <li>",
"      Kenacort T (FI, NO, SE);",
"     </li>",
"     <li>",
"      Kenacort-A (AU, CL, NZ, PE, UY);",
"     </li>",
"     <li>",
"      Kenafrent (PE);",
"     </li>",
"     <li>",
"      Kenalog (DK, EE, GB, IE);",
"     </li>",
"     <li>",
"      Ledercort (IN, IT, KP);",
"     </li>",
"     <li>",
"      Lederlon (DE);",
"     </li>",
"     <li>",
"      Lederspan (AT, CY, DK, EG, FI, IR, NO, SE);",
"     </li>",
"     <li>",
"      Rheudenolone (KP);",
"     </li>",
"     <li>",
"      Shincort (HK, MY, PH, SG, TH);",
"     </li>",
"     <li>",
"      Simacort (TH);",
"     </li>",
"     <li>",
"      Tracinone (KP);",
"     </li>",
"     <li>",
"      Triam (KP);",
"     </li>",
"     <li>",
"      Triam-Denk (HK);",
"     </li>",
"     <li>",
"      Triamcort Depot (CH);",
"     </li>",
"     <li>",
"      Triancil (BR);",
"     </li>",
"     <li>",
"      Tricort (TW);",
"     </li>",
"     <li>",
"      Trilac (ID);",
"     </li>",
"     <li>",
"      V-Nolone (TH);",
"     </li>",
"     <li>",
"      Volon (DE);",
"     </li>",
"     <li>",
"      Volon A (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9606642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; suppresses the immune system by reducing activity and volume of the lymphatic system; suppresses adrenal function at high doses",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9606644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 99.5 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~68%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biologic: 18-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: I.M.: 8-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~40%); feces (~60%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abraham E and Evans T, &ldquo;Corticosteroids and Septic Shock [editorial],&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(7):886-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/12186608/pubmed\" id=\"12186608\" target=\"_blank\">",
"        12186608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       American Academy of Orthopaedic Surgeons Clinical Practice Guidelines on the Treatment Of Osteoarthritis Of The Knee (Non-Arthroplasty)",
"      </i>",
"      . Rosemont (IL): American Academy of Orthopaedic Surgeons (AAOS); 2008. Available at file://www.aaos.org/research/guidelines/oakguideline.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs: &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Annane D, Sebille V, Charpentier C, et al, &ldquo;Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(7):862-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/12186604/pubmed\" id=\"12186604\" target=\"_blank\">",
"        12186604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper MS and Stewart PM, &ldquo;Corticosteroid Insufficiency in Acutely Ill Patients,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(8):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/12594318/pubmed\" id=\"12594318\" target=\"_blank\">",
"        12594318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coursin DB and Wood KE, &ldquo;Corticosteroid Supplementation for Adrenal Insufficiency,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 287(2):236-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/11779267/pubmed\" id=\"11779267\" target=\"_blank\">",
"        11779267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Jonghe B, Sharshar T, Lefaucheur JP, et al, &ldquo;Paresis Acquired in the Intensive Care Unit. A Prospective Multicenter Study,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(22):2859-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/12472328/pubmed\" id=\"12472328\" target=\"_blank\">",
"        12472328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frey BM and Frey FJ, &ldquo;Clinical Pharmacokinetics of Prednisone and Prednisolone,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 19(2):126-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/2199128/pubmed\" id=\"2199128\" target=\"_blank\">",
"        2199128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gutin PH, &ldquo;Corticosteroid Therapy in Patients With Brain Tumors,&rdquo;",
"      <i>",
"       Natl Cancer Inst Monogr",
"      </i>",
"      , 1977, 46:151-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/349394/pubmed\" id=\"349394\" target=\"_blank\">",
"        349394",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hotchkiss RS and Karl IE, &ldquo;The Pathophysiology and Treatment of Sepsis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(2):138-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/12519925/pubmed\" id=\"12519925\" target=\"_blank\">",
"        12519925",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kimberly RP, &ldquo;Glucocorticoids,&rdquo;",
"      <i>",
"       Curr Opin Rheumatol",
"      </i>",
"      , 1994, 6(3):273-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/8060761/pubmed\" id=\"8060761\" target=\"_blank\">",
"        8060761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liggins GC and Howie RN, &ldquo;A Controlled Trial of Antepartum Glucocorticoid Treatment of Respiratory Distress Syndrome in Premature Infants,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1972, 50:515-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/4561295/pubmed\" id=\"4561295\" target=\"_blank\">",
"        4561295",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGee S and Hirschmann J, &ldquo;Use of Corticosteroids in Treating Infectious Diseases,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2008, 168(10):1034-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/18504331/pubmed\" id=\"18504331\" target=\"_blank\">",
"        18504331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ostensen M, &ldquo;Optimisation of Antirheumatic Drug Treatment in Pregnancy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 27(6):486-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/7882637/pubmed\" id=\"7882637\" target=\"_blank\">",
"        7882637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo;",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(12):968-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/14745915/pubmed\" id=\"14745915\" target=\"_blank\">",
"        14745915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians, &ldquo;Consensus Statement on Management and Audit Potential for Steroid Responsive Nephrotic Syndrome,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1994, 70(2):151-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/8129444/pubmed\" id=\"8129444\" target=\"_blank\">",
"        8129444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salem M, Tainsh RE Jr, Bromberg J, et al, &ldquo;Perioperative Glucocorticoid Coverage. A Reassessment 42 Years After Emergence of a Problem,&rdquo;",
"      <i>",
"       Ann Surg",
"      </i>",
"      , 1994, 219(4):416-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31768/abstract-text/8161268/pubmed\" id=\"8161268\" target=\"_blank\">",
"        8161268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9962 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31768=[""].join("\n");
var outline_f31_1_31768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15387300\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606510\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606511\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606878\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606702\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606701\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606703\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606831\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606532\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606737\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606533\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606492\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606576\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606539\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606540\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300167\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606603\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887154\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606535\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606537\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606538\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606736\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322547\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390240\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606642\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606644\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9962\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9962|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5637?source=related_link\">",
"      Triamcinolone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/10/16548?source=related_link\">",
"      Triamcinolone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/56/16260?source=related_link\">",
"      Triamcinolone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/55/8052?source=related_link\">",
"      Triamcinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/31/19955?source=related_link\">",
"      Triamcinolone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/36/16963?source=related_link\">",
"      Triamcinolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/49/5910?source=related_link\">",
"      Triamcinolone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/11/27831?source=related_link\">",
"      Triamcinolone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/30/32229?source=related_link\">",
"      Triamcinolone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/46/36580?source=related_link\">",
"      Triamcinolone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/10/14500?source=related_link\">",
"      Triamcinolone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_1_31769="Gemcitabine: Drug information";
var content_f31_1_31769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gemcitabine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/42/677?source=see_link\">",
"    see \"Gemcitabine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/37/27223?source=see_link\">",
"    see \"Gemcitabine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gemzar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F175344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gemcitabine For Injection, USP;",
"     </li>",
"     <li>",
"      Gemzar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F175384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Pyrimidine Analog)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F175347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note",
"     </b>",
"     : Prolongation of the infusion time &gt;60 minutes and administration more frequently than once weekly have been shown to increase toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Pancreatic cancer, locally advanced or metastatic:",
"     </b>",
"     I.V.: Initial: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes once weekly for up to 7 weeks followed by 1 week rest; then once weekly for 3 weeks out of every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Dose escalation:",
"     </i>",
"     Patients who complete an entire cycle of therapy may have the dose in subsequent cycles increased by 25% as long as the absolute granulocyte count (AGC) nadir is &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelet nadir is &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , and nonhematologic toxicity is less than WHO Grade 1. If the increased dose is tolerated (with the same parameters) the dose in subsequent cycles may again be increased by 20%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pancreatic cancer, advanced (unlabeled dosing/combinations):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes weekly for up to 7 weeks followed by 1 week rest; then weekly for 3 weeks out of every 4 weeks (in combination with erlotinib) (Moore, 2007)",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1, 8, and 15 every 4 weeks (in combination with capecitabine) (Cunningham, 2009)",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1 and 15 every 4 weeks (in combination with cisplatin) (Heinemann, 2006)",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     infused at 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /minute every 2 weeks (in combination with oxaliplatin) (Louvet, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer, locally advanced or metastatic (in combination with cisplatin):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1, 8,  and 15; repeat cycle every 28 days",
"     <b>",
"      or",
"     </b>",
"     1250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1 and 8; repeat cycle every 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, metastatic (AGC should be &ge;1500/mm",
"      <sup>",
"       3",
"      </sup>",
"      and platelets &ge;100,000/mm",
"      <sup>",
"       3",
"      </sup>",
"      prior to each cycle):",
"     </b>",
"     I.V.: 1250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with paclitaxel)",
"     <b>",
"      or",
"     </b>",
"     (unlabeled dosing) as a single agent: 800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1, 8, and 15 of a 28-day treatment cycle (Carmichael, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer, advanced (AGC should be &ge;1500/mm",
"      <sup>",
"       3",
"      </sup>",
"      and platelets &ge;100,000/mm",
"      <sup>",
"       3",
"      </sup>",
"      prior to each cycle):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with carboplatin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Biliary tract cancer, advanced (unlabeled use):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with cisplatin) (Valle, 2010)",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with capecitabine) (Knox, 2005)",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     infused at 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /minute over 100 minutes every 2 weeks (in combination with oxaliplatin) (Andre, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bladder cancer (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Advanced or metastatic:",
"     </i>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30-60 minutes days 1, 8, and 15; repeat cycle every 4 weeks (in combination with cisplatin) (von der Maase, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transitional cell carcinoma:",
"     </i>",
"     Intravesicular instillation: 2000 mg (in 100 mL NS; retain for 1 hour) twice weekly for 3 weeks; repeat cycle every 4 weeks for at least 2 cycles (Dalbagni, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cervical cancer, recurrent or persistent (unlabeled use):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 8; repeat cycle every 21 days (in combination with cisplatin) (Monk, 2009)",
"     <b>",
"      or",
"     </b>",
"     1250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with cisplatin) (Burnett, 2000)",
"     <b>",
"      or",
"     </b>",
"     800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1, 8, and 15; repeat cycle every 28 days (as a single-agent) (Schilder, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Head and neck cancer, nasopharyngeal (unlabeled use):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1, 8, and 15 every 4 weeks (Zhang, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma, relapsed (unlabeled use):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     for post-transplant patients) over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with vinorelbine and doxorubicin liposomal) (Bartlett, 2007)",
"     <b>",
"      or",
"     </b>",
"     800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 4; repeat cycle every 21 days (in combination with ifosfamide, mesna, vinorelbine, and prednisolone) (Santoro, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malignant pleural mesothelioma (unlabeled use; in combination with cisplatin):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1, 8 and 15 every 4 weeks for up to 6 cycles (Nowak, 2002)",
"     <b>",
"      or",
"     </b>",
"     1250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1 and 8 every 3 weeks for up to 6 cycles (van Haarst, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Non-Hodgkin lymphoma, refractory (unlabeled use):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1 and 8; repeat cycle every 21 days (in combination with cisplatin and dexamethasone) (Crump, 2004)",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 15-21days (in combination with oxaliplatin and rituximab) (Lopez, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sarcoma (unlabeled uses):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Ewing&rsquo;s sarcoma, refractory:",
"     </i>",
"     675 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (Navid, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Osteosarcoma, refractory:",
"     </i>",
"     675 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (Navid, 2008)",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly for 7 weeks followed by 1 week rest; then weekly for 3 weeks out of every 4 weeks (Merimsky, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Soft tissue sarcoma, advanced:",
"     </i>",
"     I.V.: 800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with vinorelbine) (Dileo, 2007)",
"     <b>",
"      or",
"     </b>",
"     675 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (Leu, 2004)",
"     <b>",
"      or",
"     </b>",
"     900 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (Maki, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Small cell lung cancer, refractory or relapsed (unlabeled use):",
"     </b>",
"     I.V.: 1000-1250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1, 8, and 15 every 4 weeks (as a single agent) (Masters, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Testicular cancer, refractory germ cell (unlabeled use):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1 and 8 every 3 weeks (in combination with oxaliplatin) (Kohllmannsberger, 2004; Pectasides, 2004)",
"     <b>",
"      or",
"     </b>",
"     1250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1 and 8 every 3 weeks (in combination with oxaliplatin) (De Giorgi, 2006)",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes  days 1, 8 and 15 every 4 weeks for up to 6 cycles (in combination with paclitaxel) (Hinton, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Unknown-primary, adenocarcinoma (unlabeled use):",
"     </b>",
"     I.V.: 1250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 8 every 3 weeks (in combination with cisplatin) (Culine, 2003)",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1 and 8 every 3 weeks (in combination with docetaxel) for up to 6 cycles (Pouessel, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uterine cancer (unlabeled use):",
"     </b>",
"     I.V.: 900 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes days 1 and 8 every 3 weeks (in combination with docetaxel) (Hensley, 2008)",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1, 8, and 15 every 4 weeks (Look, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10927324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/37/27223?source=see_link\">",
"      see \"Gemcitabine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note",
"     </b>",
"     : Prolongation of the infusion time &gt;60 minutes and administration more frequently than once weekly have been shown to increase toxicity. Refer to specific references for ages of populations studied):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Germ cell tumor, refractory (unlabeled use):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 30 minutes days 1, 8, and 15 every 4 weeks (in combination with paclitaxel) for up to 6 cycles (Hinton, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma, relapsed (unlabeled use):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 100 minutes days 1 and 8; repeat cycle every 21 days (in combination with vinorelbine) (Cole; 2009)",
"     <b>",
"      or",
"     </b>",
"     800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 4; repeat cycle every 21 days (in combination with ifosfamide, mesna, vinorelbine, and prednisolone) (Santoro, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Sarcomas (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Ewing&rsquo;s sarcoma, refractory: 675 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (Navid, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Osteosarcoma, refractory: 675 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes days 1 and 8; repeat cycle every 21 days (in combination with docetaxel) (Navid, 2008)",
"     <b>",
"      or",
"     </b>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly for 7 weeks followed by 1 week rest; then weekly for 3 weeks out of every 4 weeks (Merimsky, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F175348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F175349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The FDA-approved labeling does not contain dosing adjustment guidelines; use with caution in patients with pre-existing renal dysfunction. Discontinue if severe renal toxicity or hemolytic uremic syndrome (HUS) occur during gemcitabine treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Mild-to-severe renal impairment: No adjustment required (Janus, 2010; Li, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     ESRD (on hemodialysis): Hemodialysis should begin 6-12 hours after gemcitabine infusion (Janus 2010; Li, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F175350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The FDA-approved labeling does not contain dosing adjustment guidelines; use with caution. Discontinue if severe hepatotoxicity occurs during treatment with gemcitabine. The following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Transaminases elevated (with normal bilirubin): No adjustment required (Venook, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Serum bilirubin &gt;1.6 mg/dL: Use initial dose of 800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; may escalate if tolerated (Ecklund, 2005; Floyd, 2006; Venook, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F175385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pancreatic cancer:",
"     </b>",
"     Hematologic toxicity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AGC &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelet count &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 100% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AGC 500-999/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelet count 50,000-99,999/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 75% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AGC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic toxicity: Refer to guidelines for pancreatic cancer. Cisplatin dosage may also need adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe (grades 3 or 4) nonhematologic toxicity (except alopecia, nausea, and vomiting): Hold or decrease dose by 50%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic toxicity: Adjustments based on granulocyte and platelet counts on day 8:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC &ge;1200/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelet count &gt;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 100% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC 1000-1199/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelet count 50,000-75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 75% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC 700-999/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelet count &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 50% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC &lt;700/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe (grades 3 or 4) nonhematologic toxicity (except alopecia, nausea, and vomiting): Hold or decrease dose by 50%. Paclitaxel dose may also need adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic toxicity: Adjustments based on granulocyte and platelet counts on day 8:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelet count &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 100% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC 1000-1499/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or platelet count 75,000-99,999/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Administer 50% of full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or platelet count &lt;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Hold dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe (grades 3 or 4) nonhematologic toxicity (except nausea and vomiting): Hold or decrease dose by 50%. Carboplatin dose may also need adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dose adjustment for subsequent cycles:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AGC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &gt;5 days, AGC &lt;100/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &gt;3 days, febrile neutropenia, platelet count &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , cycle delay &gt;1 week due to toxicity: Reduce gemcitabine to 800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 8.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For recurrence of any of the above toxicities after initial dose reduction: Administer gemcitabine 800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 only for the subsequent cycle",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F175320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 200 mg, 1 g, 2 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gemzar&reg;: 200 mg, 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 38 mg/mL (5.26 mL, 26.3 mL, 52.6 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F175305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F175324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infuse over 30 minutes; for unlabeled uses, infusion times may vary (refer to specific references).",
"     <b>",
"      Note:",
"     </b>",
"     Prolongation of the infusion time &gt;60 minutes has been shown to increase toxicity. Gemcitabine has been administered at a fixed-dose rate (FDR) infusion rate of 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /minute (unlabeled); prolonged infusion times increase the accumulation of the active metabolite, gemcitabine triphosphate, optimizing the pharmacokinetics (Ko, 2006; Tempero, 2003). Patients who receive gemcitabine FDR experience more grade 3/4 hematologic toxicity (Ko, 2006; Poplin, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For intravesicular (bladder) instillation, gemcitabine was diluted in 50-100 mL normal saline; patients were instructed to retain in the bladder for 1 hour (Addeo, 2010; Dalbaghi, 2006)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F175390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, anidulafungin, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cefazolin, cefotetan, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, cisplatin, clindamycin, cyclophosphamide, cytarabine, dactinomycin, daunorubicin HCl, dexamethasone sodium phosphate, dexrazoxane, diphenhydramine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin HCl, doxycycline, droperidol, enalaprilat, etoposide, etoposide phosphate, famotidine, floxuridine, fluconazole, fludarabine, fluorouracil, gallium nitrate, gentamicin, granisetron, haloperidol, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, idarubicin, ifosfamide, leucovorin calcium, linezolid, lorazepam, mannitol, meperidine, mesna, metoclopramide, metronidazole, minocycline, mitoxantrone, morphine, nalbuphine, ondansetron, oxaliplatin, paclitaxel, palonosetron, potassium chloride, promethazine, ranitidine, sodium bicarbonate, streptozocin, sulfamethoxazole/trimethoprim, teniposide, thiotepa, ticarcillin/clavulanate, tobramycin, topotecan, vancomycin, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amphotericin B, cefotaxime, furosemide, ganciclovir, imipenem/cilastatin, irinotecan, methotrexate, methylprednisolone sodium succinate, mitomycin, pemetrexed, piperacillin, piperacillin/tazobactam, prochlorperazine edisylate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F175323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of metastatic breast cancer; inoperable locally-advanced or metastatic nonsmall cell lung cancer (NSCLC); locally advanced or metastatic pancreatic cancer; advanced, relapsed ovarian cancer",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F175380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of biliary tract cancers (advanced), bladder cancer, cervical cancer (recurrent or persistent), Ewing&rsquo;s sarcoma (refractory), head and neck cancer (nasopharyngeal), Hodgkin lymphoma (relapsed), non-Hodgkin lymphomas (refractory), malignant pleural mesothelioma, osteosarcoma (refractory), renal cell cancer (metastatic), small cell lung cancer (refractory or relapsed), soft tissue sarcoma (advanced), testicular cancer (refractory germ cell tumors),  thymic malignancies, uterine sarcoma, and unknown-primary adenocarcinoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F175393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Gemcitabine may be confused with gemtuzumab",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Gemzar&reg; may be confused with Zinecard&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F175382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency of adverse reactions reported for single-agent use of gemcitabine only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (20%), edema (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (38% to 41%), somnolence (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (28% to 30%), alopecia (15% to 16%), pruritus (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (69% to 71%; grade 3: 10% to 13%; grade 4: 1% to 2%), diarrhea (19% to 30%), stomatitis (10% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (68% to 73%; grade 4: 1% to 2%), leukopenia (62% to 64%; grade 4: &le;1%), neutropenia (61% to 63%; grade 4: 6% to 7%), thrombocytopenia (24% to 36%; grade 4: &le;1%), hemorrhage (4% to 17%; grades 3: &le;2%; grade 4: &lt;1%); myelosuppression is the dose-limiting toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (67% to 78%; grade 3: 6% to 12%; grade 4: 2% to 5%), alkaline phosphatase increased (55% to 77%; grade 3: 7% to 16%; grade 4: 2% to 4%), ALT increased (68% to 72%; grade 3: 8% to 10%; grade 4: 1% to 2%), bilirubin increased (13% to 26%; grade 3: 2% to 6%; grade 4: &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Proteinuria (32% to 45%; grades 3/4: &lt;1%), hematuria (23% to 35%; grades 3/4: &lt;1%), BUN increased (15% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (10% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (19%), infection (10% to 16%; grade 3: 1% to 2%; grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased (6% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening; reported with single-agent use or with combination therapy): Acute/adult respiratory distress syndrome, anaphylactoid reaction, arrhythmias, bullous skin eruptions, cellulitis, cerebrovascular accident, CHF, desquamation, fulminant hepatic failure, gangrene, GGT increased, hemolytic uremic syndrome (HUS), hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive liver disease), hepatotoxicity (rare), hyper-/hypotension, interstitial pneumonitis, liver failure, MI, neuropathy, peripheral vasculitis, petechiae, pulmonary edema, pulmonary fibrosis, radiation recall, renal failure, respiratory failure, reversible posterior leukoencephalopathy syndrome (RPLS), sepsis, supraventricular arrhythmia, thrombotic thrombocytopenic purpura",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F175327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gemcitabine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F175309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: May cause bone marrow suppression (leukopenia, thrombocytopenia, and anemia); myelosuppression is generally the dose-limiting toxicity. Monitor blood counts; dosage adjustments are frequently required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fever: May cause fever in the absence of clinical infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolytic uremic syndrome: Hemolytic uremic syndrome (and/or renal failure) has been reported; monitor for evidence of microangiopathic hemolysis (elevation of bilirubin or LDH, reticulocytosis, severe thrombocytopenia, and/or renal failure).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Serious hepatotoxicity (including liver failure and death) has been reported (when alone or used in combination with other hepatotoxic medications); use with caution in patients with hepatic impairment (history of cirrhosis, hepatitis, or alcoholism) or in patients with hepatic metastases; may lead to exacerbation of hepatic impairment. Dose adjustments may be considered with elevated bilirubin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: Pulmonary toxicity has been observed; discontinue if severe and institute supportive measures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with pre-existing renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; clearance is affected by age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiation therapy recipients: Use with caution with concurrent radiation therapy; radiation toxicity, including tissue injury, severe mucositis, esophagitis, or pneumonitis, has been reported with concurrent and nonconcurrent administration; has radiosensitizing activity when gemcitabine and radiation therapy are given together or &le;7 days apart; lower doses with concurrent radiation therapy may produce less severe toxicity; however, an optimum regimen for combination therapy has not been determined for all tumor types. Radiation recall may occur when gemcitabine and radiation therapy are given &gt;7 days apart.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion time/frequency: Prolongation of the infusion time &gt;60 minutes and more frequent than weekly dosing have been shown to increase toxicity. Has been administered at a fixed-dose rate (FDR) infusion rate of 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /minute in studies (unlabeled); prolonged infusion times increase the accumulation of the active metabolite, gemcitabine triphosphate, optimizing the pharmacokinetics (Ko, 2006; Tempero, 2003). Patients who receive gemcitabine FDR experience more grade 3/4 hematologic toxicity (Ko, 2006; Poplin, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F175314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bleomycin: Gemcitabine may enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): Gemcitabine may increase the serum concentration of Fluorouracil (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Topical): Gemcitabine may increase the serum concentration of Fluorouracil (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F175339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F175316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F175329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxicity and fetal malformations (cleft palate, incomplete ossification, fused pulmonary artery, absence of gallbladder) have been reported in animal studies. There are no adequate and well-controlled studies in pregnant women. If patient becomes pregnant, she should be informed of risks. May cause fetal harm if administered during pregnancy; adverse effects in reproduction are anticipated based on the mechanism of action.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F175356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10927284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Gemcitabine HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/26.3 mL (26.3 mL): $53.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g/52.6 mL (52.6 mL): $119.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/5.26 mL (5.26 mL): $10.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Gemcitabine HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $175.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $119.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (1): $115.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Gemzar Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $889.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (1): $177.83",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F175318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     CBC with differential and platelet count (prior to each dose); hepatic and renal function (prior to initiation of therapy and periodically, thereafter); monitor electrolytes, including potassium, magnesium, and calcium (when in combination therapy with cisplatin)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F175330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abine (AR);",
"     </li>",
"     <li>",
"      Cytogem (ID);",
"     </li>",
"     <li>",
"      DBL (TW);",
"     </li>",
"     <li>",
"      Dhacibine (MY);",
"     </li>",
"     <li>",
"      Gembine (KP);",
"     </li>",
"     <li>",
"      Gemcibine (KP);",
"     </li>",
"     <li>",
"      Gemcit (PE, PH, TH);",
"     </li>",
"     <li>",
"      Gemcite (IN);",
"     </li>",
"     <li>",
"      Gemflor (TW);",
"     </li>",
"     <li>",
"      Gemita (PH, TH, TW);",
"     </li>",
"     <li>",
"      Gemmis (TW);",
"     </li>",
"     <li>",
"      Gemtavis (ID);",
"     </li>",
"     <li>",
"      Gemtra (KP);",
"     </li>",
"     <li>",
"      Gemtro (AR);",
"     </li>",
"     <li>",
"      Gemzar (AT, AU, BE, BF, BG, BJ, BO, BR, CH, CI, CL, CN, CO, CZ, DE, DK, DO, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HR, HU, ID, IE, IL, IT, KE, KP, LR, LU, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, RU, SC, SD, SE, SG, SK, SL, SN, TH, TN, TR, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Geroam (KP);",
"     </li>",
"     <li>",
"      Gitrabin (HK, SG);",
"     </li>",
"     <li>",
"      Gramagen (TH);",
"     </li>",
"     <li>",
"      Oncoril (PH);",
"     </li>",
"     <li>",
"      Pamigen (CR, EC, GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Zefei (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F175308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A pyrimidine antimetabolite that inhibits DNA synthesis by inhibition of DNA polymerase and ribonucleotide reductase, cell cycle-specific for the S-phase of the cycle (also blocks cellular progression at G1/S-phase). Gemcitabine is phosphorylated intracellularly by deoxycytidine kinase to gemcitabine monophosphate, which is further phosphorylated to active metabolites gemcitabine diphosphate and gemcitabine triphosphate. Gemcitabine diphosphate inhibits DNA synthesis by inhibiting ribonucleotide reductase; gemcitabine triphosphate incorporates into DNA and inhibits DNA polymerase.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F175326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Infusions &lt;70 minutes: 50 L/m",
"     <sup>",
"      2",
"     </sup>",
"     ; Long infusion times (70-285 minutes): 370 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized intracellularly by nucleoside kinases to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleoside metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Gemcitabine: Infusion time &le;70 minutes: 42-94 minutes; infusion time 3-4 hours: 4-10.5 hours (affected by age and gender)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Metabolite (gemcitabine triphosphate), terminal phase: 1.7-19.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 30 minutes after completion of infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (92% to 98%; primarily as inactive uracil metabolite); feces (&lt;1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Addeo R, Caraglia M, Bellini S, et al, &ldquo;Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(4):543-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/19841330/pubmed\" id=\"19841330\" target=\"_blank\">",
"        19841330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Albain KS, Nag SM, Calderillo-Ruiz G, et al, \"Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(24):3950-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/18711184/pubmed\" id=\"18711184\" target=\"_blank\">",
"        18711184",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andre T, Tournigand C, Rosmorduc O, et al, &ldquo;Gemcitabine Combined With Oxaliplatin (GEMOX) in Advanced Biliary Tract Adenocarcinoma: A GERCOR Study,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2004, 15(9):1339-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/15319238 /pubmed\" id=\"15319238 \" target=\"_blank\">",
"        15319238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartlett NL, Niedzwiecki D, Johnson JL, et al, \"Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD), a Salvage Regimen in Relapsed Hodgkin's Lymphoma: CALGB 59804,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2007, 18(6):1071-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/17426059/pubmed\" id=\"17426059\" target=\"_blank\">",
"        17426059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bredenfeld H, Franklin J, Nogova L,  et al, &ldquo;Severe Pulmonary Toxicity in Patients With Advanced-Stage Hodgkin's Disease Treated With a Modified Bleomycin, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, and Gemcitabine (BEACOPP) Regimen is Probably Related to the Combination of Gemcitabine and Bleomycin: A Report of the German Hodgkin's Lymphoma Study Group,&rdquo;",
"      <i>",
"       J Clin Oncol,",
"      </i>",
"      2004, 22(12):2424-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/15136597/pubmed\" id=\"15136597\" target=\"_blank\">",
"        15136597",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burnett AF, Roman LD, Garcia AA, \"A Phase II Study of Gemcitabine and Cisplatin in Patients With Advanced, Persistent, or Recurrent Squamous Cell Carcinoma of the Cervix,\"",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2000, 76(1):63-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/10620443/pubmed\" id=\"10620443\" target=\"_blank\">",
"        10620443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carmichael J, Possinger K, Phillip P, et al, &ldquo;Advanced Breast Cancer: A Phase II Trial With Gemcitabine,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(11):2731-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/7595731/pubmed\" id=\"7595731\" target=\"_blank\">",
"        7595731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cole PD, Schwartz CL, Drachtman RA, et al, \"Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(9):1456-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/19224841/pubmed\" id=\"19224841\" target=\"_blank\">",
"        19224841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Correale P, Cerretani D, Marsili S, et al, &ldquo;Gemcitabine Increases Systemic 5-Fluorouracil Exposure in Advanced Cancer Patients,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2003, 39(11):1547-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/12855261/pubmed\" id=\"12855261\" target=\"_blank\">",
"        12855261",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crump M, Baetz T, Couban S, et al, &ldquo;Gemcitabine, Dexamethasone, and Cisplatin in Patients With Recurrent or Refractory Aggressive Histology B-Cell Non-Hodgkin Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG),&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 101(8):1835-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/15386331/pubmed\" id=\"15386331\" target=\"_blank\">",
"        15386331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Culine S, Lortholary A, Voigt JJ, et al, \"Cisplatin in Combination With Either Gemcitabine or Irinotecan in Carcinomas of Unknown Primary Site: Results of a Randomized Phase II Study - Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01),\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(18):3479-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/12972523/pubmed\" id=\"12972523\" target=\"_blank\">",
"        12972523",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cunningham D, Chau I, Stocken DD, et al, \"Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(33):5513-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/19858379/pubmed\" id=\"19858379\" target=\"_blank\">",
"        19858379",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dalbagni G, Russo P, Bochner B, et al, &ldquo;Phase II Trial of Intravesical Gemcitabine in Bacille Calmette-Guerin-Refractory Transitional Cell Carcinoma of the Bladder,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18):2729-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/16782913/pubmed\" id=\"16782913\" target=\"_blank\">",
"        16782913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Giorgi U, Rosti G, Aieta M, et al, \"Phase II Study of Oxaliplatin and Gemcitabine Salvage Chemotherapy in Patients With Cisplatin-Refractory Nonseminomatous Germ Cell Tumor,\"",
"      <i>",
"       Eur Urol",
"      </i>",
"      , 2006, 50(5):1032-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/16757095/pubmed\" id=\"16757095\" target=\"_blank\">",
"        16757095",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dileo P, Morgan JA, Zahrieh D, et al, \"Gemcitabine and Vinorelbine Combination Chemotherapy for Patients With Advanced Soft Tissue Sarcomas: Results of a Phase II Trial,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2007, 109(9):1863-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/17385194/pubmed\" id=\"17385194\" target=\"_blank\">",
"        17385194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ecklund JW, Trifilio S, and Mulcahy MF, &ldquo;Chemotherapy Dosing in the Setting of Liver Dysfunction,&rdquo;",
"      <i>",
"       Oncology (Williston Park)",
"      </i>",
"      , 2005, 19(8):1057-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/16131047/pubmed\" id=\"16131047\" target=\"_blank\">",
"        16131047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edelman MJ, Belani CP, Socinski MA, et al, &ldquo;Outcomes Associated With Brain Metastases in a Three-Arm Phase III Trial of Gemcitabine-Containing Regimens Versus Paclitaxel Plus Carboplatin for Advanced Non-Small Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Thorac Oncol",
"      </i>",
"      , 2010, 5(1):110-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/20035187/pubmed\" id=\"20035187\" target=\"_blank\">",
"        20035187",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heinemann V, Quietzsch D, Gieseler F, et al, \"Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(24):3946-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/16921047/pubmed\" id=\"16921047\" target=\"_blank\">",
"        16921047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hensley ML, Blessing JA, Degeest K, et al, &ldquo;Fixed-Dose Rate Gemcitabine Plus Docetaxel as Second-Line Therapy for Metastatic Uterine Leiomyosarcoma: A Gynecologic Oncology Group Phase II Study,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2008, 109(3):323-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/18394689/pubmed\" id=\"18394689\" target=\"_blank\">",
"        18394689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hinton S, Catalano P, Einhorn LH, et al, \"Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(7):1859-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/11919245/pubmed\" id=\"11919245\" target=\"_blank\">",
"        11919245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, &ldquo;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knox JJ, Hedley D, Oza A, et al, &ldquo;Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(10):2332-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/15800324 /pubmed\" id=\"15800324 \" target=\"_blank\">",
"        15800324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ko AH, Dito E, Schillinger B, et al, &ldquo;Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(3):379-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/16344320/pubmed\" id=\"16344320\" target=\"_blank\">",
"        16344320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kollmannsberger C, Beyer J, Liersch R, et al, \"Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(1):108-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/14701772/pubmed\" id=\"14701772\" target=\"_blank\">",
"        14701772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leu KM, Ostruszka LJ, Shewach D, et al, &ldquo;Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treatment With Gemcitabine Followed by Docetaxel in the Treatment of Sarcoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(9):1706-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/15117993 /pubmed\" id=\"15117993 \" target=\"_blank\">",
"        15117993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li YF, Fu S, Hu W, et al, &ldquo;Systemic Anticancer Therapy in Gynecological Cancer Patients With Renal Dysfunction,&rdquo;",
"      <i>",
"       Int J Gynecol Cancer",
"      </i>",
"      , 2007, 7(4):739-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/17309673/pubmed\" id=\"17309673\" target=\"_blank\">",
"        17309673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Look KY, Sandler A, Blessing JA, et al, &ldquo;Phase II Trial of Gemcitabine as Second-Line Chemotherapy of Uterine Leiomyosarcoma: A Gynecologic Oncology Group (GOG) Study,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2004, 92(2):644-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/14766260/pubmed\" id=\"14766260\" target=\"_blank\">",
"        14766260",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      L&oacute;pez A, Guti&eacute;rrez A, Palacios A, et al, \"GEMOX-R Regimen is a Highly Effective Salvage Regimen in Patients With Refractory/Relapsing Diffuse Large-Cell Lymphoma: A Phase II Study,\"",
"      <i>",
"       Eur J Haematol",
"      </i>",
"      , 2008, 80(2):127-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/18005385 /pubmed\" id=\"18005385 \" target=\"_blank\">",
"        18005385",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Louvet C, Labianca R, Hammel P, et al, &ldquo;Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(15):3509-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/15908661/pubmed\" id=\"15908661\" target=\"_blank\">",
"        15908661",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maki RG, Wathen JK, Patel SR, et al, &ldquo;Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(19):2755-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/17602081/pubmed\" id=\"17602081\" target=\"_blank\">",
"        17602081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Masters GA, Declerck L, Blanke C, et al, &ldquo;Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(8):1550-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/12697880/pubmed\" id=\"12697880\" target=\"_blank\">",
"        12697880",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Merimsky O, Meller I, Flusser G, et al, &ldquo;Gemcitabine in Soft Tissue or Bone Sarcoma Resistant to Standard Chemotherapy: A Phase II Study,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2000, 45(2):177-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/10663634/pubmed\" id=\"10663634\" target=\"_blank\">",
"        10663634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monk BJ, Sill MW, McMeekin DS, et al, \"Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(28):4649-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/19720909/pubmed\" id=\"19720909\" target=\"_blank\">",
"        19720909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore MJ, Goldstein D, Hamm J, et al, \"Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(15):1960-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/17452677/pubmed\" id=\"17452677\" target=\"_blank\">",
"        17452677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Pancreatic Adenocarcinoma,&rdquo; Version 2.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Navid F, Willert JR, McCarville MB, et al, &ldquo;Combination of Gemcitabine and Docetaxel in the Treatment of Children and Young Adults With Refractory Bone Sarcoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2008, 113(2):419-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/18484657/pubmed\" id=\"18484657\" target=\"_blank\">",
"        18484657",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nowak AK, Byrne MJ, Williamson R, et al, &ldquo;A Multicentre Phase II Study of Cisplatin and Gemcitabine for Malignant Mesothelioma,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2002, 87(5):491-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/12189542/pubmed\" id=\"12189542\" target=\"_blank\">",
"        12189542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palmieri G, Merola G, Federico P, et al, &ldquo;Preliminary Results of Phase II Study of Capecitabine and Gemcitabine (CAP-GEM) in Patients With Metastatic Pretreated Thymic Epithelial Tumors (TETs),&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(6):1168-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/19880439/pubmed\" id=\"19880439\" target=\"_blank\">",
"        19880439",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pectasides D, Pectasides M, Farmakis D, et al, \"Gemcitabine and Oxaliplatin (GEMOX) in Patients With Cisplatin-Refractory Germ Cell Tumors: A Phase II Study,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2004, 15(3):493-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/14998855 /pubmed\" id=\"14998855 \" target=\"_blank\">",
"        14998855",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfisterer J, Vergote I, Du Bois A, et al, &ldquo;Combination Therapy with Gemcitabine and Carboplatin in Recurrent Ovarian Cancer,&rdquo;",
"      <i>",
"       Int J Gynecol Cancer",
"      </i>",
"      , 2005, 15 (Suppl 1):36-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/15839957/pubmed\" id=\"15839957\" target=\"_blank\">",
"        15839957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poplin E, Feng Y, Berlin J, et al, &ldquo;Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (Fixed-Dose Rate Infusion) Compared With Gemcitabine (30-Minute Infusion) in Patients With Pancreatic Carcinoma E6201: a Trial of the Eastern Cooperative Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(23):3778-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/19581537/pubmed\" id=\"19581537\" target=\"_blank\">",
"        19581537",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pouessel D, Culine S, Becht C, et al, \"Gemcitabine and Docetaxel as Front-Line Chemotherapy in Patients With Carcinoma of an Unknown Primary Site,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 100(6):1257-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/15022294/pubmed\" id=\"15022294\" target=\"_blank\">",
"        15022294",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Santoro A, Magagnoli M, Spina M, et al, &ldquo;Ifosfamide, Gemcitabine, and Vinorelbine: A New Induction Regimen for Refractory and Relapsed Hodgkin's Lymphoma,&rdquo;",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2007, 92(1):35-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/17229633/pubmed\" id=\"17229633\" target=\"_blank\">",
"        17229633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schilder RJ, Blessing J, and Cohn DE, &ldquo;Evaluation of Gemcitabine in Previously Treated Patients With Non-Squamous Cell Carcinoma of the Cervix: A Phase II Study of the Gynecologic Oncology Group,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2005, 96(1):103-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/15589587/pubmed\" id=\"15589587\" target=\"_blank\">",
"        15589587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seliger G, Mueller LP, Kegel T, et al, &ldquo;Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer,&rdquo;",
"      <i>",
"       Int J Gynecol Cancer",
"      </i>",
"      , 2009, 19(8):1446-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/20009905/pubmed\" id=\"20009905\" target=\"_blank\">",
"        20009905",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tannir NM, Thall PF, Ng CS, et al, &ldquo;A Phase II Trial of Gemcitabine Plus Capecitabine for Metastatic Renal Cell Cancer Previously Treated With Immunotherapy and Targeted Agents,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2008, 180(3):867-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/18635226/pubmed\" id=\"18635226\" target=\"_blank\">",
"        18635226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tempero M, Plunkett W, Ruiz Van Haperen V, &ldquo;Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      ,  2003, 21(18):3402-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/12885837/pubmed\" id=\"12885837\" target=\"_blank\">",
"        12885837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Valle J, Wason H, Palmer DH, et al, &ldquo;Cisplatin Plus Gemcitabine Versus Gemcitabine for Biliary Tract Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010 362(14):1273-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/20375404/pubmed\" id=\"20375404\" target=\"_blank\">",
"        20375404",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Haarst JM, Baas P, Manegold Ch, et al, &ldquo;Multicentre Phase II Study of Gemcitabine and Cisplatin in Malignant Pleural Mesothelioma,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2002, 86(3):342-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/11875695/pubmed\" id=\"11875695\" target=\"_blank\">",
"        11875695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Venook AP, Egorin MJ, Rosner GL, et al, &ldquo;Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565,&rdquo;",
"      <i>",
"       J Clin Oncol, 2000",
"      </i>",
"      , 18(14):2780-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/10894879/pubmed\" id=\"10894879\" target=\"_blank\">",
"        10894879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von der Maase H, Hansen SW, Roberts JT, et al, &ldquo;Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(17):3068-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/11001674/pubmed\" id=\"11001674\" target=\"_blank\">",
"        11001674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waters JS, Moss C, Puyle L, et al, &ldquo;Phase II Clinical Trial of Capecitabine and Gemcitabine Chemotherapy in Patients With Metastatic Renal Carcinoma,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2004, 91(10):1763-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/15505625/pubmed\" id=\"15505625\" target=\"_blank\">",
"        15505625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Xu Q, Zhang Y, and Trissel LA, &ldquo;Physical and Chemical Stability of Gemcitabine Hydrochloride Solutions,&rdquo;",
"      <i>",
"       J Am Pharm Assoc",
"      </i>",
"      , 1999, 39(4):509-13.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhang L, Zhang Y, Huang PY, et al, &ldquo;Phase II Clinical Study of Gemcitabine in the Treatment of Patients With Advanced Nasopharyngeal Carcinoma After the Failure of Platinum-Based Chemotherapy,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2008, 61(1):33-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/1/31769/abstract-text/17909810/pubmed\" id=\"17909810\" target=\"_blank\">",
"        17909810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8487 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-FA0D210239-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31769=[""].join("\n");
var outline_f31_1_31769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175343\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175344\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175384\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175347\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10927324\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175348\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175349\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175350\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175385\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175320\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175305\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175324\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175390\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175323\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175380\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175393\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175382\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175327\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175309\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299393\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175314\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175339\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175316\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175329\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175356\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10927284\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524622\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175318\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175330\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175308\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175326\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8487\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8487|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/42/677?source=related_link\">",
"      Gemcitabine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/37/27223?source=related_link\">",
"      Gemcitabine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_1_31770="Abdominal access techniques used in laparoscopic surgery";
var content_f31_1_31770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Abdominal access techniques used in laparoscopic surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/1/31770/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/1/31770/contributors\">",
"     Aurora Pryor, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/1/31770/contributors\">",
"     Jin Yoo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/1/31770/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/1/31770/contributors\">",
"     Jeffrey Marks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/1/31770/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/1/31770/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/1/31770/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H651891331\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic techniques have revolutionized the field of surgery with benefits that include decreased postoperative pain, earlier return to normal activities following surgery, and fewer postoperative complications (eg, wound infection, hernia). However, unique complications are associated with gaining access to the abdomen for laparoscopic surgery. Inadvertent bowel injury or major vascular injury is uncommon, but both are potentially life-threatening complications that are most likely to occur during initial access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The techniques for access to the peritoneum, choice of access, multiple port placement, and complications of access will be reviewed here. Laparoscopic issues and complications not related to abdominal access are discussed in separate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891340\">",
"    <span class=\"h1\">",
"     ABDOMINAL WALL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the anatomy of the abdominal wall is essential for the safe insertion of laparoscopic access devices. These devices traverse the skin, subcutaneous fat, variable fascial layers, preperitoneal fat, and parietal peritoneum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891348\">",
"    <span class=\"h2\">",
"     Access locations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fascial and muscular layers of the abdominal wall are variable depending upon specific location. Anatomy at typical laparoscopic access sites and related intraabdominal anatomy are discussed below. Detailed anatomy of the abdominal wall is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/18/17703?source=see_link\">",
"     \"Anatomy of the abdominal wall\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376701638\">",
"    <span class=\"h3\">",
"     Midline abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The midline abdominal wall is devoid of important vessels and nerves, and is a preferred access site for many laparoscopic procedures. (See",
"    <a class=\"local\" href=\"#H651891400\">",
"     'Advanced access techniques'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The layers of the abdominal wall in the midline include skin, subcutaneous fat and a single fascial layer that is a coalescence of variable fascial layers (ie, external oblique, internal oblique, transversalis) (",
"    <a class=\"graphic graphic_figure graphicRef77053 \" href=\"mobipreview.htm?28/40/29320\">",
"     figure 1",
"    </a>",
"    ). The round ligament of the liver and the falciform ligament join together and attach to the posterior aspect of the upper midline abdominal wall.",
"   </p>",
"   <p>",
"    Midline intraabdominal structures from cranial to caudal include the stomach, transverse colon, omentum, small intestine, sigmoid colon and bladder. Decompression of the stomach with a nasogastric or orogastric tube and the bladder with a Foley catheter can be performed to maximize visualization of upper abdominal and pelvic operating fields and minimize risk for injury. Previous midline abdominal incision is likely to be associated with significant underlying adhesions. Alternative access sites should be chosen. (See",
"    <a class=\"local\" href=\"#H651891700\">",
"     'Special considerations for access'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376701645\">",
"    <span class=\"h3\">",
"     Umbilicus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transumbilical access is the most common location for Veress access with a pneumoperitoneum (ie, Veress) needle. (See",
"    <a class=\"local\" href=\"#H651891372\">",
"     'Closed (Veress needle)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The umbilicus is a fusion of fascial layers and is devoid of subcutaneous fat. The median umbilical ligament (ie, obliterated urachus) and paired medial umbilical ligaments (ie, obliterated umbilical arteries) are peritoneal folds that join together at the inferior margin of the umbilicus forming a tough layer. A defect in the umbilical fascia with or without the presence of a mass suggests an umbilical hernia (",
"    <a class=\"graphic graphic_picture graphicRef72970 \" href=\"mobipreview.htm?38/45/39634\">",
"     picture 1",
"    </a>",
"    ). Anomalies of the urachus may also exist (",
"    <a class=\"graphic graphic_figure graphicRef79324 \" href=\"mobipreview.htm?15/5/15446\">",
"     figure 2",
"    </a>",
"    ). Alternative access sites may need to be considered. (See",
"    <a class=\"local\" href=\"#H651891700\">",
"     'Special considerations for access'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376701652\">",
"    <span class=\"h3\">",
"     Medial costal margin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Access sites in the costal margin are useful for a variety of upper abdominal laparoscopic procedures. (See",
"    <a class=\"local\" href=\"#H651891714\">",
"     'Multiple port placement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The margin of the ribs provides support to the abdominal wall as the access needle or port passes through it during entry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/6\">",
"     6",
"    </a>",
"    ]. Along the medial costal margin, the layers of the abdominal wall include the skin, subcutaneous fat, anterior rectus fascia, rectus muscle, posterior rectus fascia, transversalis fascia, preperitoneal fat and parietal peritoneum (",
"    <a class=\"graphic graphic_figure graphicRef77053 \" href=\"mobipreview.htm?28/40/29320\">",
"     figure 1",
"    </a>",
"    ). The superior epigastric artery runs along the underside of the rectus muscle in its midline. The region where the external oblique, internal oblique and transversalis fascia fuse immediately lateral to the rectus muscle contains no vessels.",
"   </p>",
"   <p>",
"    The liver descends below the rib margin 1 to 3 cm on the right and a prominent left lobe may also be present on the left. The fundus of the stomach and transverse colon are in proximity. Decompression of the stomach with an NG tube should be performed to maximize visualization of the upper abdomen. The presence of subcostal incisions (eg, open",
"    <span class=\"nowrap\">",
"     cholecystectomy/Kocher",
"    </span>",
"    incision) is likely to be associated with significant underlying adhesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376701659\">",
"    <span class=\"h3\">",
"     Ninth left intercostal space",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ninth left intercostal space is another useful site for primary insufflation of the abdomen when other sites are not available. (See",
"    <a class=\"local\" href=\"#H651891700\">",
"     'Special considerations for access'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The intercostal space is accessed in the anterior axillary line close to the superior margin of the tenth rib. This site approximates the inferior margin of the posterior spleen. The splenic flexure of the colon is also in proximity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376701666\">",
"    <span class=\"h3\">",
"     Lateral abdomen/flank",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lateral abdominal and flank access sites are commonly used for the placement of retracting instruments. (See",
"    <a class=\"local\" href=\"#H651891714\">",
"     'Multiple port placement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Palmer's point is located 3 cm below the left costal margin, just lateral to the rectus muscle in the midclavicular line. Like the left ninth intercostal location, Palmer&rsquo;s point can also be used as a site for primary insufflation of the abdomen with a Veress needle when a transumbilical site cannot be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/7\">",
"     7",
"    </a>",
"    ]. A right-sided approach can be used as well. (See",
"    <a class=\"local\" href=\"#H651891700\">",
"     'Special considerations for access'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Lateral to the rectus muscle, the layers of the abdominal wall include the skin, subcutaneous fat, fascia and muscle of the external oblique, internal oblique, and transversalis (outward to inward), preperitoneal fat and parietal peritoneum (",
"    <a class=\"graphic graphic_figure graphicRef77053 \" href=\"mobipreview.htm?28/40/29320\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66280 \" href=\"mobipreview.htm?3/45/3798\">",
"     figure 3",
"    </a>",
"    ). The deep nerves and vessels of the abdominal wall run parallel to each other traveling along the anterior surface of the transversalis muscle (",
"    <a class=\"graphic graphic_figure graphicRef71423 \" href=\"mobipreview.htm?30/56/31624\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81343 \" href=\"mobipreview.htm?11/30/11753\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376701673\">",
"    <span class=\"h3\">",
"     Hypogastrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Access sites in the hypogastric region are used for laparoscopic surgery on pelvic structures. (See",
"    <a class=\"local\" href=\"#H651891714\">",
"     'Multiple port placement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many arteries and nerves traverse the hypogastric region to supply the abdominal wall, including the inferior and superficial epigastric arteries, superficial and deep iliac circumflex arteries, and iliohypogastric and ilioinguinal nerves (",
"    <a class=\"graphic graphic_figure graphicRef71423 \" href=\"mobipreview.htm?30/56/31624\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81343 \" href=\"mobipreview.htm?11/30/11753\">",
"     figure 5",
"    </a>",
"    ). The location of port sites in the lower abdomen should be chosen to avoid these vessels and nerves. If the vessels are not visualized laparoscopically, the abdominal wall can be transilluminated with another light source. Access through the midline just medial and superior to the anterior superior iliac spine avoids these structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891356\">",
"    <span class=\"h1\">",
"     PERITONEAL ACCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before any laparoscopic procedure can begin, access to the peritoneal cavity is performed, first to establish pneumoperitoneum and subsequently to place additional port sites for the laparoscope and various laparoscopic instruments.",
"   </p>",
"   <p>",
"    Laparoscopic entry can be performed with an open (ie, Hasson), or closed (eg, Veress needle, visual entry trocar) technique. Each method has advantages and disadvantages, and neither is suitable as an all-purpose method for laparoscopic access. Different approaches can be used for primary and secondary port placement during the same procedure. (See",
"    <a class=\"local\" href=\"#H651891644\">",
"     'Choice of technique'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891364\">",
"    <span class=\"h2\">",
"     Open (Hasson)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hasson technique refers to an open method in which an incision (usually periumbilical) is made through the abdominal wall under direct vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/9\">",
"     9",
"    </a>",
"    ]. The advantage of the open technique is a low risk for major complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H736267272\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This technique generally adds to the length of the procedure, taking longer to perform at the beginning and the end of the procedure compared with a closed (Veress needle) technique. Even though the Hasson technique is most commonly used in the periumbilical region, this method can be used anywhere on the abdominal wall and is particularly useful when there is a concern for abdominal wall adhesions in a patient with a prior laparotomy. (See",
"    <a class=\"local\" href=\"#H651891644\">",
"     'Choice of technique'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159864991\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;An incision is made in the skin and a clamp (tonsil, Kelly) used to bluntly dissect the subcutaneous fat. Any vessels that are encountered are cauterized, or ligated and divided. The anterior fascia is incised and stay sutures placed in the fascial edges. These sutures aid with retraction of the abdominal wall and are used to secure the fascia to the port, preventing its displacement during the surgery. At the end of the procedure, these sutures can be removed or, alternatively, can be used to close the fascial defect. (See",
"    <a class=\"local\" href=\"#H651891636\">",
"     'Fascial closure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The preperitoneal fat, if present, is bluntly dissected and the peritoneum brought up into the wound with a hemostat. The peritoneum is opened and the index finger is used to sweep the underside of the abdominal wall to clear omentum or bowel, and confirm the absence of adhesions in the region of the incision. A blunt-ended trocar (ie, Hasson) is then placed through the incision, secured with the stay sutures, and the carbon dioxide (CO",
"    <sub>",
"     2",
"    </sub>",
"    ) gas line is attached to the port to insufflate the abdomen. (See",
"    <a class=\"local\" href=\"#H651891622\">",
"     'Establishing pneumoperitoneum'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891372\">",
"    <span class=\"h2\">",
"     Closed (Veress needle)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Veress needle technique refers to a closed method in which the Veress needle (named for Janos Veres) is used to puncture through the layers of the abdominal wall. This technique was popularized by Raoul Palmer in the mid-20th century [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/7\">",
"     7",
"    </a>",
"    ]. The Veress needle, originally developed for thoracentesis, is a small-bore (2 mm) needle with a protective sheath that recoils to cover the end of the needle, allowing entry into a body cavity without trauma to underlying organs (",
"    <a class=\"graphic graphic_picture graphicRef80571 \" href=\"mobipreview.htm?26/48/27395\">",
"     picture 2",
"    </a>",
"    ). When the needle enters the cavity, the clinician usually feels or hears the protective sheath \"click\" when it recoils, indicating that the cavity has been entered.",
"   </p>",
"   <p>",
"    The most common insertion site for the Veress technique is the umbilicus because there is no fat or muscle between the skin and peritoneum at this location. A transumbilical insertion is contraindicated when umbilical abnormalities (eg, umbilical hernia) are present or there is a concern for underlying adhesions from a prior surgery. (See",
"    <a class=\"local\" href=\"#H376701645\">",
"     'Umbilicus'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The Veress needle technique allows quicker entry into the peritoneal cavity since a direct cut down to the fascia level and suture closure of the access site are not needed, provided a &le;12 mm trocar is used. There may also be a reduced risk for access site hernia with this technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H651891970\">",
"     'Hernia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The disadvantage of this technique is an increased risk of major complications compared with the open technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/1,3,12-19\">",
"     1,3,12-19",
"    </a>",
"    ]. For this reason, some surgeons advocate alternative sites if Veress access for abdominal insufflation is chosen. (See",
"    <a class=\"local\" href=\"#H651891644\">",
"     'Choice of technique'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H736267272\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Alternative sites to establish pneumoperitoneum when the umbilicus cannot be used include other points in the midline, the ninth left intercostal space, the lateral border of the rectus muscle 3 cm below the left costal margin (ie, Palmer's point), and the lateral border of the rectus muscle at the level of the iliac crest. (See",
"    <a class=\"local\" href=\"#H376701638\">",
"     'Midline abdomen'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H376701659\">",
"     'Ninth left intercostal space'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H376701666\">",
"     'Lateral abdomen/flank'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H376701673\">",
"     'Hypogastrium'",
"    </a>",
"    above.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159864998\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The length of Veress needle needed to reach the peritoneal cavity should be estimated first. A small incision is made in the umbilicus and the subcutaneous tissue bluntly dissected to the fascia. The needle is placed to the level of the fascia, and the depth marked on the needle, which is then removed. The fascia is then grasped (eg, manually, Kocher clamp) and the abdominal wall is elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Grasping the skin itself and not the fascia may increase failed entry rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Veress needle is grasped just above the measured distance and inserted through the incision at a 45-degree angle toward the hollow of the pelvis with care not to deviate in laterally. Two \"pops\" should be felt. The first occurs when the needle passes through the abdominal fascia and the second as it passes through the parietal peritoneum.",
"   </p>",
"   <p>",
"    When the needle passes through the peritoneum and enters the peritoneal space, the displaced hub of the needle will \"click\" as the protective sheath recoils to cover the end of the needle.",
"   </p>",
"   <p>",
"    Multiple alternatives are available for confirming Veress needle placement; however, no trials are available to suggest the use of one method over another. These include one of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Saline aspiration and injection. A 10 mL syringe containing 4 mL of normal saline is attached to the Veress needle hub. The syringe is aspirated. If nothing returns, saline is injected into the presumed peritoneal space. Intraperitoneal location of the tip of the Veress needle is assumed if saline injects freely, and the location is confirmed when the water in the Veress needle cap drops freely into the peritoneal space by gravity when the syringe is removed.",
"      <br/>",
"      <br/>",
"      If blood or enteric contents are returned upon aspirating the syringe, an inadvertent vascular or visceral injury may have occurred. Under this circumstance, the needle should be left in place and alternative access obtained to assess the potential injury. The needle should be removed under direct visualization. (See",
"      <a class=\"local\" href=\"#H651891923\">",
"       'Gastrointestinal injury'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H19386192\">",
"       'Vascular injury'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H651891792\">",
"       'Failed entry'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Hanging drop method. A drop of saline is placed at the open end of the needle and the abdominal wall is elevated. The suction pressure that is generated should cause the drop of water to be drawn into the abdominal cavity.",
"     </li>",
"     <li>",
"      Measurement of intraperitoneal pressure. The intraperitoneal pressure should be &le;10 mmHg. In one large observational study, confirmation of low intraperitoneal pressure method was the most reliable method to confirm Veress needle placement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the position of the needle is confirmed to be intraperitoneal, carbon dioxide (CO",
"    <sub>",
"     2",
"    </sub>",
"    ) gas insufflation may be initiated. A properly placed needle will allow free flow of gas. Tympany should be appreciated with percussion of the abdomen in the right upper quadrant. (See",
"    <a class=\"local\" href=\"#H651891622\">",
"     'Establishing pneumoperitoneum'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once the abdomen is insufflated, the Veress needle is removed and a port placed into the Veress needle track. A visual entry port is most commonly used. Inserting the first trocar under direct vision allows early recognition and immediate management should vascular or gastrointestinal injury occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/14\">",
"     14",
"    </a>",
"    ]. Care should be taken to avoid a trocar direction (eg, lateral displacement) or depth that could result in injury to the aorta or iliac arteries. Holding the trocar shaft rather than its top during insertion may help prevent uncontrolled speed and depth of penetration. (See",
"    <a class=\"local\" href=\"#H651891392\">",
"     'Visual entry technique'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Following insufflation, blind insertion of the primary",
"    <span class=\"nowrap\">",
"     trocar/port",
"    </span>",
"    can also be performed if visual entry devices are not available or preferred. A shielded (ie, disposable) trocar is preferred because it requires less force upon insertion and tends to be sharper than reusable trocars, which are associated with more complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/16\">",
"     16",
"    </a>",
"    ]. An alternative device is a radially-dilating trocar which has no cutting mechanism. The trocar is introduced perpendicular to the skin for a distance of 2 to 3 cm, and then the angle of introduction is increased to 45 degrees but &le;60 degrees in line with the area of interest in the abdomen. Control of the force and depth of",
"    <span class=\"nowrap\">",
"     trocar/port",
"    </span>",
"    should be maintained at all times.",
"   </p>",
"   <p>",
"    One useful technique is to gently twist the trocar while exerting firm downward pressure. Excessive pressure to overcome skin or fascial resistance can lead to uncontrolled trocar entry, increasing the risk of injury to bowel or other abdominal or retroperitoneal structures. Bluntly enlarging an obstructing incision or, alternatively, changing to an open (Hasson) method is preferable to increasing the force placed upon the instrument. (See",
"    <a class=\"local\" href=\"#H651891364\">",
"     'Open (Hasson)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When a rush of gas from the peritoneal cavity is heard, the proper depth has been reached. The trocar is withdrawn slightly and the cannula advanced for 1 to 2 cm to ensure placement within the peritoneal cavity. Supplemental CO",
"    <sub>",
"     2",
"    </sub>",
"    is introduced as needed. The laparoscope (",
"    <a class=\"graphic graphic_picture graphicRef52659 \" href=\"mobipreview.htm?39/38/40559\">",
"     picture 3",
"    </a>",
"    ) is inserted into the port and the abdomen visualized, confirming that no inadvertent injury has occurred.",
"   </p>",
"   <p>",
"    If blind trocar insertion following Veress needle insufflation is used, entry complications may be reduced by hyperdistending the abdomen, which elevates the abdominal wall off the abdominal organs and provides better support for the trocar. This technique is useful for very thin patients and obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H651891700\">",
"     'Special considerations for access'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinically significant adverse effects on cardiopulmonary function have not been observed with hyperdistention, provided the duration of increased pressure is limited (ie, during trocar entry) and the patient is not in Trendelenburg position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891392\">",
"    <span class=\"h2\">",
"     Visual entry technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The visual entry technique accesses the peritoneal cavity with a specialized",
"    <span class=\"nowrap\">",
"     trocar/port",
"    </span>",
"    that has a transparent tip, allowing each layer of the abdominal wall to be seen with a 0-degree laparoscope (",
"    <a class=\"graphic graphic_picture graphicRef52659 \" href=\"mobipreview.htm?39/38/40559\">",
"     picture 3",
"    </a>",
"    ) as it is being traversed. Commercially available optical",
"    <span class=\"nowrap\">",
"     trocar/cannula",
"    </span>",
"    systems include Optiview&reg;, Kii&reg; optical access system, and Visiport&trade;. The manner in which each of these devices affects tissue dissection as the tip advances differs in minor ways.",
"   </p>",
"   <p>",
"    These devices are typically used for primary port placement after Veress needle abdominal insufflation or secondary port placement after pneumoperitoneum has already been established. (See",
"    <a class=\"local\" href=\"#H651891372\">",
"     'Closed (Veress needle)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H651891364\">",
"     'Open (Hasson)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some surgeons advocate use of an optical",
"    <span class=\"nowrap\">",
"     trocar/port",
"    </span>",
"    system as a means to establish pneumoperitoneum",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/25\">",
"     25",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    The left upper quadrant (1 cm caudal to the subcostal margin in the midclavicular line) is a safe location for this approach. (See",
"    <a class=\"local\" href=\"#H376701666\">",
"     'Lateral abdomen/flank'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H651891644\">",
"     'Choice of technique'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159864984\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;After pneumoperitoneum has been established with either the open Hasson or Veress needle technique, an incision (0.5 to 1 cm) is made in the skin at an appropriate port site. (See",
"    <a class=\"local\" href=\"#H651891348\">",
"     'Access locations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H651891714\">",
"     'Multiple port placement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The optical",
"    <span class=\"nowrap\">",
"     trocar/port",
"    </span>",
"    system is placed into the incision with the 0-degree scope (",
"    <a class=\"graphic graphic_picture graphicRef52659 \" href=\"mobipreview.htm?39/38/40559\">",
"     picture 3",
"    </a>",
"    ) perpendicular to the abdominal wall. Gentle downward pressure on the abdominal wall is applied with the device while viewing each successive layer of the abdominal wall. When a rush of gas from the peritoneal cavity is heard, the proper depth has been reached. The camera is removed and the trocar withdrawn slightly and the cannula advanced for 1 to 2 cm, the trocar removed and the laparoscope reinserted. Visualization of the omentum (midline access), confirms correct placement of the device in the peritoneal cavity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891400\">",
"    <span class=\"h2\">",
"     Advanced access techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;More advanced approaches are currently under investigation as alternative access techniques for laparoscopic surgery. These include single incision surgery (SIS) and natural orifice transluminal endoscopic surgery (NOTES).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376701701\">",
"    <span class=\"h3\">",
"     Single-incision surgery (SIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single-incision surgery (SIS) refers to a laparoscopic approach that uses a single 2 to 3 cm incision, usually at the umbilicus, to place a multichannel port or multiple co-located trocars (",
"    <a class=\"graphic graphic_picture graphicRef64522 \" href=\"mobipreview.htm?14/19/14643\">",
"     picture 4",
"    </a>",
"    ). There is no consensus on the nomenclature for this approach, and this technique has been published under many different names including SILS",
"    <sup>",
"     TM",
"    </sup>",
"    (Single-Incision Laparoscopic Surgery), SPA",
"    <sup>",
"     TM",
"    </sup>",
"    (Single Port Access), SSL (Single-Site Laparoscopy), OPUS (One-Port Umbilical Surgery), SLAPP (Single Laparoscopic Port Procedure), SPLS (Single-Port Laparoscopy), SLIT (Single Laparoscopic Incision Transabdominal Surgery), LESS (Laparoendoscopic Single-Site Surgery), and SIMPL (Single-Instrument Port Laparoscopic Surgery).",
"   </p>",
"   <p>",
"    For surgeons experienced with standard laparoscopic techniques, adopting SIS is feasible and safe provided accepted safety practices are maintained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, compared with conventional laparoscopy, SIS is technically more challenging due to several factors, including loss of triangulation because the camera and working instruments are parallel with each other, limited extraabdominal working space with creation of a \"hand clashing\" problem, and decreased visualization due to suboptimal instrument or camera position. Roticulating instruments and cameras are commercially available, and maneuvers such as crossing the hands while operating and using different length instruments can help to avoid \"hand clashing\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Newer instrumentation may improve these issues, but this has yet to be proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review identified 4595 SIS operations performed at predominantly six institutions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/31\">",
"     31",
"    </a>",
"    ]. Single-incision cholecystectomy was the most commonly reported procedure, representing 24 percent of the 4595 operations evaluated. Single-incision nephrectomy was the second most common procedure. Technical success rates were high, with conversion to a standard approach required in zero to 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. Similarly, in a systematic review of single-incision laparoscopic colectomy, the overall conversion rate was 6.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/37\">",
"     37",
"    </a>",
"    ]. Of the 378 cases, 6 (1.6 percent) were converted to hand-assisted laparoscopic procedure, 14 (4.0 percent) to conventional (multiport) laparoscopic colectomy, and 6 cases (1.6 percent) required conversion to open colectomy. &nbsp;",
"   </p>",
"   <p>",
"    The theoretical advantages of this approach are a potentially \"scarless\" abdomen if the incision is placed carefully around or within the umbilicus, decreased postoperative pain from the use of fewer port sites, and therefore earlier return to normal activities. Randomized trials comparing conventional laparoscopic surgery with single-incision surgery have been performed for cholecystectomy, appendectomy and nephrectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/32-35,38-41\">",
"     32-35,38-41",
"    </a>",
"    ]. Compared with conventional laparoscopic surgery, these trials have found similar or longer operative times, similar or shorter mean length of stay, and pain scores that are better or worse for the SIS groups studied. Where cosmetic scores were reported, they were consistently better for the SIS group compared with conventional laparoscopic surgery.",
"   </p>",
"   <p>",
"    There are several SIS ports available, including TriPort (Advanced Surgical Concepts, Wicklow,",
"    <span class=\"nowrap\">",
"     Ireland/Olympus),",
"    </span>",
"    AirSeal&trade; (SurgiQuest, Orange, CT), SILS&trade; Port and other SILS&trade; procedure kits and access devices (Covidien, Inc., Norwalk, CT), and GelPort&reg; (Applied Medical, Rancho Santa Margarita, CA). Complete SIS platforms are also available (eg, Single Port Instrument Delivery Extended Reach [SPIDER], TransEnterix, RTP, NC).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376701715\">",
"    <span class=\"h3\">",
"     Natural Orifice Transluminal Endoscopic Surgery (NOTES)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural Orifice Transluminal Endoscopic Surgery (NOTES) refers to an",
"    <span class=\"nowrap\">",
"     endo/laparoscopic",
"    </span>",
"    approach in which access to the peritoneum is obtained by traversing a \"natural\" orifice using a multichannel endoscope to achieve access to the peritoneal cavity through the stomach, bladder, vagina, or rectum. The potential advantage of NOTES is a true \"scarless\" operation and minimization of postoperative pain. Limitations include expense, a steep learning curve, need for two or more experienced surgeons, and no reliable method to close the natural orifice luminal wall defect. Degradation of this repair can lead to peritonitis. NOTES via the umbilicus, an alternative laparoscopic surgical procedure, has been published under the following names: TUES (Transumbilical Endoscopic Surgery), eNOTES (embryonic NOTES), NOTUS (Natural Orifice Transumbilical Surgery).",
"   </p>",
"   <p>",
"    NOTES approaches are at an early clinical development stage. Randomized trials are needed to compare safety and efficacy with conventional laparoscopy. The Natural Orifice Surgery Consortium for Assessment and Research (NOSCAR), is currently overseeing clinical research to ensure that NOTES is introduced into clinical practice in a safe manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. NOTES is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2103?source=see_link\">",
"     \"Natural orifice transluminal endoscopic surgery (NOTES)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376701730\">",
"    <span class=\"h3\">",
"     Alternative sites used in gynecologic laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In gynecologic laparoscopy, Veress needle insertions through the uterine fundus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/46\">",
"     46",
"    </a>",
"    ] and posterior vaginal fornix [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/47\">",
"     47",
"    </a>",
"    ] have also been employed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12168?source=see_link\">",
"     \"Gynecologic laparoscopy: Non-umbilical entry sites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891622\">",
"    <span class=\"h2\">",
"     Establishing pneumoperitoneum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once peritoneal access is established, the abdomen is insufflated, typically with carbon dioxide gas (CO",
"    <sub>",
"     2",
"    </sub>",
"    ). Other gases have also been tried, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    and helium; however, the safety of these agents has yet to be established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/48\">",
"     48",
"    </a>",
"    ]. The rate of CO",
"    <sub>",
"     2",
"    </sub>",
"    gas flow is low initially. After abdominal, and not extraperitoneal, insufflation is confirmed, the gas flow can be increased to its full flow rate (about 20",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    while the intraabdominal pressure is monitored. The pressure will initially be &lt;10 mmHg but will slowly increase. After 2 to 3 L of CO",
"    <sub>",
"     2",
"    </sub>",
"    gas has been instilled, the preset intraabdominal pressure of 15 mmHg should be reached. The gas is left on, but flows into the abdomen only if the abdominal pressure falls below the pre-set pressure. The necessary volume of gas needed for insufflation is dependent upon the depth of anesthesia, use of neuromuscular blockade, and the patient's size. Visual and manual examination (ie, tympany upon palpation) of the abdomen confirms that adequate pneumoperitoneum has been achieved.",
"   </p>",
"   <p>",
"    If the pressure rapidly increases to more than 12 to 15 mmHg, then the",
"    <span class=\"nowrap\">",
"     needle/port",
"    </span>",
"    may be displaced. The abdominal wall should be grasped and gently elevated. This will dislodge any omentum or bowel that may be blocking the opening of the needle or port. Changing the angle or rotating the trocar or Veress needle can also help free the opening. If none of these maneuvers reduces the increased pressure to an acceptable level, the needle or port should be removed and replaced.",
"   </p>",
"   <p>",
"    During insufflation, increased intraabdominal pressure stimulates the neurohumoral vasoactive systems, resulting in increased heart rate, mean arterial pressure, and systemic and pulmonary vascular resistance while decreasing vital capacity, venous return, preload, and cardiac output [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/49\">",
"     49",
"    </a>",
"    ]. In otherwise healthy patients, American Society of Anesthesiologists (ASA) Class 1 or 2, these physiologic effects are not detrimental if intraabdominal pressure does not exceed 15 mmHg and diminish as the patient's physiology accommodates.",
"   </p>",
"   <p>",
"    The CO",
"    <sub>",
"     2",
"    </sub>",
"    gas causes hypercapnia and respiratory acidosis due to absorption of the gas across the peritoneal surface. Endogenous buffering systems and accelerated elimination of CO",
"    <sub>",
"     2",
"    </sub>",
"    via the lungs prevent clinically significant acidosis under normal circumstances. Monitoring end-tidal CO",
"    <sub>",
"     2",
"    </sub>",
"    concentration is mandatory, and minute volume should be increased to maintain a normal CO",
"    <sub>",
"     2",
"    </sub>",
"    level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/49\">",
"     49",
"    </a>",
"    ]. Arrhythmias are a potentially serious consequence of hypercarbia. Renal parenchymal compression and decreased renal blood flow may result in temporary oliguria, which typically resolves upon release of pneumoperitoneum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891636\">",
"    <span class=\"h2\">",
"     Fascial closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a port was placed with the open (Hasson) technique or a port &ge;12 mm is used, the fascia should be closed with suture to reduce the risk of developing a port-site hernia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/11\">",
"     11",
"    </a>",
"    ]. However, closure of the fascial defect does not guarantee that a hernia will not develop at that site. (See",
"    <a class=\"local\" href=\"#H651891970\">",
"     'Hernia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Fascial reapproximation can be accomplished in a variety of ways. Ideally, the fascia is directly visualized with the aid of retractors. The fascial edges are grasped and sutured closed with interrupted or continuous suture.",
"   </p>",
"   <p>",
"    A number of specialized instruments have been devised for port site fascial closure (eg, Grice&reg; suture needle, Carter-Thomason needle-point suture passer, Endo Close&trade; instrument, Reverdin suture needle) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The benefit of these devices has yet to be proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891644\">",
"    <span class=\"h1\">",
"     CHOICE OF TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There continues to be controversy over which of the two principle techniques, Hasson or Veress needle technique, provides safer access to the peritoneum for laparoscopic surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/3,10,12-14,18,49,53-59\">",
"     3,10,12-14,18,49,53-59",
"    </a>",
"    ]. A systematic review of randomized trials comparing these entry techniques found no significant differences in overall complication rates, but noted that the available trials were small and results were underpowered to detect uncommon complications such as vascular or gastrointestinal injury, and postoperative hernia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/1,60\">",
"     1,60",
"    </a>",
"    ]. Retrospective reviews suggest that the risk of major complications is reduced with open access techniques or placement of trocars with visual confirmation (direct vision or visual entry devices) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/1,3,12-19\">",
"     1,3,12-19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H736267272\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The conclusions drawn from the systematic review are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radially-expanding trocars reduce port site bleeding (odds ratio [OR] 0.13, 95% CI 0.05-0.37) compared with cutting trocars.",
"     </li>",
"     <li>",
"      Not elevating the abdominal wall compared with elevating it when using a Veress needle technique was found to have lower incidence of failed entry without an increase in the risk of complications. We feel that elevating specifically the fascia, as opposed to the bulky abdominal wall, may facilitate Veress needle placement; however, there are limited data available to support this conclusion.",
"     </li>",
"     <li>",
"      A direct-entry technique or use of a radially-expanding trocar reduced extraperitoneal insufflation (OR 0.16, 95% CI 0.08-0.29]) and failed entry (OR 0.25, 95% CI 0.11-0.53) compared with use of the Veress needle alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891670\">",
"    <span class=\"h2\">",
"     Access for insufflation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgeons should adhere to the technique with which they have the most experience, but should be familiar with alternative techniques. Surgeon preference and experience likely plays a role in minimizing the risk of injury.",
"   </p>",
"   <p>",
"    Each technique should be used selectively depending upon proposed port location, the intended function of the port and patient factors, such as prior surgery (ie, likelihood of adhesions) and body habitus. For access in the region of the umbilicus, either Hasson or Veress techniques can be used. A third alternative of blind trocar access without insufflation has been described, but there are inadequate data to support its use. (See",
"    <a class=\"local\" href=\"#H736267272\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A variety of",
"    <span class=\"nowrap\">",
"     trocar/port",
"    </span>",
"    combinations are commercially available for laparoscopy. Each combines a tube with a sealing mechanism to maintain pneumoperitoneum and may be non-disposable or disposable. The most common trocars cut the myofascial layers with a blade, divide tissues with non-bladed flanges or have radially dilating outer sheaths to facilitate insertion. The dilating trocars may minimize bleeding and risk of hernia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891684\">",
"    <span class=\"h2\">",
"     Primary port placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following a Veress needle insufflation, the primary port can be placed either through the Veress needle track (except 9th rib approach) or elsewhere in the abdomen with either a simple (blind) trocar or visual entry trocar. It is our practice to place a Veress needle in a left upper quadrant location for most foregut cases and to upsize to a 5 mm trocar at the same site. If a subcostal port is not needed for the procedure, we usually obtain access with a periumbilical open technique, or Veress technique with clamps elevating the fascia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891692\">",
"    <span class=\"h2\">",
"     Secondary port placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary ports can be placed with either a non-disposable trocar, shielded disposable trocar or visual entry trocar, but always while observing the entry of the trocar into the abdomen with the laparoscope. Ports should be placed to facilitate operating in-line with the camera while maintaining triangulation and adequate spacing between the hands.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891700\">",
"    <span class=\"h2\">",
"     Special considerations for access",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376701744\">",
"    <span class=\"h3\">",
"     Umbilical hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a small umbilical hernia undergoing a laparoscopic procedure, open access into the hernia and a finger sweep to clear adhesions ensures safe access to the abdomen. The hernia can then be closed primarily at the completion of the case if the defect is small (&lt;2 cm). Larger defects may be associated with significant adhesions and will likely require mesh hernia repair to minimize the risk of recurrence. Under this circumstance, access away from the umbilicus is suggested (eg, subcostal location) to facilitate visualization of the hernia and to perform lysis of adhesions, if needed. The management of umbilical hernias is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of abdominal hernias\", section on 'Umbilical hernia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376701751\">",
"    <span class=\"h3\">",
"     Prior abdominal surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior abdominal or pelvic surgery is associated with an increased risk for access site complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/61\">",
"     61",
"    </a>",
"    ]. Initial access should avoid prior surgical incisions due to the potential for adhesions. Once the abdomen is insufflated and the primary port placed, the abdomen should be inspected to determine whether adhesiolysis is needed prior to the placement of additional ports. If port placement is necessary at the site of a previous incision, open access should be performed. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376701758\">",
"    <span class=\"h3\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In obese patients, longer trocars and Veress needles may be needed due to the thickness of the abdominal wall. With the open technique, a larger skin incision may be necessary to adequately expose of the fascia.",
"   </p>",
"   <p>",
"    With a Veress needle technique, entry location should be based upon bony landmarks and not the location of the umbilicus since it can be displaced several centimeters inferiorly. The pannus can be retracted caudally, for better positioning and to thin the abdominal wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/62\">",
"     62",
"    </a>",
"    ]. Skin folds on the abdominal wall should be avoided. During Veress needle placement, a 90 degree insertion angle is used to maximize the available needle length. The use of dilating trocars may reduce the incidence of postoperative hernia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H651891644\">",
"     'Choice of technique'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Instrument mobility may also be limited depending upon the depth of the subcutaneous fat. Care must be taken during trocar placement to align their axes as needed for the procedure. Occasional repositioning of trocars may be necessary if procedures involve multiple abdominal quadrants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376701765\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gravid uterus may displace many intraabdominal organs. Initial access is chosen to avoid contact with the uterus. Open access is often advocated in pregnant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Laparoscopic surgery in pregnant patients is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8727?source=see_link\">",
"     \"Laparoscopic surgery in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891714\">",
"    <span class=\"h1\">",
"     MULTIPLE PORT PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The port locations for various laparoscopic surgeries depend upon the location in the abdomen where the majority of the surgical procedure is to take place. Typically, the operating surgeon should be standing opposite this location.",
"    <strong>",
"    </strong>",
"    Multiple access sites are chosen to maintain a comfortable operating position for the surgeon with triangulation of the instruments around the surgical focal point within the abdomen.",
"   </p>",
"   <p>",
"    Depending upon the largest instrument needed for a particular port, the appropriate-sized trocar should be used. A &ge;12 mm trocar is needed for surgical staplers, and &ge;10 mm trocar is needed for other specialized surgical instruments (eg, Endo Stitch&trade;). In general, the smallest size port possible should be used to minimize the risk of subsequent incisional hernia. (See",
"    <a class=\"local\" href=\"#H651891970\">",
"     'Hernia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Typical port placements and the role of the operating and assistant surgeon in utilizing these ports are presented for various general laparoscopic procedures. Different clinicians may use alternative port locations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891722\">",
"    <span class=\"h2\">",
"     Cholecystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use an open technique to enter the peritoneal cavity and place a 5 to 12 mm Hasson trocar at the umbilicus. The laparoscope is introduced through this port and three additional 5 mm ports are placed under direct visualization 1 to 2 cm inferior to the right subcostal margin (",
"    <a class=\"graphic graphic_figure graphicRef50974 \" href=\"mobipreview.htm?33/14/34018\">",
"     figure 6",
"    </a>",
"    ). The surgeon operates from the patient's left side using subxiphoid and one of the subcostal ports. The surgeon manipulates the infundibulum to provide counter-retraction with the left hand and uses a dissector with the right hand through the subxiphoid port (",
"    <a class=\"graphic graphic_figure graphicRef52727 \" href=\"mobipreview.htm?25/19/25910\">",
"     figure 7",
"    </a>",
"    ). The assistant works from patient's right side using the right lateral port and umbilical port. The assistant uses the left hand to retract the fundus for exposure and operates the camera with their right hand.",
"   </p>",
"   <p>",
"    Alternatively, one of the 5 mm ports can be placed halfway between the xiphoid and umbilical ports. In this case, the surgeon retracts the infundibulum of the gallbladder through the midline port and uses the dissector through the subxiphoid port (shown in red) (",
"    <a class=\"graphic graphic_figure graphicRef65844 \" href=\"mobipreview.htm?21/17/21778\">",
"     figure 8",
"    </a>",
"    ). The assistant retracts the fundus of the gallbladder cephalad through the right lateral port and operates the laparoscope via the periumbilical port.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891730\">",
"    <span class=\"h2\">",
"     Appendectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use an open technique to enter the peritoneal cavity and place a 5 to 12 mm Hasson trocar at the umbilicus. The laparoscope is introduced through this port and two additional 5 mm ports are placed under direct vision in the left lower abdomen (",
"    <a class=\"graphic graphic_figure graphicRef65327 \" href=\"mobipreview.htm?15/5/15442\">",
"     figure 9",
"    </a>",
"    ). The first is placed lateral to the left rectus muscle and medial to the anterior superior iliac spine, and the second is placed in the suprapubic region at least 2 finger breadths superior to the pubic tubercle.",
"   </p>",
"   <p>",
"    Both the surgeon and the assistant stand on the patient's left side. The surgeon operates through the two 5 mm ports and the assistant operates the laparoscope. One 12 mm port is required to pass a surgical stapler to transect the appendix. The appendix is removed through the periumbilical port site, usually with a specimen bag (",
"    <a class=\"graphic graphic_figure graphicRef78264 \" href=\"mobipreview.htm?41/26/42403\">",
"     figure 10",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Alternatively, the two 5 mm ports can be placed in the \"bikini line\" (",
"    <a class=\"graphic graphic_figure graphicRef76074 \" href=\"mobipreview.htm?6/49/6930\">",
"     figure 11",
"    </a>",
"    ). The surgeon retracts the appendix using a grasper through a right lower quadrant port and dissects using the periumbilical port site while the assistant operates the laparoscope through a left lower quadrant port.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159861899\">",
"    <span class=\"h2\">",
"     Hernia surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Access for inguinal hernia repair can be totally extra-peritoneal (TEP), or trans-abdominal pre-peritoneal (TAPP). Laparoscopic hernia repair is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26393?source=see_link\">",
"     \"Inguinal and femoral hernia repair: Laparoscopic techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For TEP access, a large balloon dissector is placed via a periumbilical incision through the rectus sheath into the preperitoneal inguinal space (",
"    <a class=\"graphic graphic_figure graphicRef54751 \" href=\"mobipreview.htm?7/8/7298\">",
"     figure 12",
"    </a>",
"    ). As the balloon is inflated, the peritoneum is dissected from the abdominal wall. Additional ports are placed in a preperitoneal location for subsequent hernia repair.",
"   </p>",
"   <p>",
"    For the TAPP approach, access is typically via an open transumbilical approach, with subsequent trocars placed lateral to the rectus muscles bilaterally and into the peritoneal space (",
"    <a class=\"graphic graphic_figure graphicRef63523 \" href=\"mobipreview.htm?7/59/8114\">",
"     figure 13",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891738\">",
"    <span class=\"h2\">",
"     Foregut surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic foregut cases include Heller-type myotomy, hiatal hernia repair, gastroesophageal fundoplication procedures, gastrectomy, and bariatric procedures (eg, Roux-en-Y gastric bypass, gastric banding).",
"   </p>",
"   <p>",
"    We use a Veress needle technique in the left upper quadrant to insufflate the peritoneal cavity, a 5 mm port is placed through the Veress tract and a laparoscope is placed. Four additional ports are placed under direct vision (",
"    <a class=\"graphic graphic_figure graphicRef56074 \" href=\"mobipreview.htm?1/41/1683\">",
"     figure 14",
"    </a>",
"    ). A 5 mm port is placed in the subxiphoid region for a laparoscopic liver retractor to aid in exposing the gastroesophageal junction. Right and left subcostal ports (5 mm) are placed and two additional ports are placed midway between these subcostal ports and the umbilicus. One of the midabdominal ports is used to pass the surgical stapler (12 mm)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    special suturing instruments, such as the Endo Stitch&trade; (11 mm) (Covidien, Norwalk, CT).",
"   </p>",
"   <p>",
"    The surgeon stands on the patient's right side using the dissector and stapler through the right-sided ports. The assistant stands on the patient's left side operating the laparoscope with his or her left hand through the 5 mm midabdominal port site, and providing counter-traction for the surgeon through the left subcostal port site.",
"   </p>",
"   <p>",
"    Alternatively, the patient can be placed in a split leg (ie, lithotomy) position, and the surgeon operates from a position between the legs. For this approach, the larger port may be placed in the patient&rsquo;s left upper quadrant to facilitate right-handed suturing. For complicated foregut procedures, an additional left abdominal port may be added.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891746\">",
"    <span class=\"h2\">",
"     Colectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;To enter the peritoneal cavity, we use an open technique at the umbilicus and place a 5 to 12 mm Hasson trocar.",
"   </p>",
"   <p>",
"    The port sites for right colectomy are similar to those for laparoscopic appendectomy (",
"    <a class=\"graphic graphic_figure graphicRef65327 \" href=\"mobipreview.htm?15/5/15442\">",
"     figure 9",
"    </a>",
"    ) with the addition of one or more 5 mm ports in the upper midline region (",
"    <a class=\"graphic graphic_figure graphicRef75513 \" href=\"mobipreview.htm?13/28/13762\">",
"     figure 15",
"    </a>",
"    ). Both the surgeon and the assistant stand on the patient's left side. A 5 mm upper midline port is useful during mobilization of a difficult hepatic flexure. Once the colon is mobilized, the umbilical port site is extended to a mini-laparotomy incision and extracorporeal bowel resection and ileo-colic anastomosis performed through a wound protector. The mini-laparotomy incision is closed according to standard principles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10633?source=see_link\">",
"     \"Principles of abdominal wall closure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For left colectomy and sigmoid colectomy, the port sites are almost a mirror image of right colectomy port sites (",
"    <a class=\"graphic graphic_figure graphicRef70436 \" href=\"mobipreview.htm?19/29/19922\">",
"     figure 16",
"    </a>",
"    ). Both the surgeon and the assistant stand on the patient's right side. Either the suprapubic port or the right lower quadrant port can be used to introduce the surgical stapler (12 mm) for transection of the sigmoid colon at the peritoneal reflection. The upper midline port is useful for mobilizing the splenic flexure. The resected sigmoid colon can be removed through a mini-laparotomy at the umbilicus, similar to the right colectomy, transrectally or through a small Pfannenstiel incision. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30265?source=see_link&amp;anchor=H19#H19\">",
"     \"Principles of abdominal wall incisions\", section on 'Pfannenstiel's incision'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891754\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is placed in a right lateral decubitus position (60 to 90 degrees) with a bean bag for support. The patient&rsquo;s abdomen is hyperextended to open the space between the patient's left iliac crest and left subcostal margin.",
"   </p>",
"   <p>",
"    We use an open technique to enter the peritoneal cavity at the umbilicus (enlarged spleen) or in a subcostal location (normal-sized spleen) and place a 5 to 12 mm Hasson trocar (",
"    <a class=\"graphic graphic_figure graphicRef79408 \" href=\"mobipreview.htm?21/27/21938\">",
"     figure 17",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A port is placed in the left flank region in the anterior axillary line between the left subcostal margin and the left iliac crest under direct vision. This port is used to pass a stapler (12 mm) to transect the hilar vessels after dissection has been completed. Two other 5 mm ports are placed for dissection and counter traction.",
"   </p>",
"   <p>",
"    After the hilum has been transected and the perisplenic attachments are divided, the spleen is captured into a large laparoscopic bag placed through the primary port site and is removed by morcellation (cutting it up). Alternatively, if the integrity of the spleen is important for pathologic analysis, a mini-laparotomy is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891762\">",
"    <span class=\"h2\">",
"     Adrenalectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is positioned in a decubitus position (with the right side down for a left-sided procedure and vice-versa for a right-sided procedure) in a 60 to 90 degree reverse Trendelenburg position using a bean bag for support. The patient&rsquo;s abdomen is hyperextended to extend the space between the patient's left iliac crest and left subcostal margin.",
"   </p>",
"   <p>",
"    We access the peritoneal cavity with a Veress technique through a midclavicular, subcostal site. The port site placements for the left and right adrenal gland are mirror-images of one another (",
"    <a class=\"graphic graphic_figure graphicRef61077 graphicRef67773 \" href=\"mobipreview.htm?27/7/27767\">",
"     figure 18A-B",
"    </a>",
"    ). Three additional ports are placed under direct vision, including a flank port in the mid-axillary line between the subcostal margin and the iliac crest, an epigastric port and a medial subcostal port. An additional port may be needed for the right adrenalectomy to retract the liver to expose the right retroperitoneum.",
"   </p>",
"   <p>",
"    Once the adrenal gland is resected, it is captured in a laparoscopic bag placed through the 12 mm subcostal port site and removed by extending this incision, as needed, to maintain the integrity of the adrenal gland for pathologic analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4133680\">",
"    <span class=\"h2\">",
"     Pelvic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of laparoscopic procedures are performed in the pelvis, including ovarian cystectomy, hysterectomy, and tubal ligation, among others. Primary access is obtained at the umbilicus using an open (Hasson) or Veress needle technique. For manipulation of pelvic structures, ports are placed, bilaterally as needed, in the lower quadrants, or, occasionally, lateral to the rectus muscle low in the abdomen at the level of the umbilicus (",
"    <a class=\"graphic graphic_figure graphicRef58323 \" href=\"mobipreview.htm?30/56/31631\">",
"     figure 19",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715077816\">",
"    <span class=\"h1\">",
"     TROUBLESHOOTING ACCESS ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891792\">",
"    <span class=\"h2\">",
"     Failed entry",
"    </span>",
"    &nbsp;&mdash;&nbsp;If bile, enteric contents or blood returns at placement of the Veress needle, the needle should be left in place and alternative access gained immediately. Alternative access can be laparoscopic unless the bleeding is significant, in which case open laparotomy is warranted.",
"   </p>",
"   <p>",
"    Any failed entry site should be inspected to assess for any associated injury which, when identified, is appropriately repaired.",
"    <strong>",
"    </strong>",
"    If entry fails but there is no complication, access can be reattempted at the same site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H736267209\">",
"    <span class=\"h2\">",
"     Leaking port",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a port leaks during a procedure, it is usually due to the fascial defect being too large. This can be mitigated with additional sutures or the placement of a towel clamp to cinch the tissue closed around the trocar. Petrolatum coated gauze may also be used to control the flow of any air.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H736267227\">",
"    <span class=\"h2\">",
"     Loss of port position",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a port is sliding within the abdominal wall, the port may need to be repositioned",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    secured with additional sutures. The use of longer or larger diameter trocars may also be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891821\">",
"    <span class=\"h2\">",
"     Bleeding port",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vessels of the abdominal wall can be injured during the access procedure. Access sites are carefully chosen to avoid these vessels. (See",
"    <a class=\"local\" href=\"#H651891348\">",
"     'Access locations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Bleeding from the abdominal wall may not become apparent until after the port is removed because the port may tamponade muscular or subcutaneous bleeding. In addition to visually inspecting the access site upon its creation, the site should also be inspected during and following removal of the port. Bleeding points can usually be identified and managed with electrocautery. On occasion, the skin incision may need to be enlarged to control the bleeding.",
"   </p>",
"   <p>",
"    If persistent bleeding continues, a Foley catheter can also be inserted, inflated, and gentle traction applied to tamponade the site. If this maneuver fails, U-stitches can be placed into the abdominal wall under direct laparoscopic visualization using a suture passer with absorbable braided suture. Care must be taken to suture above and below the injured vessel. A number of specialized instruments have been devised for port site fascial closure and these may also be useful for managing abdominal wall bleeding. (See",
"    <a class=\"local\" href=\"#H651891636\">",
"     'Fascial closure'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891855\">",
"    <span class=\"h2\">",
"     Loss of pneumoperitoneum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under some circumstances, the established pneumoperitoneum may need to be temporarily released (eg, patient intolerance, hemodynamic instability), or is lost due to a leaking port, or equipment malfunction. Most trocars have stopcock valves to easily release pneumoperitoneum if this is required. To reinstitute pneumoperitoneum, the stopcock can be turned back in line with the gas flow. To troubleshoot inadvertent loss of pressure, all potential loss sites should be assessed, including the gas supply, tubing, insufflator, valves, and port sites (eg, extraperitoneal trocar).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891868\">",
"    <span class=\"h2\">",
"     Extraperitoneal insufflation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous, preperitoneal or omental insufflation can occur with any access technique. Some authors suggest that direct access without insufflation minimizes the incidence; however, these data are limited. Any benefit of preventing erroneous insufflation is outweighed by the potential for bowel or vascular injury by placing a trocar prior to insufflation. (See",
"    <a class=\"local\" href=\"#H736267272\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Intraperitoneal placement of the Veress needle or Hasson trocar may have initially been confirmed. However, if the device is inadvertently withdrawn out of the peritoneum, subcutaneous insufflation of CO",
"    <sub>",
"     2",
"    </sub>",
"    gas will occur and insufflation pressure will quickly rise &ge;15 mmHg. The abdominal wall becomes full, but is not tympanitic, and crepitus instead will be noted in the subcutaneous tissues.",
"   </p>",
"   <p>",
"    Subcutaneous CO",
"    <sub>",
"     2",
"    </sub>",
"    insufflation may increase the end-tidal CO",
"    <sub>",
"     2",
"    </sub>",
"    , and anesthesia personnel should be notified if extraperitoneal insufflation has occurred. Small amounts of extraperitoneal air are usually quickly resorbed once intraperitoneal insufflation is achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891896\">",
"    <span class=\"h2\">",
"     Access-related pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain from trocar placement is expected, but can be minimized by using the least number of ports required to perform the procedure safely, minimizing the number of large ports (ie, &ge;10 mm), and injecting local anesthetic at the port sites either before or at the end of the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other measures relating to insufflation that may reduce access-related pain include reducing the initial insufflation rate and insufflation pressure, warming and humidifying the CO",
"    <sub>",
"     2",
"    </sub>",
"    gas and removing residual CO",
"    <sub>",
"     2",
"    </sub>",
"    gas at the end of the procedure (facilitated by placing the patient in Trendelenburg position) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/65-71\">",
"     65-71",
"    </a>",
"    ]. The displacement of trapped CO",
"    <sub>",
"     2",
"    </sub>",
"    gas may be improved with the instillation of normal saline, or by using pulmonary recruitment maneuvers, which involve multiple manual pulmonary inflations by the anesthesiologist (increases intraabdominal pressure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/65-71\">",
"     65-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methods for more fully evacuating pneumoperitoneum were compared in a trial that randomly assigned 158 women undergoing gynecologic laparoscopic surgery to one of three groups to evaluate the effectiveness of these treatments in preventing postoperative laparoscopy-induced abdominal or shoulder pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/65\">",
"     65",
"    </a>",
"    ]. After pneumoperitoneum was released, the abdomen was either filled with normal saline, pulmonary recruitment maneuvers were used, or no additional procedure was used (control). The incidence of postoperative shoulder pain was significantly decreased in the saline group (41 versus 65 and 73 percent at 24 hours after surgery, respectively; 24 versus 51 and 55 percent at 48 hours after surgery, respectively) compared with the pulmonary recruitment group or control group. Upper abdominal pain was improved for both treatment groups compared with the control group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H736267272\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of access-related fatalities following laparoscopic surgery are due to a vascular or gastrointestinal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/15\">",
"     15",
"    </a>",
"    ]. Most severe injuries are due to blind insertion of access devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/1,13,16,72\">",
"     1,13,16,72",
"    </a>",
"    ]. We recommend not using blind trocar entry techniques for primary or secondary trocar placement, especially prior to insufflation of the abdomen. Visual entry devices are readily available for the placement of primary trocars, and secondary trocars should always be placed under direct laparoscopic vision. Although earlier retrospective reviews attempted to justify the use of blind trocar techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/54,55,57-59\">",
"     54,55,57-59",
"    </a>",
"    ], the negligible benefit of a quicker entry does not justify the risk of a potentially lethal complication.",
"   </p>",
"   <p>",
"    A review of 1399 trocar-associated injuries and fatalities reported in the Food and Drug administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database, interestingly found that a high proportion of reports were associated with laparoscopic cholecystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/15\">",
"     15",
"    </a>",
"    ]. This likely reflects the high prevalence of this procedure as the most common laparoscopic procedure performed in the United States. Whether a Veress or Hasson technique was used for primary abdominal insufflation was not specified; other studies have not identified significant differences in overall complication rates for Veress needle insufflation when performed by experienced surgeons. The majority of complications were related to user technique. A device issue or failure contributed to the complication in 8 percent of reported complications; however, about one-third of devices were not assessed because they were not returned to the manufacturer or the condition of the device prevented evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19386192\">",
"    <span class=\"h2\">",
"     Vascular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common vascular injury is laceration of the mesenteric vessels during insertion of a Veress needle at the umbilicus or during primary trocar placement, particularly if there are adhesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/21,73\">",
"     21,73",
"    </a>",
"    ]. Laceration of the inferior epigastric artery is the most common vascular injury during placement of lateral trocars. The reported rate of vascular complications is 0.1 to 6.4 per 1000 laparoscopies; underreporting is common. Vascular injury may not be appreciated immediately, due to bleeding into the mesentery or retroperitoneum rather than into the peritoneal cavity.",
"   </p>",
"   <p>",
"    Minor bleeding sites can usually be identified using probing instruments or an irrigator-aspirator. Once identified, the site can be coagulated or clipped. If moderate bleeding occurs, a damp sponge can be introduced through a 10 mm trocar and direct pressure applied, which will often control the problem or provide time to consider other options. Other methods to manage bleeding are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14984?source=see_link&amp;anchor=H16#H16\">",
"     \"Devices for dissection and hemostasis in laparoscopic surgery\", section on 'Management of hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Major vascular injury during access for laparoscopic surgery occurs in 0.3 to 1.0 percent of procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/1,16,72\">",
"     1,16,72",
"    </a>",
"    ]. Injury to the aorta or iliac vessels during access can lead to rapid exsanguination and death unless prompt vascular control and repair are undertaken [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/5\">",
"     5",
"    </a>",
"    ]. The aorta is injured more commonly with laparoscopic cholecystectomy and the iliac vessels during appendectomy and gynecologic procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/15\">",
"     15",
"    </a>",
"    ]. Injury to major venous structures (eg, inferior vena cava, iliac vein) can also occur, and air embolism due to unrecognized intravenous Veress needle placement and subsequent insufflation has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/72\">",
"     72",
"    </a>",
"    ]. The diagnosis and management of air embolus is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Injury to the major vasculature requires subspecialty expertise, and consultation with a surgeon experienced with vascular procedures should be obtained without delay. The abdomen should be opened with a midline incision and direct pressure should be applied to the bleeding site for initial control. If a vascular surgeon is not immediately available (community facility, ambulatory surgery center), damage control trauma surgery techniques with abdominal packing, fluid resuscitation and arrangement for immediate transfer have been advocated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/72\">",
"     72",
"    </a>",
"    ]. The technique of packing the abdomen in the setting of hemorrhage is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7049?source=see_link&amp;anchor=H13#H13\">",
"     \"Surgical management of splenic injury in the adult trauma patient\", section on 'Packing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891923\">",
"    <span class=\"h2\">",
"     Gastrointestinal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the gastrointestinal tract occurs in about 1 percent of patients undergoing laparoscopic surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/1\">",
"     1",
"    </a>",
"    ]. The small bowel is the most commonly injured gastrointestinal structure during access for laparoscopic surgery, but stomach, liver and colon injury have been reported with subcostal access techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/13,59,74\">",
"     13,59,74",
"    </a>",
"    ]. Decompressing the stomach with an orogastric or nasogastric tube prior to upper abdominal access may minimize the potential for inadvertent injury to the stomach.",
"   </p>",
"   <p>",
"    Half of all inadvertent bowel injuries occur during initial peritoneal access, and this complication is potentially life-threatening if unrecognized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/13,61,63,73,75\">",
"     13,61,63,73,75",
"    </a>",
"    ]. The open technique could be expected to have a decreased incidence of bowel injury; however, data are conflicting with some studies reporting a higher incidence of bowel injury with open compared with closed techniques. One large retrospective study reported a lower incidence of bowel injury with closed techniques (0.1 percent) compared with open techniques (0.2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/3\">",
"     3",
"    </a>",
"    ]. A possible reason for this higher incidence may be a selection bias, as some surgeons reserve open access techniques for patients anticipated to have complicated entry (eg, adhesions).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891931\">",
"    <span class=\"h2\">",
"     Bladder injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;When anticipating port placement below the level of the umbilicus, a Foley catheter should be placed to decompress the bladder and minimize the potential for bladder injury. If bladder injury occurs, the bladder should be repaired with absorbable suture and the Foley catheter left in place at the completion of the procedure for continued bladder decompression. If the surgeon is unsure of bladder management, an urologist should be consulted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891944\">",
"    <span class=\"h2\">",
"     Nerve injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of port sites should be chosen to avoid abdominal wall nerves (",
"    <a class=\"graphic graphic_figure graphicRef71423 \" href=\"mobipreview.htm?30/56/31624\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H651891340\">",
"     'Abdominal wall anatomy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/18/17703?source=see_link\">",
"     \"Anatomy of the abdominal wall\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nerve injury is unlikely to be recognized intraoperatively, and usually results in persistent postoperative pain. Nerve injury due to port site placement can be differentiated from other causes of pain by demonstrating relief of pain with the administration of local anesthesia to the previous port site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891970\">",
"    <span class=\"h2\">",
"     Hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trocar site hernia is uncommon. A systematic review found a prevalence of 0.5 percent among patients undergoing laparoscopic surgery in 21 studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/76\">",
"     76",
"    </a>",
"    ]. The risk of developing incisional hernia is low with the use of trocars &le;12 mm, radially dilating trocars, or bladeless trocars [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/11,76\">",
"     11,76",
"    </a>",
"    ]. Other risk factors include older age and a higher body mass index. Most authors close fascial defects if a port &gt;12 mm is used, regardless of site or trocar type. Some advocate closure if &gt;10 mm in size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H651891636\">",
"     'Fascial closure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although rare, hernia has been reported even for 5 mm trocar sites. When port site hernia is identified following laparoscopy, the site should be repaired to prevent the development of intestinal complications (ie, obstruction, strangulation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/78\">",
"     78",
"    </a>",
"    ]. The management of incisional hernias is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=see_link\">",
"     \"Overview of abdominal hernias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19386384\">",
"    <span class=\"h2\">",
"     Wound infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound infection is less common after laparoscopic compared with open procedures; nonetheless, it can produce significant morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/79\">",
"     79",
"    </a>",
"    ]. The presence of significant peri-incisional erythema, wound drainage and fever may indicate the presence of a necrotizing fascial infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. The diagnosis and management of necrotizing fasciitis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the umbilicus is more commonly associated with surgical site infection than other trocar sites, this finding correlates with the use of the umbilicus as a specimen extraction site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/1/31770/abstract/83\">",
"     83",
"    </a>",
"    ]. Wound infections are prevented by appropriate administration of antibiotic prophylaxis, sterile technique and use of specimen bags during specimen extraction. Once present, infections are treated with drainage, packing and antibiotics as appropriate (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H651891990\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laparoscopic techniques have revolutionized the field of surgery. Before any laparoscopic procedure can begin, the peritoneal cavity needs to be accessed to establish pneumoperitoneum and place ports for the laparoscope and various laparoscopic instruments. (See",
"      <a class=\"local\" href=\"#H651891331\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial laparoscopic access is performed with open (ie, Hasson), or closed (eg, Veress needle) techniques. The Hasson technique refers to an open method in which an incision is made through the abdominal wall and a blunt",
"      <span class=\"nowrap\">",
"       trocar/port",
"      </span>",
"      (ie, Hasson) is placed under direct vision. The Veress needle technique refers to a closed method in which a Veress needle punctures through the abdominal wall. Once the needle is in place, the abdomen is insufflated and a",
"      <span class=\"nowrap\">",
"       trocar/port",
"      </span>",
"      is placed through the Veress needle tract. (See",
"      <a class=\"local\" href=\"#H651891356\">",
"       'Peritoneal access'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial access for abdominal insufflation is typically performed at the umbilicus. Open access techniques can be performed anywhere on the abdominal wall. Alternative sites for Veress needle insufflation include the ninth left intercostal space, the lateral border of the rectus muscle 3 cm below the left costal margin (ie, Palmer's point), and the lateral border of the rectus muscle at the level of the iliac crest. (See",
"      <a class=\"local\" href=\"#H376701638\">",
"       'Midline abdomen'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H376701659\">",
"       'Ninth left intercostal space'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H376701666\">",
"       'Lateral abdomen/flank'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H376701673\">",
"       'Hypogastrium'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      The locations for multiple ports in laparoscopic surgery are chosen to triangulate the camera and instruments around a focal point within the abdomen, thereby maintaining optimal access for manipulation of the instruments and providing comfortable positions for the surgeon and assistant. (See",
"      <a class=\"local\" href=\"#H651891714\">",
"       'Multiple port placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Advanced approaches under investigation as alternative access techniques for laparoscopic surgery include single incision surgery (SIS) and natural orifice transluminal endoscopic surgery (NOTES). These approaches are largely investigational. (See",
"      <a class=\"local\" href=\"#H651891400\">",
"       'Advanced access techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For initial peritoneal access, we suggest that surgeons should adhere to the technique with which they have the most experience (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Overall complication rates for laparoscopic access are not significantly different between the Hasson and Veress needle techniques for abdominal insufflation when performed by experienced surgeons; however, the surgeon should be familiar with alternative techniques. (See",
"      <a class=\"local\" href=\"#H651891644\">",
"       'Choice of technique'",
"      </a>",
"      above.) Conditions that may require an alternative approach for laparoscopic access include the presence of umbilical hernia, prior abdominal surgery, obesity and pregnancy. (See",
"      <a class=\"local\" href=\"#H651891700\">",
"       'Special considerations for access'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using blind trocar techniques for peritoneal access, wherever possible, but particularly prior to insufflation of the abdomen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Blind trocar entry is associated with a greater risk of severe complications, including vascular and gastrointestinal injury. Strict adherence to proper technique minimizes the risk of injury with Veress needle insufflation and visual entry devices are readily available for the placement of primary trocars. Secondary trocars should always be placed under direct laparoscopic vision. The negligible benefit of a quicker entry does not justify the risk of a potentially lethal complication. (See",
"      <a class=\"local\" href=\"#H651891644\">",
"       'Choice of technique'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H736267272\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Access-related issues including failed entry, extraperitoneal insufflation, leaking or bleeding ports, and loss of port position or pneumoperitoneum are unique to laparoscopic surgery. Troubleshooting these issues should be approached in a systematic manner to minimize the loss of time and prevent the development of other complications. (See",
"      <a class=\"local\" href=\"#H715077816\">",
"       'Troubleshooting access issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/1\">",
"      Ahmad, G, Duffy, JM, Phillips, K, Watson, A. Laparoscopic entry techniques. Cochrane Database Syst Rev 2008; CD006583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/2\">",
"      Hasson HM. Open laparoscopy as a method of access in laparoscopic surgery. Gynaecol Endosc 1999; 8:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/3\">",
"      Molloy D, Kaloo PD, Cooper M, Nguyen TV. Laparoscopic entry: a literature review and analysis of techniques and complications of primary port entry. Aust N Z J Obstet Gynaecol 2002; 42:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/4\">",
"      Jansen FW, Kolkman W, Bakkum EA, et al. Complications of laparoscopy: an inquiry about closed- versus open-entry technique. Am J Obstet Gynecol 2004; 190:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/5\">",
"      Sharp HT, Dodson MK, Draper ML, et al. Complications associated with optical-access laparoscopic trocars. Obstet Gynecol 2002; 99:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/6\">",
"      Tulikangas PK, Robinson DS, Falcone T. Left upper quadrant cannula insertion. Fertil Steril 2003; 79:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/7\">",
"      Palmer R. Safety in laparoscopy. J Reprod Med 1974; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/8\">",
"      Rahn DD, Phelan JN, Roshanravan SM, et al. Anterior abdominal wall nerve and vessel anatomy: clinical implications for gynecologic surgery. Am J Obstet Gynecol 2010; 202:234.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/9\">",
"      Hasson HM. A modified instrument and method for laparoscopy. Am J Obstet Gynecol 1971; 110:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/10\">",
"      Hasson HM, Rotman C, Rana N, Kumari NA. Open laparoscopy: 29-year experience. Obstet Gynecol 2000; 96:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/11\">",
"      Johnson WH, Fecher AM, McMahon RL, et al. VersaStep trocar hernia rate in unclosed fascial defects in bariatric patients. Surg Endosc 2006; 20:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/12\">",
"      Bonjer HJ, Hazebroek EJ, Kazemier G, et al. Open versus closed establishment of pneumoperitoneum in laparoscopic surgery. Br J Surg 1997; 84:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/13\">",
"      Sigman HH, Fried GM, Garzon J, et al. Risks of blind versus open approach to celiotomy for laparoscopic surgery. Surg Laparosc Endosc 1993; 3:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/14\">",
"      Sch&auml;fer M, Lauper M, Kr&auml;henb&uuml;hl L. Trocar and Veress needle injuries during laparoscopy. Surg Endosc 2001; 15:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/15\">",
"      Fuller J, Ashar BS, Carey-Corrado J. Trocar-associated injuries and fatalities: an analysis of 1399 reports to the FDA. J Minim Invasive Gynecol 2005; 12:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/16\">",
"      Chapron CM, Pierre F, Lacroix S, et al. Major vascular injuries during gynecologic laparoscopy. J Am Coll Surg 1997; 185:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/17\">",
"      Larobina M, Nottle P. Complete evidence regarding major vascular injuries during laparoscopic access. Surg Laparosc Endosc Percutan Tech 2005; 15:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/18\">",
"      Merlin TL, Hiller JE, Maddern GJ, et al. Systematic review of the safety and effectiveness of methods used to establish pneumoperitoneum in laparoscopic surgery. Br J Surg 2003; 90:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/19\">",
"      Azevedo JL, Azevedo OC, Miyahira SA, et al. Injuries caused by Veress needle insertion for creation of pneumoperitoneum: a systematic literature review. Surg Endosc 2009; 23:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/20\">",
"      Teoh B, Sen R, Abbott J. An evaluation of four tests used to ascertain Veres needle placement at closed laparoscopy. J Minim Invasive Gynecol 2005; 12:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/21\">",
"      Shirk GJ, Johns A, Redwine DB. Complications of laparoscopic surgery: How to avoid them and how to repair them. J Minim Invasive Gynecol 2006; 13:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/22\">",
"      Reich H, Ribeiro SC, Rasmussen C, et al. High-pressure trocar insertion technique. JSLS 1999; 3:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/23\">",
"      Abu-Rafea B, Vilos GA, Vilos AG, et al. High-pressure laparoscopic entry does not adversely affect cardiopulmonary function in healthy women. J Minim Invasive Gynecol 2005; 12:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/24\">",
"      Vilos GA. The ABCs of a safer laparoscopic entry. J Minim Invasive Gynecol 2006; 13:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/25\">",
"      String A, Berber E, Foroutani A, et al. Use of the optical access trocar for safe and rapid entry in various laparoscopic procedures. Surg Endosc 2001; 15:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/26\">",
"      Hernandez J, Ross S, Morton C, et al. The learning curve of laparoendoscopic single-site (LESS) cholecystectomy: definable, short, and safe. J Am Coll Surg 2010; 211:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/27\">",
"      Rawlings A, Hodgett SE, Matthews BD, et al. Single-incision laparoscopic cholecystectomy: initial experience with critical view of safety dissection and routine intraoperative cholangiography. J Am Coll Surg 2010; 211:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/28\">",
"      Romanelli JR, Earle DB. Single-port laparoscopic surgery: an overview. Surg Endosc 2009; 23:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/29\">",
"      Canes D, Desai MM, Aron M, et al. Transumbilical single-port surgery: evolution and current status. Eur Urol 2008; 54:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/30\">",
"      Pryor AD, Tushar JR, DiBernardo LR. Single-port cholecystectomy with the TransEnterix SPIDER: simple and safe. Surg Endosc 2010; 24:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/31\">",
"      Pfluke JM, Parker M, Stauffer JA, et al. Laparoscopic surgery performed through a single incision: a systematic review of the current literature. J Am Coll Surg 2011; 212:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/32\">",
"      Champagne BJ, Papaconstantinou HT, Parmar SS, et al. Single-incision versus standard multiport laparoscopic colectomy: a multicenter, case-controlled comparison. Ann Surg 2012; 255:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/33\">",
"      St Peter SD, Adibe OO, Juang D, et al. Single incision versus standard 3-port laparoscopic appendectomy: a prospective randomized trial. Ann Surg 2011; 254:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/34\">",
"      Lee PC, Lo C, Lai PS, et al. Randomized clinical trial of single-incision laparoscopic cholecystectomy versus minilaparoscopic cholecystectomy. Br J Surg 2010; 97:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/35\">",
"      Tugcu V, Ilbey YO, Mutlu B, Tasci AI. Laparoendoscopic single-site surgery versus standard laparoscopic simple nephrectomy: a prospective randomized study. J Endourol 2010; 24:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/36\">",
"      Elsey JK, Feliciano DV. Initial experience with single-incision laparoscopic cholecystectomy. J Am Coll Surg 2010; 210:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/37\">",
"      Makino T, Milsom JW, Lee SW. Feasibility and safety of single-incision laparoscopic colectomy: a systematic review. Ann Surg 2012; 255:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/38\">",
"      Tsimoyiannis EC, Tsimogiannis KE, Pappas-Gogos G, et al. Different pain scores in single transumbilical incision laparoscopic cholecystectomy versus classic laparoscopic cholecystectomy: a randomized controlled trial. Surg Endosc 2010; 24:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/39\">",
"      Lai EC, Yang GP, Tang CN, et al. Prospective randomized comparative study of single incision laparoscopic cholecystectomy versus conventional four-port laparoscopic cholecystectomy. Am J Surg 2011; 202:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/40\">",
"      Marks J, Tacchino R, Roberts K, et al. Prospective randomized controlled trial of traditional laparoscopic cholecystectomy versus single-incision laparoscopic cholecystectomy: report of preliminary data. Am J Surg 2011; 201:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/41\">",
"      Asakuma M, Hayashi M, Komeda K, et al. Impact of single-port cholecystectomy on postoperative pain. Br J Surg 2011; 98:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/42\">",
"      Sodergren MH, Clark J, Athanasiou T, et al. Natural orifice translumenal endoscopic surgery: critical appraisal of applications in clinical practice. Surg Endosc 2009; 23:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/43\">",
"      Pearl JP, Ponsky JL. Natural orifice translumenal endoscopic surgery: a critical review. J Gastrointest Surg 2008; 12:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/44\">",
"      Flora ED, Wilson TG, Martin IJ, et al. A review of natural orifice translumenal endoscopic surgery (NOTES) for intra-abdominal surgery: experimental models, techniques, and applicability to the clinical setting. Ann Surg 2008; 247:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/45\">",
"      de la Fuente SG, Demaria EJ, Reynolds JD, et al. New developments in surgery: Natural Orifice Transluminal Endoscopic Surgery (NOTES). Arch Surg 2007; 142:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/46\">",
"      Morgan HR. Laparoscopy: induction of pneumoperitoneum via transfundal puncture. Obstet Gynecol 1979; 54:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/47\">",
"      Neely MR, McWilliams R, Makhlouf HA. Laparoscopy: routine pneumoperitoneum via the posterior fornix. Obstet Gynecol 1975; 45:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/48\">",
"      Cheng Y, Xiong X, Wu S, et al. Gases for establishing pneumoperitoneum during laparoscopic abdominal surgery. Cochrane Database Syst Rev 2013; :CD009569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/49\">",
"      Neudecker J, Sauerland S, Neugebauer E, et al. The European Association for Endoscopic Surgery clinical practice guideline on the pneumoperitoneum for laparoscopic surgery. Surg Endosc 2002; 16:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/50\">",
"      Ost MC, Tan BJ, Lee BR. Urological laparoscopy: basic physiological considerations and immunological consequences. J Urol 2005; 174:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/51\">",
"      Berguer R. A technique for full thickness closure of laparoscopic trocar sites. J Am Coll Surg 1995; 180:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/52\">",
"      Carter JE. A new technique of fascial closure for laparoscopic incisions. J Laparoendosc Surg 1994; 4:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/53\">",
"      Zaraca F, Catarci M, Gossetti F, et al. Routine use of open laparoscopy: 1,006 consecutive cases. J Laparoendosc Adv Surg Tech A 1999; 9:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/54\">",
"      Jarrett JC 2nd. Laparoscopy: direct trocar insertion without pneumoperitoneum. Obstet Gynecol 1990; 75:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/55\">",
"      Copeland C, Wing R, Hulka JF. Direct trocar insertion at laparoscopy: an evaluation. Obstet Gynecol 1983; 62:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/56\">",
"      Poindexter AN, Ritter M, Fahim A, Humphrey H. Trocar introduction performed during laparoscopy of the obese patient. Surg Gynecol Obstet 1987; 165:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/57\">",
"      Borgatta L, Gruss L, Barad D, Kaali SG. Direct trocar insertion vs. Verres needle use for laparoscopic sterilization. J Reprod Med 1990; 35:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/58\">",
"      Byron JW, Markenson G, Miyazawa K. A randomized comparison of Verres needle and direct trocar insertion for laparoscopy. Surg Gynecol Obstet 1993; 177:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/59\">",
"      Kaali SG, Bartfai G. Direct insertion of the laparoscopic trocar after an earlier laparotomy. J Reprod Med 1988; 33:739.",
"     </a>",
"    </li>",
"    <li>",
"     Laparoscopic Entry Techniques. www2.cochrane.org/reviews/en/ab006583.html (Accessed on June 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/61\">",
"      Jansen FW, Kapiteyn K, Trimbos-Kemper T, et al. Complications of laparoscopy: a prospective multicentre observational study. Br J Obstet Gynaecol 1997; 104:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/62\">",
"      Lamvu G, Zolnoun D, Boggess J, Steege JF. Obesity: physiologic changes and challenges during laparoscopy. Am J Obstet Gynecol 2004; 191:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/63\">",
"      H&auml;rkki-Sir&eacute;n P, Kurki T. A nationwide analysis of laparoscopic complications. Obstet Gynecol 1997; 89:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/64\">",
"      Curet MJ. Special problems in laparoscopic surgery. Previous abdominal surgery, obesity, and pregnancy. Surg Clin North Am 2000; 80:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/65\">",
"      Tsai HW, Chen YJ, Ho CM, et al. Maneuvers to decrease laparoscopy-induced shoulder and upper abdominal pain: a randomized controlled study. Arch Surg 2011; 146:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/66\">",
"      Phelps P, Cakmakkaya OS, Apfel CC, Radke OC. A simple clinical maneuver to reduce laparoscopy-induced shoulder pain: a randomized controlled trial. Obstet Gynecol 2008; 111:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/67\">",
"      Sharami SH, Sharami MB, Abdollahzadeh M, Keyvan A. Randomised clinical trial of the influence of pulmonary recruitment manoeuvre on reducing shoulder pain after laparoscopy. J Obstet Gynaecol 2010; 30:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/68\">",
"      Tsimoyiannis EC, Siakas P, Tassis A, et al. Intraperitoneal normal saline infusion for postoperative pain after laparoscopic cholecystectomy. World J Surg 1998; 22:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/69\">",
"      Tsimoyiannis EC, Glantzounis G, Lekkas ET, et al. Intraperitoneal normal saline and bupivacaine infusion for reduction of postoperative pain after laparoscopic cholecystectomy. Surg Laparosc Endosc 1998; 8:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/70\">",
"      Barczy��ski M, Herman RM. Low-pressure pneumoperitoneum combined with intraperitoneal saline washout for reduction of pain after laparoscopic cholecystectomy: a prospective randomized study. Surg Endosc 2004; 18:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/71\">",
"      Esmat ME, Elsebae MM, Nasr MM, Elsebaie SB. Combined low pressure pneumoperitoneum and intraperitoneal infusion of normal saline for reducing shoulder tip pain following laparoscopic cholecystectomy. World J Surg 2006; 30:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/72\">",
"      Sandadi S, Johannigman JA, Wong VL, et al. Recognition and management of major vessel injury during laparoscopy. J Minim Invasive Gynecol 2010; 17:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/73\">",
"      Magrina JF. Complications of laparoscopic surgery. Clin Obstet Gynecol 2002; 45:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/74\">",
"      Philosophe R. Avoiding complications of laparoscopic surgery. Fertil Steril 2003; 80 Suppl 4:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/75\">",
"      H&auml;rkki-Siren P, Sj&ouml;berg J, Kurki T. Major complications of laparoscopy: a follow-up Finnish study. Obstet Gynecol 1999; 94:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/76\">",
"      Swank HA, Mulder IM, la Chapelle CF, et al. Systematic review of trocar-site hernia. Br J Surg 2012; 99:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/77\">",
"      Tonouchi H, Ohmori Y, Kobayashi M, Kusunoki M. Trocar site hernia. Arch Surg 2004; 139:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/78\">",
"      Bruy&egrave;re F, Sun J, Cosson JP, Kouri G. Incarceration of bowel through opening of a 5-mm port. J Endourol 2004; 18:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/79\">",
"      Chen LF, Anderson DJ, Hartwig MG, et al. Surgical site infections after laparoscopic and open cholecystectomies in community hospitals . Infect Control Hosp Epidemiol 2008; 29:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/80\">",
"      Tan LG, See JY, Wong KS. Necrotizing fasciitis after laparoscopic colonic surgery: case report and review of the literature. Surg Laparosc Endosc Percutan Tech 2007; 17:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/81\">",
"      Losanoff JE, Richman BW, Jones JW. Trocar-site hernia complicated by necrotizing fasciitis--case report and review of the literature. Hernia 2003; 7:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/82\">",
"      Bharathan R, Hanson M. Diagnostic laparoscopy complicated by group A streptococcal necrotizing fasciitis. J Minim Invasive Gynecol 2010; 17:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/1/31770/abstract/83\">",
"      Voitk AJ, Tsao SG. The umbilicus in laparoscopic surgery. Surg Endosc 2001; 15:878.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15103 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31770=[""].join("\n");
var outline_f31_1_31770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H651891990\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651891331\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651891340\">",
"      ABDOMINAL WALL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891348\">",
"      Access locations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376701638\">",
"      - Midline abdomen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376701645\">",
"      - Umbilicus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376701652\">",
"      - Medial costal margin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376701659\">",
"      - Ninth left intercostal space",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376701666\">",
"      - Lateral abdomen/flank",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376701673\">",
"      - Hypogastrium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651891356\">",
"      PERITONEAL ACCESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891364\">",
"      Open (Hasson)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H159864991\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891372\">",
"      Closed (Veress needle)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H159864998\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891392\">",
"      Visual entry technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H159864984\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891400\">",
"      Advanced access techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376701701\">",
"      - Single-incision surgery (SIS)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376701715\">",
"      - Natural Orifice Transluminal Endoscopic Surgery (NOTES)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376701730\">",
"      - Alternative sites used in gynecologic laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891622\">",
"      Establishing pneumoperitoneum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891636\">",
"      Fascial closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651891644\">",
"      CHOICE OF TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891670\">",
"      Access for insufflation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891684\">",
"      Primary port placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891692\">",
"      Secondary port placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891700\">",
"      Special considerations for access",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376701744\">",
"      - Umbilical hernia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376701751\">",
"      - Prior abdominal surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376701758\">",
"      - Obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376701765\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651891714\">",
"      MULTIPLE PORT PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891722\">",
"      Cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891730\">",
"      Appendectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H159861899\">",
"      Hernia surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891738\">",
"      Foregut surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891746\">",
"      Colectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891754\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891762\">",
"      Adrenalectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4133680\">",
"      Pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H715077816\">",
"      TROUBLESHOOTING ACCESS ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891792\">",
"      Failed entry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H736267209\">",
"      Leaking port",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H736267227\">",
"      Loss of port position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891821\">",
"      Bleeding port",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891855\">",
"      Loss of pneumoperitoneum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891868\">",
"      Extraperitoneal insufflation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891896\">",
"      Access-related pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H736267272\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19386192\">",
"      Vascular injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891923\">",
"      Gastrointestinal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891931\">",
"      Bladder injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891944\">",
"      Nerve injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H651891970\">",
"      Hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19386384\">",
"      Wound infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H651891990\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15103\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15103|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/40/29320\" title=\"figure 1\">",
"      Sectional view of the abdominal wall musculature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/5/15446\" title=\"figure 2\">",
"      Anomalies of the urachus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/45/3798\" title=\"figure 3\">",
"      Muscles of the lateral abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/56/31624\" title=\"figure 4\">",
"      Nerves of the abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/30/11753\" title=\"figure 5\">",
"      Blood vessels of the anterior abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/14/34018\" title=\"figure 6\">",
"      Port placement for laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/19/25910\" title=\"figure 7\">",
"      Laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/17/21778\" title=\"figure 8\">",
"      Alternative port placement for cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/5/15442\" title=\"figure 9\">",
"      Port placement for laparoscopic appendectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/26/42403\" title=\"figure 10\">",
"      Laparoscopic appendectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/49/6930\" title=\"figure 11\">",
"      Alternative port placement for appendectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/8/7298\" title=\"figure 12\">",
"      Port placement for TEP hernia repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/59/8114\" title=\"figure 13\">",
"      Port placement for TAPP hernia repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/41/1683\" title=\"figure 14\">",
"      Port placement for foregut surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/28/13762\" title=\"figure 15\">",
"      Port placement right colectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/29/19922\" title=\"figure 16\">",
"      Port placement left colectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/27/21938\" title=\"figure 17\">",
"      Port placement splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/15/16626\" title=\"figure 18A\">",
"      Port placement left adrenalectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/57/16274\" title=\"figure 18B\">",
"      Port placement right adrenalectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/56/31631\" title=\"figure 19\">",
"      Port sites for vaginal hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15103|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/45/39634\" title=\"picture 1\">",
"      Umbilical hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/48/27395\" title=\"picture 2\">",
"      Veress needle for insufflation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/38/40559\" title=\"picture 3\">",
"      Types of laparoscopes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/19/14643\" title=\"picture 4\">",
"      Single incision laparoscopic surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/18/17703?source=related_link\">",
"      Anatomy of the abdominal wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14984?source=related_link\">",
"      Devices for dissection and hemostasis in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12168?source=related_link\">",
"      Gynecologic laparoscopy: Non-umbilical entry sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26393?source=related_link\">",
"      Inguinal and femoral hernia repair: Laparoscopic techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8727?source=related_link\">",
"      Laparoscopic surgery in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2103?source=related_link\">",
"      Natural orifice transluminal endoscopic surgery (NOTES)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10633?source=related_link\">",
"      Principles of abdominal wall closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30265?source=related_link\">",
"      Principles of abdominal wall incisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7049?source=related_link\">",
"      Surgical management of splenic injury in the adult trauma patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_1_31771="Clin classif DM foot infx";
var content_f31_1_31771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical classification of a diabetic foot infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Infection severity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical manifestations of infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uninfected",
"       </td>",
"       <td>",
"        Wound lacking purulence or any manifestations of inflammation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        Presence of &ge;2 manifestations of inflammation (purulence, or erythema, pain, tenderness, warmth, or induration), but any cellulitis/erythema extends &le;2 cm around the ulcer, and infection is limited to the skin or superficial subcutaneous tissues; no other local complications or systemic illness.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Infection (as above) in a patient who is systemically well and metabolically stable but which has &ge;1 of the following characteristics: cellulitis extending &gt;2 cm, lymphangitic streaking, spread beneath the superficial fascia, deep-tissue abscess, gangrene, and involvement of muscle, tendon, joint or bone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        Infection in a patient with systemic toxicity or metabolic instability (eg, fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe hyperglycemia, or azotemia).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Foot ischemia may increase the severity of any infection, and the presence of critical ischemia often makes the infection severe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lipsky, BA, Berendt, AR, Deery, HG, et al. Diagnosis and Treatment of Diabetic Foot Infections. Clin Infect Dis 2004; 39:885. Copyright &copy;2004 The University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31771=[""].join("\n");
var outline_f31_1_31771=null;
var title_f31_1_31772="Neurologic follow-up in GD";
var content_f31_1_31772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F64752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F64752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minimum clinical protocol for neurologic follow-up in GD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        1. Clinical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurological examination: Every 3 months during year 1, every 6 months thereafter. Neurological examination to include scoring as defined in the Severity Scoring Tool for NGD",
"        <sup>",
"         [1]",
"        </sup>",
"        to monitor changes. In adolescent and adult patients who are stable, neurological examination once a year may be sufficient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If eye movements were considered to be normal at the time of initial assessment or if the result was equivocal (often the case with very young or sick children), such testing should be repeated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Additional neuro-ophthalmological investigation: Only if clinically indicated; eg, development of sixth-nerve palsy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral hearing (audiometry or electro-acoustical emissions depending on age, as stated above): Evaluating trends every 2 or 3 years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        2. Brain imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Only if clinically indicated. The risk of anaesthesia should be considered. An exception to this may be made in patients who have the D409H allele. Such patients may be at risk of hydrocephalus",
"        <sup>",
"         [2,3]",
"        </sup>",
"        , and may therefore need to be scanned on a regular basis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        3. Neurophysiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EEG: Only if clinically indicated; eg, by presence of seizures. If myoclonus is suspected, telemetry may be needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nerve conduction velocity: Only if clinically indicated with reported symptoms of tingling, numbness, pins and needles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        4. Neuropsychometry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Annual assessments are probably not necessary as they are time-consuming. We suggest the following: assessment at school entry, then at transition from primary to secondary school, then when transitioning to college/adult education. Age-appropriate scales should be used.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Davies EH, Surtees R, DeVile C, et al. A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J Inherit Metab Dis 2007b; 30:768.",
"       </li>",
"       <li>",
"        Inui K, Yanagihara K, Otani K, et al. A new variant neuropathic type of Gaucher's disease characterized by hydrocephalus, corneal opacities, deformed toes, and fibrous thickening of spleen and liver capsules. J Pediatr 2001; 138:137.",
"       </li>",
"       <li>",
"        Shiihara T, Oka A, Suzaki I, et al. Communicating hydrocephalus in a patient with Gauchers disease type 3. Pediatr Neurol 2000; 22:234.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced from: Vellodi A, Tylki-Szymanska A, Davies EH, et al. Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis 2009; 32:660, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2009.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31772=[""].join("\n");
var outline_f31_1_31772=null;
var title_f31_1_31773="LD Psychoeducation evaluation";
var content_f31_1_31773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tests of psychoeducational and neuropsychologic assessment to evaluate children with learning disabilities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intellectual/cognitive ability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Differential Ability Scales - Second Edition (DAS-II)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kaufman Assessment Battery for Children - Second Edition (KABC-II)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leiter International Performance Scale - Revised (Leiter-R)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stanford-Binet Intelligence Scale - Fifth Edition (SB-V)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wechsler Abbreviated Scale of Intelligence (WASI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wechsler Intelligence Scale for Children - Fourth Edition (WISC-4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wechsler Preschool and Primary Scales of Intelligence - Third Edition (WPPSI-III)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Academic achievement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gray Oral Reading Test - Fourth Edition (GORT-4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kaufman Test of Educational Achievement - Second Edition (KTEA-II) Comprehensive Form",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peabody Individual Achievement Test - Revised - Normative Update (PIAT-R/NU)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wechsler Individual Achievement Test - Second Edition (WIAT-III)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wide Range Achievement Test - Fourth Edition (WRAT4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Woodcock-Johnson Tests of Achievement - Third Edition (WJ-III)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Perceptual, visual-motor, and motor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beery-Buktenica Developmental Test of Visual-Motor Integration - Fifth Edition (Beery-VMI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Finger tapping test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grooved pegboard test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hooper Visual Organization Test (VOT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Purdue Pegboard",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rey-Osterrieth Complex Figure Test (ROCF)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensory-Perceptual examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wide Range Assessment of Visual Motor Ability (WRAVMA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Language",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boston Naming Test (BNT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinical Evaluation of Language Fundamentals- Fourth Edition (CELF-4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Expressive Vocabulary Test (EVT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peabody Picture Vocabulary Test- Third Edition (PPVT-IV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preschool Language Scale (PLS-4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Token Test for Children, Revised (TTFC-II)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Attention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conners' Continuous Performance Test II (CPT-II)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gordon Diagnostic System (GDS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children's Paced Auditory Serial Addition Test (CHIPASAT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Random A's test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Test of Everyday Attention for Children (TEA-Ch)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Test of Variables of Attention (TOVA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Memory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        California Verbal Learning Test for Children (CVLT-C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children's Auditory Verbal Learning Test - 2 (CAVLT-2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children's Memory Scale (CMS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Test of Memory and Learning - Second Edition (TOMAL-2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wide Range Assessment of Memory and Learning - Second Edition (WRAML2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Executive function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children's Category Test (CCT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delis-Kaplan Executive Functioning System (D-KEFS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Go/No-Go inhibition task",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stroop Color-Word interference task",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tower of London",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trail Making Test (TMT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Verbal fluency test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wisconsin Card Sorting Test (WCST)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Emotional/Behavioral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adaptive Behavior Assessment System - Second Edition (ABAS-II)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behavior Assessment System for Children, Second edition (BASC-2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child Behavior Checklist (CBCL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conners' Rating Scales - Revised (CRS-R)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vineland Adaptive Behavior Rating Scales, Second edition (Vineland-II)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Personal Communication: Kevin R Krull, PhD, ABPP, Judith Z Feigin, EdD, 2003; Learning Support Center, Texas Children's Hospital, Houston, Texas.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31773=[""].join("\n");
var outline_f31_1_31773=null;
var title_f31_1_31774="Avulsion fracture mallet finger";
var content_f31_1_31774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Avulsion fracture with mallet finger",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 3 to 4 mm avulsion fracture is evident accompanying rupture of the extensor profundus tendon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31774=[""].join("\n");
var outline_f31_1_31774=null;
var title_f31_1_31775="Preauricular pit";
var content_f31_1_31775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Preauricular pit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 343px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFXAQUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDmo/N3bHRlXr/qyM478NVaRrhHIt95U5+URHB/Wu2mZWl8kEkLzwnP51g3VpHNdh422FjnPXj+Vc9z0eXsYkqXKxvO6rxyAxGePT0quscxmUyCMbjuYL1/GtOKWKX+AkDKnZzk9OKhEM93KqOoRAcEnqcf1oJGTW0W/LAM2OMNyfpimiwkZlG1YiRwAu0/U1p/ZYdP+e3jczsuGLNyR+tW4Y52Hm3VyqyPwRtGEH/1qLjsYcdgqOxuF3rgnPUk+tPmjfDeQjbRjG8ZOfataQRW5VYJAxY43bcE+poEGN0zuSWOcUXHymXa2o3Mbu1mkcnC8Hj8eagvLVXRY4UIcA/I64x9K2PNeOPdvfzjkDb0H9akCLLFgj5jncTxz1p3QcrOT8rY4QjBCjB75zj/ACKzNQij8xnYgKeBj+H/APXXQ39oxaTewYAbwAentnvVO6spPLZUXdF03Ee3ShNEtHMyYEYBHAAPzdT9PaqU672HlISvYAcVqXNqCw+bgZG3nioUhSJGXvntzVpmTiZgsDjcjKM87OlSxKyj906xjncm3JqzIx24cjZ/D6/SoPKDgeUMZ6buhrRGTQ6GdmyvnOiKp2gt0+mKe8lsYwqRSSyY+90waLewa7mCKg3g4x7102k+FSzLJclS4A6EgY96mVRR3LhSlPY5BrWWUfuUOcY2gk1fsvDN5OAXUKpH8Qr0m00WJB9zB61p2unKcDaQBWE6/Y7KeC7nntl4NTd++w/P3QvWtaDwhp6HP2ZST6knFdv9ijXB+YYGOO9PWyLFsnA9CaxdVvqdEcLBdDmIdGijQLHGAoGMdRVtdPCpjCqvXAFbogyxjVcsBnGePzpJbcR8zH5iOmOv0FCqvuX7CPYyI0ZeQMDP4mr1rMytlW2kdRmpJoGKbkjcem4YFVngkRt0hAH+z0rSNdkSoLobMOtSxECV/MX0Zq2LDV7e6Y7EEZHXzDjJ9q4Ib4hmMYB6571V1bUksrR5JN5wOw710QqKRzTpuO52finUY4odhm82cnACnAX8P8a4m71BYYirMqgenWuHuPEErSvIWO9vboKybvXpGPync3rjpUv3noTKooo6HW9cWJGI4ODhc8muGvLqS5mZ3JOTwPSmTzvPJuk5PvUYYjgfyppWOSpVc/QTB9KKcFzRVGVj6CfWBcxFYTiQjlVGefyrPFibhma5kCkj7mN7D69qpXeoiQxRrC0bggHsx59OtbmlPFGplSRCxH3HBJHvWB6KsLFpjLEX2GNQeMYyazZ4pIr0uWOHyFX0Nb7X52st1I3XAUAYP9awdSiZ2DhxlXDDechcc4Hr0oAksSzZkl3+af7g3fkfwpFt557kGViig5A2Env1Nadl5UaowHmSt1djjd/9anQzTFJCqgbmJGDwo9CaktIrOIVZD8w28BtuCxx/OmHdPOZWVj2Ck/KPwFWYrO7u5yxl2RochgOPwPf61chs4gX/AHm3BC4DH+eelFyuUitrdBnA2rz05JOP8ajeF2dFByp6sfStF1tYTgo7k8hMsB9Oar+V5qkRW/zd3LHH+RRcdipqEKLHIpBYsMhj2rKl8qeJUaTbkDKjk/p+FW76ybeRNMzcjAXKiq8UNvboxEYXIB+ViOcU0yWjBvNPmldwLfy0A5Zzz9a568sxatw7FiMH2rqL65LtIElYDOfvE59hWVJatcZVN/HcjNNSsZuHMc2It7YVjvP8JNbOi6FNIweYuqEcLxWzp2h7CHdUduo+XHNdTY2EpUZtyR/s8mplW7Fwwy3ZR0vSo4owF/PAretdOPmEjdt7dOau2cduigs4RsZIZSpxVy3uFwqwxlx03E4z+FYOTZ2RjGIwWapgqCMDPNOdB/yyOR3Y8AVJIN4zPKuT75AH0qKS6gBWNcO3Q88VJqhyRxwguzl2J47/AICk+ztMxxlFx+J+tPhkXIyzSPknOOlW4mJzuwAeAetSykijp2khAsW+WQKON7Z6/wA6txWqRdMsR1KjOPrxWlbQoSshyFPB5wT7GtBREq+VCqqu7dgdD7GgWxzbwzOrEny1I4UjNUZLMKADjP8AeYd67JrdZGyxXZ79KzLq2bymChW2HJ96LhozjZ7baxzkisq+tllBBAPHQ9/rXWXkIjUEjd34rJuYgc7O9XGRM4XR5D4q8MSRO9xY73VmyY+OPpXHNGythgQfeveb21DqwI+vFeceLPD5R3urZcAD5lC9/WuqnPozysRhre9E40R5BJbHsOaMKD3/ADqQJyQflPvSmP5M4Ga2ucdiPcV6D8qKVWPO4GigWh7xd29rd/NPEH6kOSAewrKitrm2ujHpkjbdpIyckH3z2rbuLguyAoo54UcZGaljOyT9wGkY85A2nFYXPTcUzMLajYx+bexAuTksihh+XXvUdzf/AG+BleaJ2U7j8oH/AOquqitjtLT/ACryx5z+pqGS0tZ4GHkjygMM5AyTjoKVw5Gc3Cktv+7Ro/Ox8uCDx+fatmG1uDbmJ5X3g/MFxg9+aoWukRxXpRZ5o8KSMncP19q11tbzduiZZQF5JUAjAH/16TZcYdx0djewx7cxbXG0FnIzjntU8duYwWdIwQRuw3156VV+yXMsoaWBuTkbCOO/Y1JNBGhDbZC7YJzuHp/U/pSuVyksj26T5jTfzkk/MT/nJptxdk/cgIUk4BPP41UlbYflLAjoNzD+n0rLupXzxM/PsTj9KQ7C6lcPwuMYPAHY9/0zWXcrLM+yJcKPvc0+XzP4XfexwAV6CpkgaOHHmyl+wwBRcnluZ8dg7zYAjCrx1NalvabdoZlPoFGTU9lZEYJMhI6kjPNbVpaSLtJMgU88IKls1jTILPTpXVWjAGe7ECtyytHi/wBdOQSp+VcD+lMFnHEyu8lwVbJwc4B/Kobi5t7ckKvzDqGBOBUGqiWJXsLLJKbnJ5LEkn86xNQ1WIyN5CYkz1Xj+VZ2qaoLuTbDgIO6g81STbjgn9aasJlySa4nHMxAPtToTMvBKcccH/GoIsDAByBViJlHLHj0qtBW8yxBqLwyYdtv1GP1rWg1UsAdwxnB4rFbaXCggr1zRMsbFtp4HccVLii1Jo7C3vgyjpjGMVrWd5iQnGCexH8q89gmkiRdrnAHRuc1fttXmSTZJGpHfBqHFormTPQIXILYwQwPAx6U94dyBgi7mGevFc1a6rwCSy4IIwDxWrDqsMihVeJjnBA449aVgZHdWkbqFEZVjwD6Vzd3bN5hQp8xY9iM12zyR3EWVXe7jACjp71kaigZQOMg4HH50bBFnHXNuVJz39P5Vi3tqrKVcZz1+ldZcwBi3UEVj3UZ/iBIxg81pCRE4JnkPijRfs0xlhUBCSW56HNc6S8TFWA/nXres2SzwSK43ZBGK851axNrKyFPlzwSea7Kcr6HkV6XK7ozknfHGwj/AHAaKR40U/63H1FFaWOa57xZxgSmOWSFZI/+Winhvxq1GoslaeWVsH2wD6YqS9tLNVwVDAjAVTgqPU+1RWemNNHvs5SFTojEnB9fXvXLuepqi5Y/ab9UnuYnt42ACwO2SMHqwxjPt2rQO1junIf0BwMc5zUFqZ8osrQknhCGIJ/HB5qTUBIrGNFZXkO0ZKn9eMipZpEqSxm7XMbiJt25Tn/PbrU7TSKIy8Xyuu1nUZHPr6VFFHcRRhkYckp8yjH86daTTrI6FQ5YkgEYHv6+1IuxcjmQjG9Qep21WklQFiScjHbH+RUuZVVt8CMN3GCDhfQ02VSxLQwxqOvUc0WKKVxKHbjJYjt6fWsyaE5YsfwPQVelZtpLbj1GQBVK6UH7ysSxwM9v1oCxShXzZt4BYngD0FaVpZtI3zDJz6UyBfnBRCBjGPatK0SbOUUD3JpMuMbE9vaKpyOcEZGO9aMO0YyCPXjGKZawTEks6rkdh1pbvG3LEkgdKhmiKuo3xEZSI5wM7hyAR/WuR1XUTPOYYWbg/M2c59queIL4W0W1MiR8hR6ViWFowOzIdzjp600r6kzdnZE0MbLjg8+gq0gxxz09K3pPD89vI0M0Z85fvbSGC/lWf9nKu6qVJHX2oaKjG5FDg4PT61dCIygHH+NV3hKAZHahHwRzSTG4WL0cCtKpKggfrSyWahgcDknNNglAcYz+VW1YM/JHXinchootYsN2DwOenWqU1vIi5YMvXnFdXCivtHBBHX0q/FpkU0bBVJPQk0C0OAS5uIcbXfaD3rSsdRimbZOuGz/Ee9buoeHsFjEQQD0rlb6wa3cqy/P7Gpsy1Y7ewSNolKyOvOPlfHWrNzYsVk8u7fHfOCM+1cdpF+yt5UjEHsa7G0u/OXbgZPUmpE0ZN5ZTIvMjkfTj69Kw7qCTJHmsM+oFd9KiTQAE/N35rnNRtlVCDjjpzTTsK1ziLyFzj5z36pXJeI9Na4iJ3glTuyF9q9Cv4cAMvQg5rndQhJDAgbc+lbwkc1andHkrpk8kg+hXNFb2r2zxXhMQJVhnj1orrTueVKDTse5WiQyTlHKqEwAOcs3p71tMiMVATHHBPHtWfZ2ixMS7DdgEsRnnqTmtJFBVUDB/4T3B+lcbZ6yiQTW0b5kbAlJwgBxnPpVSO0YTySsMKPulT/T0q2zkrI75YoPlPT8v8ParVqQ+POA3AZY5xk8mlcrlM6XcnACFgeVA2kj+VJcLtXIXa38JxnHfNa0iRsuHEZUdyM1FLBESDGpUAbSUOO9IpIy0mEqbAwZ+jKD05zn8qZMNhYE4KgjOaszWEUoDRnEh6E8n8T9KqXUZUkskhOeTkkGmUjOlIxjI3AdqqsDLKAgyFHJq3PFl8/d46Hkmo7VG+dgFAJ6YoHYktISJArdhyPSty2jAI2g+2azrcEAM2193HA6VqwiVtp3qo74FSaFlnVEBbHPTnFZmoTfIQnI7nPSrkhXysNl/djWFq05SJsDC46ZpFWOG1e6N1rbJHysZ2/jnmuu0SxmjgWdUBVD8x7VyekxC4vZJSh+Zyc4967rTTLDEUB+QgfKelO9jKMbu5t28ZmmjnjRUDAoRngn27npVq80keWGRtr7R0AH17c1Not5DazozQiWPOWjwCRxyR6VpX5iMgljnUwOoCR/xR885Pv6Ur3NNU7WOIvbPZgADGMnPr3rIljIbpkfyrstUg3sWC4VsnBGDXNXkBQtkHGeKk03RQjcK3Xn0q7C+QBjp+lZr/LJx9angc9c49aoyaN23uMleBgdOetb9lcfLxgZ4x2rk7V8tuB59a3LQHCsSeOcdzQHKjpUmaUBXCkjhQetc5rlokrYSLDDl2B/lXT2XK7lVlfGN2Mmo71UkBcqAenzL1PvRcmOjPKdRtZYGOEK81Y0zVzE6xy8Y4BNddqthC4bcgI6+tcXqWm+S+Qh7ngUrFs7S0vVaABSu44zk9aSeJZPkPAGBmuR0m+a1k8uUlk4wT2rs7WQTqm3BJzz17UidjC1G0KI+F5A4J71zF9EWJDLyeld9qcWY8EAAeg5+tcnqECq5Cj5QeBVxIkro4m/tN8oLIOnaitW4jG/kjpRWtzkcT0cqiMYyxYY4xyQfenpGroUIkIx8xPH0pj7oFUIP9bhM55HcmrpbylWFl24GDkAn36VB0FWRQXjjYD52HAz2Gf6VcgKgttUkY5JHSoGiCyK2QTtPzDtk0/a2wZJ5XpzUjSJiqnKuSODxxxVd22heMjHQ9BinMFEGGJzn7ucD/wCtSySMAHJUED5SO1BSRUfG8GHcMjLZ78nFVbrdIRjIA71oEDZuDE7u3qeP/r1RJLlnLHOf89aC0jOuVClnC5+XPIqvCFVPlz+XtVi+5dUGQXOcH0psZ2MQ3rg0xpakqv8AKOcPjI9KuwXW0bGB5/ujNUF4bIJOOlWInKjK55HJ7UjRItXMjFBgfN0we1c9q4ZoGyecfhW5y4HQY/WsbVuVdGz6GpYWM7wrZrJGvUdM45rrfspjAyD9K5fwbcrBcBHJ+VsV6fGEvFRgWeQ9R04+tKREHY56MMhxyB7VoWLhJs8bhz83P86dd27xPl0wvUDI596hRoskZ+YdRt6VmrnRui5fXE95IZbpt07cAgYGPwrm9Vj/AISck81pzTsseCwz6Csi8kD/AH25yCSB0FUtRclloYtwOTwM+1NhDY65BOMGp5SdxTs3UGpIIgnLDA61aMpIs2cTY3ADNbFlJhgcNwRms6JiflzxmtS0KqM8A55J7UmK50Wn3JLu2SGcDLEdKluM3AG4llBz06VW04b1UnBwenSr8qeauQwZwBx0ouQ9zBuVIDh3Oc8Y6Gsm/hDgjjOD71s3cQaVggZB6Z71mSLuwSxLAkU0y0jmLu0kC7iMAGtXw/clAqkng4+oq1dRgxYzle1Uoh5F38px/SmS0dBdFZEGVKtyOa5i+ixk45HXj0rqi6zwr5hJG3kjqB0rntUQliQCRxQSuxzMsab8Hp2oqzMDG+BwOvIorQysd1BFHEjF23yHBJYAk/5zUojy5yh2bSB9cVLGq7st97qO2D7VJMDk8BkxkkD86gFoUlbEhBK7gAMbs/Wn7cEo4wQOCOo/z0qtF88kjAL989Rz24oYtKeCRggc+nag0SJwRJGiFgeMjJ5qvjhgCGYDhSetWYYgeAc4zznj/PBqFyvmAmNSM9hj8KBoilVjhyu3GMY6VBcMqtwCAOfqKuPtZHAAHXA6gex71RnQbCf7vPPPFBaMuTLXIJGcDHHNQTHkkDA6ZNWYxuBIBySf51DOmRyBk0FIaHOAOhHQZqxCzcjnGOmelVVC7G4HpjHNMDYbCEjt0xmixdzRMrFSPukdTnms+7w33mBPen7jgtxz1FQzHhuOPT1oaA4GXUn0jX5g+7y2k3A5969Q8J+JY7pFEcyMBjOGya828aWG9kuo1GR8rfSua02+utNuPMtpWjbocd6dro5OZwk0fXNrBa6lEzTOqnbhSOx9aoXuipCd0cpKk8bupFec+CfHBlVUmJVwQD0/SvULfU0voAzENgcDg1lJW3LU5J3T0OavrQRbl8zcACQQOvt0rnbwEEhQByTz0rtNUjURqUBDFcsff/OK5i4tyzYA781NzpU7oyI0I5Iz6mrAQkAe9W1tdhOV/Lih1wMYHoDVGbdyuh2N078GtCFzuG3lT3z0qioJIAwatR9htGKbA6HT5WBBIJJrWcq8JPBPt3rnbS4CuBggj2rU+0Zj2opXBznHFIhrUgv13MAgGTjlelZcyEB+gGPz5q5cXB8zKDyyOPWqc/KEbRyeaaKWhUYfMy5Bx71TnbEgyuQT1q5KMvg9ap3S7gccDjAqkhs3YkR4InWYvleVx0PpWRqKgqvIBx3qTTZiwwc8d/Sm36ui5YfIT8tJGRhXEJWQgjnr+FFNu5GEmSeSMflRVpkNHoIiYsdzAFMDAGOO4p0jIiq0Z2sD0ByAOtBkTIHlkNtw/wCvzDNQtv2CNQxj4Y56gD/61ISVytaDCbgcMrN0+p5ok27mZs8nqOPwFQwrnIVuVc8r+dS5DLnBOMYoL2DeSCV+UjuOuc+lPcj7hByOPr3p/krEfmY88ZYdOO9RyttC4LSYXOKBleQfvCwB2E4we496hux+6YYG1htB9frVp97AFywPXBqpMwdvLJPBpFlIjEQDLkdcn/PtVSVgSePqfar0o3KSOnSqkkeM8HOeaEUU2OWLD7x5yRzimzoFAJbDgYxUsi4bKjgcZ/Cqdxltuw4z1Oen+FWK4+SXDBsZ5ANRyzgrhshj7cVbS5DqI4o1yjABtuS3HX8ap311vkbzIY48MMFeoAquXQnnKN3GJoWTGQwrjr7TADIVB4PrXaTMEkZPMz2z0zWLe/LKW6DvmpWjIn7xgaZIbW4Uucc+ma9G0PW5rYoEOQexHauKubYSscDvyauWYWNghnlVfbPFDVyEer22uR3aZkbjPpVqOeGTkHORXmkFw0RURzNIM/xHrWrBdOqL5Mxk4yVzytZ8vY06HXXZQjGTt9qzJ3B6YAHSs1tVJGCQfx9qa14HXqaLDWhpQlcjPPvVmMrkk9B6CsVLoBuDwO2aswXXGMkfjSaHc6K1Ybwe4NbMJV42VQScYzjrXMWc+5+c4643da37C4UYUNhccfypA2RajFkk5y3c9KxpS8attweK6K7cMpwO/cfjisK7C7s8gEklaEOLKDSfOHGcjr7U9l3uRjnGTVeQEE885AIBq5HwmcnPoatFsqRqIrkpyQT/APXNW7hjIu4DKgYAPaoZY2Esc45BPU1L5ayIfmOc9u4pmTMS5UvJuODn2NFXbjaszqcAA8cUUakXOunlRkVsOH5HHHv+XNVkeUyfOAVYYyTg9achiLhmOW5BbPSk6spdSpxgY6DHp+lA0rDreIoWzkAHnvTwP3g4GenTg0yNh5ZAOG/nTlT5m+6QT6n0oBhKSRubq3HPqKazhS3ykA9B1/z3pZlx8ylc889M08EeWpU+2QOlIZDMU8gsSM4yR3rLBOS7Kfm6e1XLg7ysQ2k9wPzqFh93pgY5PpQVEqyBirMeAMnHeq8ufmTgdO9XJhkljtJPWqxVcn5cux6GkWUJEJHynn37VnXuVk2xg447du9bTRqc5+ozzVTyIW8xZHKPjIJ6GtIu5nLYiZI1RHtnbL/NgL0HqKq7BNdxhzkcnJHBAHepZHeDypLB1jZGJO49D6ipLi4jsLdiY1knmjKE4yBk5PPT1rS5jexgs4aOSVwOPlx6GsudxLKf7uOhrTvI4jZxxxszXDSZcdh6D61C9l5MQM23zGIwoPOPes2WjIEjRS4bJ5q/AC+Sh44HI5qO5sy6ggDjvmmW2+KTBHNS3YaReMEi5YHcfWpo5WjLZDKfrVm0cP8A6wc9KttaRuuCdue5pGiRSiuGjKvgbl74B+nFSxMzf6wMA3fHAqKezcEKNuR1B7UQPNFIrIRtTpz07U7iaLRWRFJyGX/Z5xSwTYbBPFPluJHt1woAOQDtwDzzVGUfITxv56UyHodHa3O3BB9q2rC5YkAtg9a4q1uRkA4zXRabO2cggc9elQ0Unc7aREltAEcEAdD3PeufvEUsQD15H1rX0oNLa/uVXjue/rxWbdQp5jk8SHpj1pBF2MgqQW6epJqRZQTjGScc1HKGEhUcrk4pkW4LjjgcVSNC5dhTbI0Zwm4AqT39akhbMJ5461WmQGOMgqMN0z1P+RU6phTwAcdKb3M2Zd622dvlJ9/xopt0EM7F12npxmihWIOqjg2RKTycnHGcmn7CVyc8rnA7f5zTbfhQxU5HBBqwrFlI52t82O5ouMb5J2g7uccL607CgDAAAIPPb60DOVf7uD0pqFpZGycAfNyMZpMNxkhKktgZ5PPrTJJiUJKYwO/f/OamY+WAm3I9cfrVdk82VI1yUx82RQMIvmbzHXknOBxj8KjmcH73/fPoauNEBGMcBTjGO1RGAdBgEdaQ0UJVIQAc+gqmFzgE4J9K1kjw+CRgk/5zVaaMbmx19fWkPmKLxDeTkZx09TzVK5Qk9OPXFaEwCqSrc+h/nVSd/wB2wYnI5zTTM5NmZPEvbpVUxBsDGTj60XU2JODj3ohn6g5J/wA9KvmErMRYPLA+TfnoTxiq88B5kxkkVpBhjAX8h7VJGqHGQcD1ptmkYmBaKJmdcYYHBFLeWZDAoM444rfFnCkm9FAY9SO9RXFuAnvUNl2Ma0RlYEdB+VbFqAxw5AXHXrioobYHgDrVmGHCtxyKktIcsQCsxILLzSRaarnkcscr6VMiYVQWPp2q7YuCCg6YG4Y+8Kq9waMS4snRSFycdx/OqF0NhAGMAcZGM9eteg2tlBc7f3H7w4yeSTzyfauZ1awRZCf4gdrd+meaqxm10OX8xlcNgjB/Ouj0aXei/QZNYV1Em5h3B7Dmr+iyEMEbJ7YNJoz2Z6LojKIwQe54qDVATcFmxt3Y3Y7UaCxYBRkDrnHSptSVG4AJCg5OOlQCephFMSA7TnHU+lNgTGABuBHapghzksQDwvsKbEPLkJ5I74qkaIJgWaEHhSefwq1j90egI7VHIG8xVIKqBu6UksrG3BGS2RnPcU7iZh3q7ZBvY7iOQe1FV9QkP2g4JHtjpRVWM3udtCQ0zdT1zgYq1GcKAhJYEYBPeo1Rht2g5OM/r/galzsUEKxYcZxz2qAuIY1JypJz268/5zQAFK7GUg5PuB7elCyEL0GTyRmnEAsACdzHuPakNkU5klBjjB3dcYxU8cUaEAH5sccinRoBy3LHip/LO3OMAjOc0CuMK5VQMjB5OOtRtGzRsVK4PGcVZVSzYxjHPFSTKEJGFwT0JpBexkyW/wAvyn6GqsykfOe3WtiRFWNSW6ZOOtVZ0Dbgy8Y780Bc59yhfcdyjofasjVphDG5JIwMmty6jABwPeuF8dXLRWDKp5JA4NNasU3ZFEXwuNx3jrhRjr9KtFjCV8w4cgNjjpXHabd5nBYhQD37VtIRLLlW+TPX2rVxOeM2mdDb3YKcnjHpVlLpeMtx6mueaNo1ykgbjPB7+lKXmKKMEHrn1rN6HTGodV9tiVQfM3d+hzURulkYlB34zXPRmduoY1dtopwTkHcOMVOpopGzAw6DP4da0IkJVdoyT1zxWRamSE5cHI55Hata2uVO0ygdOhoNUx722WRhkr14qaAeVIMgg5zV222SyRFCh6cen1q1NYqV4Advuk+hpFXRYszDHJ5jMyRyp83OMDPas7V0jaRmhDsoJA3Hk4NTalbS2qwiL5izDchP3ao6nI+WAXDHt6CqTZNk9Tkr2Eb2z6nGKi0g7JyOoFWL7cA4Jyc+vWq+lAtOcYxnFVfQxnoz0TQQhAYnD4IOelS3rsqzRZIRj9eR0/nSaBG3lgbW2kE8c1DrGRIQVKcZ+Y1LM1uZUhwMA9DT1IBLYGRz9arwfefJ3Dtn+lTmQKcBf4fXNNGwIf3jOmcE9+9S3jbLYInXuMe1R2sbMruq7gPmPPTFQ6pdEwqioEGfmPr9aaRLZzOov/pJCk9O1FZ2pTJHMNzkZ9DRVnM56nsEbKQpyRzj60jyKpLAA5bqPeqwLKvzHC57+1SQ4aIK3XGQKzN7WCcInIX5uxPap7eLC5b5sDIz602FMfMMD6VNHtDMH69OB1NK4mThWRNwwGIHFSRoHXnac9CaZGoEgYEEkZpxB+4G5H6UEkgQKxC5wOcjvTCuUHHOe9NXdtC43AdKUhg2046/r1oERyZPBHTrmoXQYPHAzgGpwSm0D7oHPem3Dq2NpPI79KRRg3yqQRt4x0rzv4hQn7AQApKkHke//wBevSrtCSQDx0HYVwXi2LzLOYDnjr75pw3FNXizzzRrMzv90AV2Wm6YoQcBj+lZnh+HZISufQ13GlwkooI4boP8a1k7GdONzPTTF42x5xxyKeulbnJKjFdLBFErBSfvY4Papp02zDoEBALVnc35UjmU0woRuUcnA4xVpLIAFyOewcnn/P1rUk2jeAPujJ5OaoF13HymJlPXOenamikiqYMMMjHrhaQKEx6AnBpXlIl++2/OQeOtRtc7XYDHPWlY1TsaFncFZOSOvA9K6e0lhkixKyncdwwOprgXuEEnXI7dq0bO+aMKA+MHIxU2K0Z2F/cxSpCwUGSPrnj35/WuZ1KZGkYnnPAxyDTZrtniOSDu/AVj3DbiQPxFOxNkipqMgDHbjvinaDGWm3DHPPPeqt2ylT8x3A4rY8N233ev1qrWMJO7O70ndDYu4JwOoFZWpTeYzMScY7mtSRo47QKwbOORjPeuZ1GYksTznP4VIorW4luCS2MBRyBUpx5agLgnp9Kqwbtq7eavwptl3AZ2DaDimalhYSISV+XA5965zW52LFc9K6WWSOO3O7IYDk5ritamOJHbk5Jq0Yydjj9evkS7GSTxRXM65M09+xVugAorVQRwSqan08QNwx8xwCR7+v1qe0jVm+clRjHSnpEFUbgCc4/xqZ8BiVAweg9BiuZnfe4wICqgscDnOKjYkZGehBJFSByGCBTuPf0qKQBnYr+A9KQIVJs5AG4dCc446dquJztIY4POfSqCYByBgenpVqJyFO48dOaBS8ixEQWJB9OeuabMcOAFbOeQarljgCPg5oyXkyOOPSmTYWQjAIOKhYqiEBvY5PNLMwQjcPl/nVeRuAS2Ux3/AM+9Iop3XEYwSc989K4nxA37mXuMHgV1d/PtDAHjNcVrl0ACOTk4OKqK1HJ2iyhosRWb5WBUkYGPeu2shsg245PG73rmNAgy2R9Sa6iBvLO0xnOSfarmRR2LgbCASA8cAHgkVWknIkwSfz9fb2omuCE+7kDqc9DWfeSsrlcgseeuDzU2N7jpZhJGxVgM9QKzWucIVZnLYzg/ypzyk7uGXjk1TLAKcJubIGSelOwXHNLtHJfHpmqd1ISoYSMrdweDT5TuA/uk4IOcA1SZJfmIPQ4IxzihiuSeexbLEY9c1KlydwwSCOgz1qie4bgjPNQSM45JBA7jrU2HzG0dRYFgxIJ469aFulKbs84rCabK4Gc8YNW7CGW5lCLwvqe1NIHIu20Zu7ofKSoOc4rvfD1p5I3EYUA9e3vWZoulsgUgDjGTiun3x2ybSgIGGGeMjFBmVtXuwmCmDj179K5eeUSXA3FgCSSD2Gau6ndMXOTk+tZsEZlk3HoT3oNIouWZYrhd27oOela8C7AUbJDDvVG2iwy4OMfrWkJQiqwIDqQc4pAylrcymL5D2+bHbGK878UXwSI7Tjr39jXW6zdcyuTwckc/jXlnim8Ms5QZ6/pWkEctaVkc/wAuxY9SfWipUTjmiug4T6tUhnAbJI9e9EjqqkPnnqcmooGc43kAnJJIz9KczoRkcmuI9SwXLlwWO3IAHAAGPwpi/Ntbjn1pMh/vErn7tPjA5GCCPb9aCnsSjO3Cgeh5oRtoLH7uOo4qEnDcZIOMjNWYlxuDAZ65Paghke9iDyCD0OO9OHzDAXAU9CKjIMcjDG4HvUqEgE/ePuOtAitdSZC5wqgYAxnBrLuZNqHk/wD1qvaixGc4B56Gua1W8KRNls4B6dqViolPVNQCK3IyfauRkuDPNvUhl7YqrresB5zGcLj3PPtTdFbd8zjGc8VtCNlcwqz5nZHY6LH8o2kbsEnGeK1FdlbDLgHsO/oKw7WYqAU654A+lW2lK7gx+b3OcUmaQVi3JcAyMpfEfUVVnAwVkbB9l4xUKpI/CoxUjGfSrUOnSOBu3E9+KV7GqKJdXZzjPpn8qIopMfImT3zW9HpDLyYzjGcdM1aSyQEYUcfl9KTkOxzItpwp+RfmHNB06Vh8q8Y+tdSbUBuQPp6VIlqqgkjINLmY7I4ttJYkBgBj0NVZdHkVidoAzxzXof2aMdVHTPAqtNErDGMAkgZouw5UcLHpe0AOi5zya6DS7JIyo2gmrD24wDtwDT4sx87c44ouS4m2JEhiYxqCuOeemKxtQvGYYQLgdD3x6VFPITjnCtzxVGXfISnXHfHJoHGJGzszEk8egq7bRYA2jqcVFDAyxlwM+x/nWnbp+7BHJwMe596GaWsWreFY9hVck+nWoNQuXWBkPCA9vX61bikfy+V29/TNYOsXbEspwoXnbQkZSZyniC6KRO2QBg15zcSGa4aQkHNdL4tvQzeUj5JyCB9a5uCMyOM5C5/OumCsefWlzOxNFGQPfvRWlBB8nyjFFVczPouZXL8MNucYHSmjKsig5Ueg6mpGXDcde+e5pqMFYF+hBPSuM9G5IF5yc8dqQgplm5OeT60b2QFecDnJ7ZpiyFj0wR+tDAfjJOMZBzn071KjFBljkYznBqujr90kHtnHrUqyj1z6UAx7lTyuRk8HFSKxywJJHp/WqzOcn0PB9akSTaGJy3r/APrpEtGdrR2xkHv14ryzxhq5g3QqeSG9K9N1XDqx5wemfr614v4yVF1KQOsvmFTzuGCe2P1q4LUUm1E5ySR5Zg0jbsqDx06V02jOWwDx6n+lYNhZl2GM5NdXpFm/CKOT61qzKKNm3JJAXOfYVr21izkNJknOeelWdK05YlBA+Y4zz3robO3UhQwOeuBWTl2OiKsVNP03d94YX0xWzBYRjaWU8kYNW4lVUIIzxlRUEt0VYY+6T2FSUrsjukUnhiNvTjpUBCq5wCTjOSOKlkIMh3Y65H/16hLFsLncc55pFoHQNLheG7Gjy8jHoMHinxHlsg4B7dqfgsCFycjI96BlfhjtIP1PTFQzxErlnDe2OnbirrgyLukAyOhxVeYNsZMDk8YH9aYXMyRAAQoIHXA+tVZwy5OWJPPI5q+Ul6jOwcA5yP1qo0JBB5J64NMqxSw7/LhgM5x2pYkOeQdvUDvWgI1iOWHzHn1xUDyNK7fNwaNhjIV3HaoYgeo4xVxAFcDnOOwzimxwqhA7epqeVlVQ2Tu6jNC1IlIr3Vx5URGW9V7YrifEmpCKN2DHdjHatnW7sgtlunb2rzTxBem4lYKTjvWkVc5as7Iyp5Gurou+epxVi2Qb1wOg5FMtkz+eK0YYRwSeQOa3ONeZahRdg3KD7kUVIEL52ZwDRUhY94diuRnP9KgmkZQCeR1xn/PrU5Ic9AMevNR7BsztGRwNv6YrmPQRKjblbGT7HvTHBVwMgc9PQelEX3MkAduetMlJYgggEHtQAqsFlduv+znpinKxYZ46HpSLh8j16n270pGPlOPTFJgIhbI6c+pqfJwAduegqsrELn2xRE5ZecdcUmO1yK8jDBl9feuG8VaE2oMkgJDJkDvxXfSYZssOtU7iFSBkc9+aSk09BNX3PMrLQ5o2AaMDHXNdPpOnfZ15Xn1NbaWi9dg5HcU9YFXgL9arnbEopE9iqgH8setacEoVfkw2DWdBlTkEZHX3qxu5460i7FhpznBIOTjg81BLIvmKdxIx1z0NJF85GRwT24waf9nU8tjB4z60ykN3ZIIzgHPXjFPDr94qQB0NMdQrdj2p2CqjAUA9hQUPkyVGAeaFfbwO3emllwGweOxpkhMeCvAPUfWgQ55XAPyBifxqB2Z9o2lCT6ZpkpJAKMAOmD6VELkBMc7h3FBSRZeEHLSMEx3A4qldSAIyq2T7cVHLeZj2qGY8/SqgZnY7uR0IzSuA6Ri+DzjnnPWnQIMjFKsZAHCn6VdiiCqo2AtnAxVJXJchQAkO6XCOD6c47Vh6rfhc4IUAHH+1VjW7lo/3avjuR71w3iDVDt27ySc596uxlKWhS13UyzMqNyTzg+1csytICxGeetWZJPNkZmHFIsWCPQdh3raKscU5czC3jOenQ9q0RGfLUjtziorcDgAc1cQA8EZ+lBJNCdq8/pRSRxsRhcAD2opage6BOWVcAdz2pdqoRxtfA6dMUi4QbsZ6df51FIV3kNncF7cDFc52rUey7upxn8KrMxJzkgkgjipSV25Jwx6YOarSLubJB29R6CgpE6MVPz4PY0s/BXkFj39KSIBs5B4HemzMCvsOScUgGs/HsRnp2pqygk+lRgjJzmmlcOcZA65zxiky0iwxGBu9eQKRsbRnn0FRggFTn2NIHUj/ADwaQ7DiRnk8YpmAWBY5+gpW4UcZz2pmcAgjP0oSCxYJXd3z7etA67cjI9KgVtnLdO9OZlIyDyOmTVILFm34cgn2I9alcbjjkDjFVonH3iakLk9W5xyKBA8m2Tj+H1pUbJy+GAPWoJSDz2znrjFRq3zFV55xikUi/gsFOOMkdaicFehZu2B/SkikwcnBx3PSlMueFbjPPtj0oArSIXkCsee/vVZ0444+o/pWhtJBfHOODjvTBEW7dep644osNyMsRFSSOGxnOOtTRQjspB68960FtinOCCRjJqCaRIo85AYAjmqSIcgykaEKAD2JrC1PVHDtsOCTzxx/+uk1O/UjhvlHIrk9S1H7yrnPXAq0jOUktRNb1Q7COhNchcs0hYsSat3GZWy+etQ7ARlc4+taxVjklPmIEDDg5xxj8amCkYA+8eM44oSMsT128cZqVeDuPJHNUQOtzuYA8+9W7YBSD82TxjFVoY2ODnaM5z6VbiKxqMng/wCNIC15YP8ArG5+lFOClxuw4z2GDRSA9iEhbcSQOM9ahG5W3EhkxySev/1qVF2vyAcjHFSFRtIC4Ycc1zndsJ5gbrjP06UrAKTkLz6561GysAQMYPPNKgAA3AkdjnFFwFIwDk/Xj/CoiqrlTznnmlLEKGJPFMbDkk8D0NAXEbHOBx2zUROCTkH2xSzyEjHA7keuahVmcfNzzmky4k5VvmGffmnbG6YHHWmbyqDOMe/NPViCCcc0h3FJwMlMdqiOVBJGfXNSO4A2jt6VWkYPkcCmNDZJcHGBg0zecZUrnHY8ikXBPOA2OAf6VUu0bH7ohW7nsefSqSGX0nwDk8Z6mnPcEDg1kQvNsInKs2evtVgbutJjSLnnjv3/AApUkyN6nkVT+YkbuSemKljyAFClueo6c1Iy0kzYG707HNTBst8ucY5PTNQpCRgHhv5VaEYX7xCngHPSmkQ2Txj5c5ycUpwIizMBk8+tQS3sMEW0DLenGBWHe6l1YNjPWrsZ3NbUNREQChgfxrmr/UdwO9z0xzWdqWq5Xh+nSuduruWbILYWmlcznUUUXtSvvMJWN8j1Wsc7j83Vj3NPTHAxgd/U0nAPAwc8fStUrHJKbkQvHuJLcVEzLgrirMg4ORwT9KqMO/rxTEhFBIz2JHFW44sn5vpUMEXIJA56VehHRQBn9BSYyMrhMbck5IA70+3h53OMnsOwq2luByTliOpPSpdnBUAZB9KAGp83zYI7UVPAmEByoz14ooKR6gWGOCT680isC2eenrTBhgG6d/8A61N+dnG3O41zHYSlwQF49OnbNIXCEquCD+H+e1RtJwFGOOMimkNxtyN3YVSAmIJJABzj14qJm2qTxzz19qPNK53NyOeaa7lgwBIyOtAmQSgjLYPp9KiLMCGXqvepGHy4JznHHeoJE2/KTkd+aVi0x7S72wcZGRVhZCoAGST7Y/z0rKMuH+bI9M077RubGVBJoQ7l55CThgB3yOtOIGR1zjpjiq0UoPLHJHuKlEgGMnOBRYXMBHOOeT0pXQtjCng88VICCRgcqOMjpTtgJznJPSmVcpvGrLnnj9KkaFo1x0A/OrcUCruGCDnP04olIyT90kcA0WHzFVYueR+VTxKq+3HbpVWe5EfTBY+pqhc6i2eTxjHNKw2zeuLpI4FPmYYjpj9ay73UdvRjxWDdaiAPmf8AWsO71fcxVCWPTrVJXMJTUTfvtVGGYkE1z19qjOSqE5NZstxLMPmPynnikdOT14z0rRQ7nPOs3ohrPI+WJyakB3AE+nI6VEuRwQSc9asIVwcH/wCvWhi3cZnJ7mgg9Ac8VIMFs+tQlhyAcnpwM5pCBvfkY/WmOoQjPr09RUhV5Onygnv1qQRdz16ZNBRFEGLYwACMYxWnaxDaOCM+tJBCvJwBz6VcRABuwe/akMayLvHXNOAwnueOackWNpO7PpSPjfk9etAWEXjnJ59qKcpPOM/TFFAz0FGO3OOaVSeASN2eMnpUIYAfMQPxzUe9tu4YzzzXOdhKxKjAJyTnp0pyyg9+SeOO9NyAm0EHP40gGxtrYIJyck+lMGOfIOXPzY5IppcHg8/0pJAcY4CkZ60rHpgDkd6AEckkYIIPvUNwByDyOoqZTnOMYwBmo3Xcnykeo+lAXMu45DfKRjHWqMsrRnkDnpitSdewA3e9Zl3bk8AY700gbFhvACAfu+hNW473dnB68VzVxHLG5IOfaoo710J3Dp6U7GfMdjFdHILHnjHPSra3I8sfN17VxyakCuGIBzVhdQXbneOPeixXOjppL7HIJBHWqdzftn73A4rBl1JAuSw/OqFxqyKOuc+lFg9okbVzejqW5FYd7qeMhSTWTcX80+QOAfSq45B45z19RVKF9zKVbsS3FzJKcMSB2wajUdzn37ZpoO4gHvT1weR071qkkYNt7kkf3QucVIcgMD61Au7nqeMVIuSx9+M0Eio2W4HsOaVlHOR82OcUgAyQvJ71KkZLHv05oKGiIY+YfN7mpoYgVBUbQewFPRC3bNW4YSGy3ftSAgitQTu6HrU/2fkHsOgq5HGoAz0/nSlRgt1Gen4UBYiihGc54q0SsYLMCcc4HtSKVA5wR2pCAVJx7AUmUiPdnBOetQykM5PXHFWdqqOwyOaqhxhm4IPSkgY0lzyr7KKVfmJbbkHpRTuI9DO1kUMozjNRPkRqAoxxz+FKGCrtAG7HAzSlTnkZ5/Cuc7AJKgrjnrkHNIFLMeQQMDkcCmyIBhsjuMGpIHHOCRxg80DEkHHIBA4PvSqAyk/xe1IWwzZBLfpQFyuccEZ+gpki8D0HFRMcggnBGMmpGYgLg5OMHP8AjUOAu4hRjPFAEcwU5xwe9U5FXDZ6Z4q2wyrKOPaq0oBJ4xnnmmgM2SFZSR+Zx1rI1G0KglfyFdEdqnODnFVJVDklhzjHSrREkco8ZXORkGoXQqpCjBroLm1356bR2FZ1zbkE/WmZMypQQADzio2HJxVqdAW+vtUTpjjOD0qrkFXaBjnHtUgyQAB/jTljbv37GpI4yGAxkimIhRSSDnA6c1KgPHGOOtWEhxHgjtmpY7cnsc9+KBFZU6HPapVhIAX1NXEtRyT349qsxQZG0n8qAKMVvkc4znrjrU6W/XjH4VeWLAwQSPpUpixz1FFyrFRICf4eB3FWEiG3pUn3crjoR0qSOM8A8AdvWkx2BYwBkjPNIwReCO/NSsq8uCeDjioWOFb3FJMdiIAZJPXsPSmg559fSnhdyYXJPU0sUeDyRxkZPpQxkM4brjLHgVE8JXaCB6YHarW7c69SuSelOn25JGc55oIZURHbJXOPbiipFIGQTtooA7pVA57DmnPjIYdfriiisDre5XcNvXrlj60mBGMEcniiimUOcttGDg9qdDyw3ZzRRQJit0Ix82MVXkOBt/KiihAiLIKk9s8VFKDk/wB31ooqkIgIBBx3qCYYTnpmiimJkYQkfNwM9vSq8lurYB5PX/P6UUVSM5FCazVmOB06VTNkAcnJOcUUVSRkw+y+uOucVItsF5bv0xRRTJJkiU9cmrEUQPJ4B60UUDsLt7Y5+tWEULgEdqKKVykhQoZRQAN+eoFFFIaGOu0dOvPWlQkcE4oooAczZGDwo5qFwXOSfoKKKSAeCEUjnimv8ygYO2iin1EN34YYz0xUTuMcjOf0oopiI0Qtk4yTyaKKKQH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the small punctum in the preauricular area. This preauricular pit is draining squamous material.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_1_31775=[""].join("\n");
var outline_f31_1_31775=null;
